

# Procedures and guidelines for company submissions to the Agency for Care Effectiveness for funding consideration

Version 1.5

April 2024



## Record of updates

<b>Date</b>	<b>Version</b>	<b>Summary of changes</b>
December 2020	1.0	Publication of initial procedures and guidelines for company submissions to ACE.
March 2022	1.1	Updated to clarify the ERC critique process and include information about process for companies to discuss risk-sharing arrangements with ACE for their products, and to revise the MOH Drug Advisory Committee's terms of reference.  Minor additions, wording changes and amendments of Figures throughout the document have also been made to improve the clarity of the text.
March 2023	1.2	Minor additions, wording changes and amendments of Figures throughout the document and templates have been made to improve the clarity of the text and streamline processes.
September 2023	1.3	Minor additions and wording changes throughout the document have been made to improve the clarity of the text and streamline processes.
January 2024	1.4	Updated to clarify the pricing resubmission process, re-registering submission intent, pre-submission meetings, ERC's response to the company response template and including a detailed change record for changes made to the evidence submission.
April 2024	1.5	Minor changes regarding submissions for related indications and updated reference links.

# Table of Contents

Foreword.....	7
Abbreviations and acronyms .....	9
Part 1:.....	11
Procedures for funding consideration of medicines.....	11
Introduction .....	12
<b>Section 1 Pre-submission process .....</b>	<b>13</b>
1.1 Application process .....	13
1.1.1 Eligible applications.....	13
1.1.2 Registering intent to submit evidence.....	13
1.2 Pre-submission meeting with ACE.....	14
1.2.1 Scheduling a pre-submission meeting.....	14
1.2.2 Discussions at the pre-submission meeting.....	15
1.2.3 After the pre-submission meeting .....	16
1.2.4 Consultation with ACE while preparing evidence submission.....	16
1.2.5 Charging procedure .....	16
<b>Section 2 Submitting evidence to ACE.....</b>	<b>17</b>
2.1 Confidentiality .....	17
2.1.1 Handling information submitted by a company .....	17
2.1.2 Copyright legislation .....	17
2.2 Types of evidence submissions.....	17
2.2.1 Submissions for full evaluation .....	18
2.2.2 Submissions for expedited evaluation.....	18
2.2.3 Request for Proposal (RFP) .....	18
2.3 Submission process .....	18
2.3.1 Submission check by ACE.....	19
<b>Section 3 Review of evidence submission .....</b>	<b>20</b>
3.1 Overview of the evaluation process .....	20
3.2 Clinical and patient expert advice .....	20
3.3 ERC review and critique .....	22
3.3.1 Clarification request .....	22
3.3.2 Preparation and review of ERC commentary .....	22
3.4 ACE summary report .....	23
<b>Section 4 Funding decisions.....</b>	<b>24</b>
4.1 MOH Drug Advisory Committee (DAC).....	24
4.1.1 Factors informing funding decisions.....	24
4.1.2 DAC recommendations.....	26
<b>Section 5 Guidance and funding implementation.....</b>	<b>27</b>

5.1	Post-DAC processes .....	27
5.1.1	Drafting ACE guidance .....	27
5.1.2	Notification of outcome .....	28
5.1.3	Letter of Acceptance and/or Deed of Agreement .....	28
5.1.4	Resubmission following a negative recommendation.....	28
5.1.5	Funding implementation .....	29
<b>Part 2:</b>	.....	<b>30</b>
<b>Guidelines for preparing an evidence submission for funding consideration</b>	.....	<b>30</b>
<b>Introduction</b>	.....	<b>31</b>
<b>Section 1 Context for the submission</b>	.....	<b>33</b>
Introduction	.....	33
1.1	Defining the evaluation framework and clinical claim .....	33
1.1.1	Rationale for submission .....	33
1.1.2	Evaluation framework.....	33
1.1.3	Target population and health condition .....	33
1.1.4	Intervention and comparator(s) .....	35
1.2	Clinical management .....	37
1.2.1	Clinical treatment algorithm.....	37
1.2.2	Clinical need.....	38
1.2.3	Administration, assessment and monitoring requirements.....	38
1.3	Clinical criteria for MAF listing.....	39
1.3.1	Proposed clinical criteria for MAF listing .....	39
<b>Section 2 Clinical evaluation</b>	.....	<b>40</b>
Introduction	.....	40
2.1	Literature search methods.....	40
2.1.1	Search strategy .....	40
2.2	Identifying and selecting relevant studies .....	43
2.2.1	Study selection.....	43
2.2.2	List of selected studies.....	44
2.2.3	Ongoing studies.....	45
2.2.4	Copies of included studies .....	45
2.2.5	Selecting studies for an indirect comparison .....	45
2.3	Assessing risk of bias in included studies .....	46
2.3.1	Risk of bias assessment for randomised trials.....	46
2.3.2	Flow of participants .....	48
2.3.3	Risk of bias assessment for systematic reviews and meta-analyses.....	48
2.3.4	Risk of bias assessment for non-randomised studies.....	48
2.4	Characteristics of included studies .....	49
2.4.1	Characteristics of included randomised trials.....	49
2.4.2	Participants.....	50

2.4.3	Treatment details.....	50
2.4.4	Outcomes .....	51
2.4.5	Minimal clinically important difference (MCID) .....	54
2.4.6	Non-inferiority margin .....	55
2.5	Results: whole trial population .....	55
2.5.1	Clinical effectiveness.....	56
2.5.2	Adverse events .....	58
2.6	Results: additional analyses.....	59
2.6.1	Subgroup analyses .....	59
2.6.2	Meta-analyses.....	60
2.6.3	Indirect comparisons.....	61
2.6.4	Adjustment for treatment switching.....	63
2.7	Applicability of study results to the Singapore setting.....	65
2.7.1	Identification of important differences across settings.....	66
2.8	Interpretation of the clinical evidence.....	67
<b>Section 3</b>	<b>Economic Evaluation.....</b>	<b>68</b>
	Introduction .....	68
3.1	Published economic evaluations .....	70
<b>Section 3A</b>	<b>Cost-effectiveness analysis .....</b>	<b>70</b>
3A.1	Overview of the economic evaluation .....	70
3A.1.1	Summary of the economic evaluation.....	70
3A.1.2	Type of economic evaluation .....	71
3A.1.3	Perspective of the economic evaluation .....	71
3A.1.4	Discounting .....	71
3A.1.5	Structure of the economic model.....	71
3A.1.6	Model types .....	72
3A.1.7	Fully executable electronic copy of the economic model.....	73
3A.1.8	Time horizon.....	73
3A.1.9	Model inputs .....	74
3A.2	Population and setting.....	74
3A.2.1	Patient characteristics and circumstances of use .....	74
3A.3	Transition probabilities.....	75
3A.3.1	Transition probabilities and variables .....	75
3A.3.2	Extrapolation.....	76
3A.4	Measuring and valuing health outcomes .....	77
3A.4.1	Health outcomes.....	77
3A.5	Healthcare resource use and costs.....	80
3A.5.1	Healthcare resource use .....	80
3A.5.2	Allocation of prices (unit costs) to resources.....	81
3A.6	Summary of base-case model inputs and assumptions.....	83

3A.7	Model validation .....	83
3A.8	Results of the base-case economic evaluation .....	84
3A.8.1	Base-case results .....	84
3A.8.2	Disaggregated and aggregated base-case results .....	85
3A.9	Sensitivity analysis.....	86
3A.9.1	Defining uncertainty in the model .....	86
3A.9.2	Handling uncertainty - one-way sensitivity analyses and scenario analyses .....	87
3A.9.3	Multivariate and probabilistic sensitivity analyses.....	89
3A.10	Summary of economic evaluation .....	90
<b>Section 3B</b>	<b>Cost minimisation .....</b>	<b>91</b>
3B.1	Overview and rationale for the cost-minimisation approach .....	91
3B.2	Estimation of equi-effective doses.....	91
3B.3	Additional costs and cost offsets .....	92
3B.3.1	Comparison of administration profiles .....	92
3B.3.2	Comparison of safety and toxicity management profiles.....	92
3B.4	Results .....	93
<b>Section 4</b>	<b>Utilisation and financial impact.....</b>	<b>94</b>
	Introduction .....	94
4.1	Utilisation and financial impact of the proposed medicine.....	96
4.1.1	Epidemiological approach .....	96
4.1.2	Market-share approach.....	97
4.1.3	Cost impact.....	98
4.1.4	Uncertainty surrounding utilisation and cost estimates .....	98
4.1.5	Risk-Sharing Arrangements .....	99
4.1.6	Patient assistance programmes.....	101
4.1.7	Summary of costing template calculations.....	101
<b>References</b>	<b>.....</b>	<b>102</b>
<b>Appendix 1</b>	<b>Submission Checklist.....</b>	<b>105</b>

# Foreword

---

Established by the Ministry of Health (MOH), the Agency for Care Effectiveness (ACE) is the national health technology assessment (HTA) and clinical guidance agency in Singapore. It produces evidence-based evaluations of health technologies (e.g. medicines, vaccines and medical technologies) to inform funding decisions by MOH committees and publishes technology guidance documents for public hospitals and institutions in Singapore to promote appropriate use of clinically effective and cost-effective treatments.


Funding decisions for medicines are made by the MOH Drug Advisory Committee (DAC) which comprises senior healthcare professionals and healthcare finance representatives who follow a deliberative framework which takes into consideration four core criteria:

- Clinical need of patients and nature of the condition;
- Clinical effectiveness and safety of the technology;
- Cost-effectiveness (value for money) – the incremental benefit and cost of the technology compared to existing alternatives; and
- Budget impact.

On the basis of the available evidence, the DAC recommends to MOH:

- whether a medicine should receive government subsidy through inclusion on the Standard Drug List (SDL) or the Medication Assistance Fund (MAF), subject to finance approval; and/or
- whether a cancer medicine should be included on the Cancer Drug List (CDL) and be eligible for government subsidy and/or claims under MediShield Life and MediSave.

**Figure 1: High level steps for evidence generation and decision-making for medicines under evaluation**



The SDL includes low- to moderate-cost therapies essential for the management of common conditions affecting the majority of patients. The MAF typically includes moderate- to high-cost medicines that are not on the SDL but have been assessed to be clinically and cost effective. Medicines listed on the MAF are subsidised for specific indications governed by clinical criteria to ensure appropriate use, whereas medicines on SDL are subsidised for any indications approved by the Health Sciences Authority (HSA). More information about government subsidies for medicines is available on the [MOH website](#).

The [Cancer Drug List \(CDL\)](#) outlines all cancer drugs and their clinical indications that are claimable under MediShield Life and MediSave, and their corresponding claim limits. Generally, only cancer medicines that have been assessed to be clinically effective and cost-effective are included on the CDL.

Since ACE was established in 2015, topics for evaluation have been identified predominantly through applications from public healthcare institutions, and technical evaluations have been conducted by ACE staff in line with ACE's [Drug and Vaccine Evaluation Methods and Process Guide](#). However, from 1 January 2021, under the company-led process, companies have been able to request for certain products to be evaluated for funding consideration and provide an evidence submission to ACE to support the DAC's deliberations.

The aim of this process is to enable medicines to be evaluated close to the anticipated date of regulatory approval by HSA, and expedite funding considerations, to improve patient access to clinically necessary treatments.

This document is divided into two parts which outline:

- evaluation and decision-making procedures for medicines being considered for funding through the company-led process (Part 1), and
- methodological guidelines that companies are expected to follow when preparing evidence submissions to ACE (Part 2).

It has been developed in consultation with the Singapore pharmaceutical industry, and technical experts from overseas HTA agencies and academic centres.

ACE will continue to review and update this document to ensure that it remains a useful resource for companies who intend to prepare an evidence submission for funding consideration.

Find out more about ACE at [www.ace-hta.gov.sg/about](http://www.ace-hta.gov.sg/about).



# Abbreviations and acronyms

---

<b>Term</b>	<b>Definition</b>
ACE	Agency for Care Effectiveness
BIA	budget impact analysis
CADTH	Canadian Agency for Drugs and Technologies in Health
CI	confidence interval
CDL	Cancer Drug List
CMA	cost-minimisation analysis
CrI	credible interval
CSR	clinical study report
CUA	cost-utility analysis
DAC	Drug Advisory Committee
EMA	European Medicines Agency
ERC	Evidence Review Centre
FDA	Food and Drug Administration
HSA	Health Sciences Authority (Singapore)
ICER	incremental cost-effectiveness ratio
ITT	intention to treat
LOA	Letter of acceptance
LOO	Letter of offer
MAF	Medication Assistance Fund
MAUI	multi-attribute utility instrument
MCID	minimal clinically important difference
MOH	Ministry of Health, Singapore
NICE	National Institute for Health and Care Excellence (England)
NMA	network meta-analysis
CDS	Cancer Drug Subcommittee
NOO	notification of outcome
OR	odds ratio
PAP	patient assistance programme
PBAC	Pharmaceutical Benefits Advisory Committee (Australia)
PHARMAC	Pharmaceutical Management Agency (New Zealand)
PICO	population, intervention, comparator, outcome
PSA	probabilistic sensitivity analysis
PSM	proposed surrogate measure
PVA	price-volume agreement
RCT	randomised controlled trial
RD	risk difference
RFP	Request for Proposal
RR	relative risk
RSA	risk-sharing arrangement
SD	standard deviation
SDL	Standard Drug List

QALY	quality-adjusted life year
TCO	target clinical outcome
TGA	Therapeutic Goods Administration (Australia)

Part 1:

Procedures for funding  
consideration of medicines


# Introduction

Part 1 outlines the core procedures and associated timelines underpinning the company-led submission process (Figure 2). Specifically, it aims to:

- provide support to companies intending to prepare evidence submissions for funding consideration;
- explain all steps that typically take place during an evaluation, from pre-submission through to implementation of funding decisions, and the associated timelines;
- describe the decision-making framework followed by the MOH Drug Advisory Committee (DAC) when making national funding recommendations; and
- describe the role of companies, ACE, ERCs, local experts and decision-makers throughout the process.

Information on charging procedures for company submissions is located on the [ACE website](#) and should be referred to in conjunction with Part 1.

**Figure 2: Overview of company-led submission process**



# Section 1 Pre-submission process

---

## 1.1 Application process

This section provides guidance on the type of medicines that are eligible for consideration through the company-led submission process and the procedures that companies are expected to follow when registering their intent to submit evidence to ACE for evaluation.

### 1.1.1 Eligible applications

A company can propose to submit evidence for a:

- **new medicine** - a new active ingredient approved by the Health Sciences Authority (HSA) that has not been previously marketed in Singapore; or
- **new indication** – a new clinical condition or broader patient population that has been approved by HSA for an existing medicine.

Companies are not required to prepare evidence submissions for biosimilars. All newly approved biosimilars will be evaluated internally by ACE staff in line with ACE's *Drug and Vaccine Evaluation Methods and Process Guide*. Companies are encouraged to inform ACE when submitting a biosimilar to HSA for regulatory approval to facilitate timely evaluation by ACE for subsidy consideration.

Proposals to submit evidence for new formulations or strengths of medicines which are already included in the MOH List of Subsidised Drugs (Standard Drug List [SDL], Medication Assistance Fund [MAF]) or Cancer Drug List (CDL), or have previously been evaluated and not recommended for subsidy and/or inclusion on the CDL are not permitted. Revisions to medicines that are on the SDL, MAF, or CDL, or listings for new strengths or formulations of medicines that have previously received a negative recommendation should be requested by public healthcare institutions during the annual call for topics, which is described in ACE's *Drug and Vaccine Evaluation Methods and Process Guide*. Any new strengths or formulations prioritised for evaluation will be assessed internally by ACE.

### 1.1.2 Registering intent to submit evidence

A company can register their intent to submit evidence for a specific medicine with ACE once a regulatory application for that product has been submitted to HSA for marketing approval. Discussions with ACE about submitting evidence for funding consideration can be initiated by the company concurrently with the regulatory process or after the product has been approved by HSA. Key process deadlines and DAC meetings dates have been published on ACE's website and companies should plan their submissions accordingly.

Each submission should usually only contain evidence for one medicine for one indication. Multi-drug regimens for one indication are also permitted. Class reviews comprising multiple medicines, or submissions which include evidence for one medicine used for multiple unrelated indications are not permitted.

To notify ACE of an impending evidence submission, companies should complete the [Company Pre-submission Form](#) and submit it to [ace\\_submissions@moh.gov.sg](mailto:ace_submissions@moh.gov.sg). The pre-submission form outlines the proposed evaluation framework and appropriate comparator, and the evidence that will inform the submission, including the type of economic model being developed. Anticipated regulatory approval

timelines (if medicine is being assessed by HSA) and proposed timelines for providing an evidence submission to ACE should also be included. Any technical issues, process enquiries or questions relating to the evaluation that the company wishes to discuss with ACE can also be included in the form.

The form should be completed with reference to Part 2 in this document (*Guidelines for preparing an evidence submission for funding consideration*). The content of the pre-submission form will be treated as confidential. Companies are encouraged to complete the pre-submission form as comprehensively as possible to facilitate discussions with ACE.

Companies who wish to proceed with a previously deferred submission will need to reregister their intent via email by the registration deadline for the respective DAC meeting.

## 1.2 Pre-submission meeting with ACE

A summary of the pre-submission process is shown in Figure 3.

### 1.2.1 Scheduling a pre-submission meeting

ACE will confirm receipt of a *Company Pre-Submission Form* and schedule a pre-submission meeting, if required. ACE will prioritise pre-submission meetings for complex submissions or companies who are new to the process. The pre-submission meeting should be held **at least 16 weeks** before a company intends to provide an evidence submission to ACE.


ACE reserves the right to decline a pre-submission meeting request if the proposed medicine is unsuitable for evaluation through the company-led submission route or the *Company Pre-Submission Form* does not have sufficient information to guide discussions between ACE and the company.

Only one pre-submission meeting will be held for each submission. The company will be requested to confirm their attendance via email and provide details of attendees. Up to five company representatives may attend a pre-submission meeting. If the company has appointed third-party consultants to prepare the evidence submission, they may also attend the meeting as part of the five representatives. The company is responsible for ensuring that the consultant agrees to any confidentiality requirements.

The number of ACE staff who attend the meeting will be dependent on the complexity of the topic and the questions that the company includes in the pre-submission form for discussion. The company cannot request for specific ACE staff to attend. Members of the DAC do not attend the pre-submission meeting, however, ACE may invite local clinical experts, at its discretion.

To ensure that ACE has sufficient information for the meeting and that the pre-submission discussion is useful for the company, ACE may contact the company prior to the meeting to seek clarification on information provided in the pre-submission form.

**Figure 3: Pre-submission process and timelines**



### 1.2.2 Discussions at the pre-submission meeting

The company will not be required to pay a fee to have a pre-submission meeting with ACE. The pre-submission meeting is intended to provide an opportunity for companies to seek non-binding advice from ACE about the proposed evidence submission. Discussions will be based on the content provided by the company in the pre-submission form. If insufficient information is included in the form, ACE may not be able to adequately address all questions raised during the meeting. Companies will be expected to highlight key issues and areas of uncertainty in their evidence submission during the meeting, and discuss potential ways to address them through pricing, risk-sharing arrangements (RSAs), or any other arrangements.

Any discussion during the pre-submission meeting will not influence the DAC's consideration of the submission or guarantee a positive recommendation for the medicine under evaluation.

No formal minutes will be taken during the pre-submission meeting. It is the responsibility of the company to note any discussions that are useful to help them finalise their evidence submission.

### 1.2.3 After the pre-submission meeting

After the pre-submission meeting, ACE will issue a **Letter of Offer** which forms a contractual agreement between the company and ACE that:

- ACE will accept the company's evidence submission for evaluation; and
- the company agrees to pay the required fee for the submission (refer to charging procedures for company submissions).

If a company is providing an evidence submission to ACE **for the first time**, ACE will also issue a perpetual Confidentiality Agreement which forms a legal contract between the company and ACE to ensure that all confidential or commercially sensitive materials, information, or knowledge that are shared during the course of the evaluation, and during all other evaluations and interactions with ACE thereafter, are not disclosed to any other individuals outside of the parties stipulated in the agreement.

The company will also receive detailed timelines for the evaluation, which outline the submission date, the date, determined by ACE, that the submission will be considered by DAC, and the expected dates for other key steps in the process that require company involvement (e.g. clarification responses and factual accuracy checks). If the company wishes to change their submission date, they should notify ACE via email as soon as possible so that the timelines for all subsequent steps in the evaluation process can be adjusted. In the event of any delay, the evaluation will be rescheduled to a later DAC meeting.

### 1.2.4 Consultation with ACE while preparing evidence submission

After the pre-submission meeting, if a company has additional queries while preparing their submission or wishes to clarify any specific procedural steps relating to the evaluation, they may email ACE for advice. Companies should be mindful of the resource required by ACE to address queries and should allow sufficient time for ACE to respond. In some instances, ACE may propose a teleconference to address the issues raised. All advice given by ACE is non-binding.

### 1.2.5 Charging procedure

All evidence submissions will be reviewed and critiqued by one of ACE's ERCs, which have experience in conducting and appraising health technology assessments (HTAs) to inform decision-making (Subsection 3.2). Companies are responsible for paying the charged fees. The fees take into account the time and personnel required by the ERC to complete a written commentary of the company evidence submission and to review additional information or analyses provided by the company in response to clarification questions.

ACE will issue the company with an invoice via email and all fees must be paid in full within 30 calendar days, or by the due date on the invoice before an evidence submission will be accepted by ACE for evaluation. Please refer to the [Charging Procedure for Review of Company Evidence Submissions to the Agency for Care Effectiveness](#) on the ACE website for more information about the type of fees charged and for payment guidelines.



## Section 2 Submitting evidence to ACE

---

### 2.1 Confidentiality

The company is responsible for highlighting information that is academic-in-confidence or commercial-in-confidence within their submission in accordance with the instructions in *Part 2: Guidelines for preparing an evidence submission to the Agency for Care Effectiveness*. It is not acceptable to classify an entire submission as “confidential”. Any information included in the submission that is published or in the public domain is not considered confidential and should not be marked as such.

#### 2.1.1 Handling information submitted by a company

ACE will use its best efforts to prevent unauthorised use, disclosure or dissemination of information that has been deemed as confidential or commercially sensitive by the company. ACE will use information received from a company solely for the purpose of carrying out its responsibilities with respect to the evaluation of the submission.

ACE follows the Ministry of Health’s policies and procedures to ensure the appropriate management of sensitive information. The contents of a submission and any correspondence received from the company during the course of the evaluation are stored in the Ministry of Health IT system. Access to the contents of the submission is limited to ACE staff involved in the evaluation, technical staff within the ERC assigned to provide an independent commentary of the submission, and to DAC members who are all aware of their obligations to safeguard information provided by the company:

- ACE staff are required, as a condition of employment, to comply with MOH’s confidentiality requirements, Code of Conduct and Conflict of Interest guidelines;
- Specific conditions regarding the storage, management and disposal of evidence submissions are explicitly stated in contracts between the ERCs and ACE, and all ERC staff are required to declare and manage any conflict of interest for each evaluation that they are assigned;
- DAC members are required to declare any conflict of interest for every evaluation, and to sign a Non-Disclosure Agreement at the start of their membership term which prohibits them for disclosing any confidential information to a third-party. DAC members are advised how to securely handle and dispose of confidential material appropriately.

#### 2.1.2 Copyright legislation

Full text copies of articles cited in an evidence submission must be provided by the company as part of the submission. The company is responsible for ensuring that appropriate copyright permissions have been obtained for electronic copies of articles that are shared with ACE and the technical staff at the assigned ERC.

### 2.2 Types of evidence submissions

Companies can submit evidence to ACE as either a **Full Evaluation** or **Expedited Evaluation**. The most appropriate type of submission for each medicine will be confirmed by ACE during the pre-submission meeting (Subsection 1.2.2). Both types of submissions follow a similar evaluation process. All submissions must adhere to the structure and information requirements described in Part 2 of this document.

### 2.2.1 Submissions for full evaluation

A full evaluation is required for a submission which includes a cost-utility economic model to support a claim of cost-effectiveness or cost-utility. This type of submission is required when a company intends to demonstrate that the medicine under evaluation is:

- therapeutically superior to the comparator, but is likely to result in additional costs to the healthcare system, or
- therapeutically inferior to the comparator but is likely to result in lower costs to the healthcare system.

### 2.2.2 Submissions for expedited evaluation

An expedited evaluation is required for a submission which includes a therapeutic claim of non-inferiority (i.e. the medicine under evaluation and the comparator are considered to be clinically equivalent and the use of the medicine is anticipated to result in equivalent or lower costs to the healthcare system compared to the comparator). A cost-utility analysis should not be included in a submission for expedited evaluation; however, companies may choose to include a cost-minimisation analysis (CMA). Companies should discuss their intended approach for the CMA during the pre-submission meeting with ACE. In the event a complex CMA is submitted by the company, full evaluation fees may be charged to the company, as determined by ACE, to cover the cost of the additional time needed by the ERC to complete their commentary.

### 2.2.3 Request for Proposal (RFP)

As part of the submission, companies are required to submit their best cost prices (i.e. the prices at which they sell the medicine to public healthcare institutions) and details of risk-sharing arrangements (RSAs) in a [Request for Proposal](#) (RFP) template. The impact of any proposed arrangements on the effective cost price should be clearly stated. In instances where a company is required to submit more than one RFP throughout the evaluation process, any new proposal submitted shall supersede previous proposals.

## 2.3 Submission process

Submissions to ACE should be sent by the agreed timeline via email(s) to [ace\\_submissions@moh.gov.sg](mailto:ace_submissions@moh.gov.sg). If a file size exceeds email limits, the company should discuss alternative secure file transfer arrangements with ACE. All correspondence with ACE during the evaluation should also be sent via email to [ace\\_submissions@moh.gov.sg](mailto:ace_submissions@moh.gov.sg).

The submission should include a signed cover letter (an electronic signature is acceptable) from the company which contains the following information:

- Type of submission (full or expedited evaluation)
- Medicine and indication under evaluation
- Confirmation of whether an economic model has also been provided (for full evaluation)
- Name(s) of third-party consultant(s) appointed to prepare the evidence submission (if applicable)
- Names and contact information (email and phone number) of company representatives (primary contact and an alternative) that ACE can contact regarding the submission.

### 2.3.1 Submission check by ACE

ACE will acknowledge receipt of the submission and will review all documents to identify if any files or key information are missing. ACE will also confirm the timelines for the key steps in the evaluation process leading up to the DAC meeting (Subsection 3.1).

If a submission is considered incomplete and/or not fit for purpose, it will not be accepted, and the company will be advised to revise the submission. In this situation, the company can choose to withdraw the submission and not progress with the evaluation or can advise ACE when a revised submission will be provided so that the evaluation timelines can be amended accordingly.

## Section 3 Review of evidence submission

---

### 3.1 Overview of the evaluation process

The key steps that take place during the evaluation process once a submission is accepted by ACE are shown in Figure 4. The timelines indicate the minimum time needed for each step. The actual length of time needed may vary depending on the quality of the submission received and whether additional time is requested by the company to prepare revised analyses or submit more evidence to address any uncertainties identified by ACE or the ERC during the evaluation. ACE will work with each company to revise the timelines as needed.


### 3.2 Clinical and patient expert advice

Before the pre-submission meeting and during the course of the evaluation, ACE will seek advice from local healthcare professionals experienced in the management of the indication under review, to confirm local treatment practices; validate the clinical assumptions included in the company evidence submission; and confirm the clinical need for the medicine under evaluation compared to alternative options (if available). Local patient organisations with members who are likely to have an interest in the medicine under evaluation are also invited to share their views and lived experiences during the evaluation by completing a qualitative survey. All clinical and patient experts are required to declare any conflicts of interest relating to the medicine or comparator(s) under evaluation.

For evaluations of cancer therapies, ACE seeks clinical expert advice from the MOH Cancer Drug Subcommittee (CDS) which comprises senior public and private clinicians experienced in the management of different cancer types in Singapore. The CDS assists ACE to ascertain the clinical value of cancer medicines under evaluation, and provides clinical advice on the appropriate and effective use of cancer therapies based on the available clinical evidence.

CDS members are not required to comment on the prices or cost effectiveness of cancer medicines. All members are required to sign a Non-Disclosure Agreement at the start of their membership term and declare any conflicts of interest relating to the medicines under evaluation prior to every meeting.

**Figure 4: Key steps in the evaluation process**



## 3.3 ERC review and critique

All submissions are sent to one of ACE's Evidence Review Centres (ERCs) which have experience in conducting and critically appraising HTAs for decision-making. Companies are unable to request for a specific ERC and will not be told which ERC has been assigned to review their submission. The ERC will be given **5 weeks** to review an expedited evaluation submission and **8 weeks** to review a full evaluation submission (including economic model).

### 3.3.1 Clarification request

Within the first two weeks after receiving a submission, the ERC will advise ACE if any information requires clarification or if any additional analyses are needed from the company. ACE will collate the ERC's clarification request with any questions from the ACE technical team and send it to the company to address within **7 calendar days**. If substantial additional analyses are required, or errors in the economic model are identified which require additional time to rectify, the company can discuss with ACE if a short extension to respond is permitted. Companies should be mindful that any extended delays may impact subsequent timelines in the evaluation process and the evaluation may have to be rescheduled to a later DAC meeting. Any changes made to the evidence submission document should be accompanied with a detailed change record.

The company's response to the clarification questions will be sent to the ERC by ACE upon receipt.

### 3.3.2 Preparation and review of ERC commentary

The ERC will prepare a commentary of the company evidence submission, economic model (if provided), and clarification responses in line with ACE's reference case described in Part 2, Section 3 (Economic evaluation), and the methods outlined in ACE's *Drug and Vaccine Evaluation Methods and Process Guide*.

The ERC will use a standardised template issued by ACE to prepare the commentary and will be responsible for the content and quality of the document. Once the commentary is complete, ACE will send it to the company for **factual accuracy checking**.

Companies should address any key clinical and economic issues highlighted by the ERC in the **Company Response Template** and return it to ACE within **7 calendar days**. In addition, any factual inaccuracies in the ERC commentary that are identified by the company should also be recorded in the same template. No new information or analyses will be accepted in the template.

In the event of any factual inaccuracies, the ERC will revise the commentary as required. ACE will send the company the final ERC commentary and an executive summary of the ERC's response to the Company Response Template for information. No further comments on the commentary will be accepted from the company. Companies are advised not to submit a revised price proposal after the ERC commentary is completed, otherwise updated economic and budget impact analyses will be required using the new price.

## 3.4 ACE summary report

ACE will prepare a summary report for DAC which includes:

- ACE's assessments and commentary on the available clinical and economic evidence which informs the evaluation, including any limitations in the evidence base;
- local clinical expert opinion on the clinical need for the medicine and its role in the local treatment algorithm for the indication under evaluation;
- patient testimonials (if available) about their condition, unmet needs, current treatment, and the medicine under evaluation;
- a summary of the company evidence submission;
- a summary of the ERC commentary on the company evidence submission;
- any pricing proposals and risk-sharing arrangements from the company; and
- any other key considerations that the DAC should take into account.

The summary report is not shared with the company. ACE will discuss the summary report with the DAC Chairman at a pre-DAC meeting, to ensure that it contains all of the relevant information that the DAC will require to inform their funding decision. After the pre-DAC meeting, the summary report is finalised by ACE and circulated to DAC members at least two weeks before the meeting date, along with all other relevant documents including the company evidence submission and ERC commentary.

## Section 4 Funding decisions

---

### 4.1 MOH Drug Advisory Committee (DAC)

The DAC is an expert committee comprising senior clinicians (specialists and general practitioners) and pharmacists from public healthcare institutions, and senior regulatory affairs and healthcare finance representatives from MOH. It is chaired by the MOH Director-General of Health (DGH). In view of the members' request to remain anonymous, DAC membership is not published. Members are appointed for a 3-year term by the Chairman and may be re-appointed to serve for more than one term.

The DAC is responsible for providing evidence-based advice to MOH so that funding decisions for drugs, vaccines and gene therapies, are made in an equitable, efficient and sustainable manner. The terms of reference of the DAC are to:

- prioritise drug applications for subsidy consideration which hold potential for driving significant improvement in health outcomes;
- appraise the clinical and cost-effectiveness of drugs, vaccines and gene therapies based on available therapeutic, clinical and pharmacoeconomic evidence;
- provide listing recommendations to MOH, including conditions and/or criteria for subsidy (SDL and MAF);
- provide recommendations to MOH about MediShield Life coverage for cancer treatments, including conditions and/or criteria for inclusion on the Cancer Drug List (CDL); and
- monitor the impact of ACE guidance on prescribers' behaviours.

The DAC usually meets three times per year. A minimum attendance of half the number of members plus one at the DAC meeting is required for a quorum. Additional meetings may be called by the Chairman, when necessary.

#### 4.1.1 Factors informing funding decisions

All relevant documents, including the company evidence submission, RFP, ERC commentary and ACE summary report inform the DAC's deliberations.

Based on the available evidence, the DAC makes funding recommendations which take into account four core decision-making criteria:

- Clinical need of patients and nature of the condition;
- Clinical effectiveness and safety of the technology;
- Cost-effectiveness (value for money) – the incremental benefit and cost of the technology compared to existing alternatives; and
- Budget impact.

Specific factors and judgments which are discussed by DAC when considering each criterion are described in Table 4.1.1. Additional factors, including social, cultural, and ethical issues, and other value judgments, may also inform the DAC's funding considerations.



**Table 4.4.1: MOH Drug Advisory Committee decision-making framework**

Core Criteria	Factors considered	Judgement will also take account of:
<b>Clinical need of patients and nature of the condition</b>	<ul style="list-style-type: none"> <li>▪ Disease morbidity, mortality and patient clinical disability with current standard of care</li> <li>▪ Impact of the condition on patients' quality of life</li> <li>▪ Extent and nature of current treatment options</li> </ul>	<ul style="list-style-type: none"> <li>▪ The nature and quality of the evidence and the views expressed by clinical specialists on the experiences of patients with the condition and those who have used the technology</li> <li>▪ Uncertainty generated by the evidence and differences between the evidence submitted for regulatory approval (from clinical trials) and that relating to effectiveness in clinical practice</li> <li>▪ The possible differential benefits or adverse outcomes in different groups of patients</li> <li>▪ The balance of clinical benefits and risks associated with the technology</li> <li>▪ The position of the technology in the overall pathway of care and the alternative treatments that are established in clinical practice</li> </ul>
<b>Clinical effectiveness and safety</b>	<ul style="list-style-type: none"> <li>▪ Comparative clinical effectiveness and safety of the technology</li> <li>▪ Overall magnitude of health benefits to patients</li> <li>▪ Heterogeneity of health benefits within the population</li> <li>▪ Relevance of the technology under evaluation to current clinical practice</li> <li>▪ Robustness of the current evidence and the contribution ACE guidance might make to strengthen it</li> </ul>	
<b>Value for money (Cost effectiveness)</b>	<ul style="list-style-type: none"> <li>▪ Technical efficiency (the incremental benefit of the technology under evaluation compared to current treatment)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Robustness of costing information</li> <li>▪ Out of pocket expenses to patients</li> <li>▪ Key drivers of cost-effectiveness</li> <li>▪ Uncertainties around, and plausibility of assumptions and inputs in the model</li> <li>▪ Any specific groups of people for whom the technology is particularly cost effective</li> <li>▪ Any identified potentially significant and substantial health-related benefits that were not included in the economic model</li> <li>▪ Existing or proposed value-based pricing and risk-sharing arrangements</li> </ul>
<b>Budget impact</b>	<ul style="list-style-type: none"> <li>▪ Estimated annual cost to healthcare system (Singapore government, insurance provider and patient)</li> </ul>	

The DAC has the discretion to take account of the full range of clinical and economic evidence available, including RCTs, non-randomised studies and qualitative evidence related to the experiences of local healthcare professionals and patients who have used the medicine or are familiar with the condition under evaluation.

The impact of the various types of evidence on decision-making depends on the quality of the evidence, its generalisability to Singapore clinical practice, the level of uncertainty surrounding the clinical and cost estimates, and the suitability of the evidence to address the medicine and indication under evaluation. In general, the DAC places greater importance on evidence derived from high-quality studies with methodologies designed to minimise bias.

The DAC does not use a precise maximum acceptable ICER (i.e. an ICER threshold) to determine if a medicine is cost effective. ICERs are not precise values and are associated with a degree of uncertainty. Therefore, the DAC considers sensitivity analyses, in addition to the base-case point estimate when determining if a medicine represents good value for money. When assessing the annual cost of the medicine to the healthcare

system, the DAC is not restricted to only make recommendations below a certain budget impact threshold; however, medicines with a large budget impact will be subject to additional scrutiny to ensure that the estimated cost to the healthcare system that has been calculated by the company is robust.

#### 4.1.2 DAC recommendations

Unless a company intends to seek funding for an off-label use of a registered medicine under exceptional circumstances (Part 2, 1.1.3), a medicine cannot be considered by the DAC until it has regulatory approval from HSA, or at a minimum, the company has received an **approvable letter** from HSA **at least two weeks prior to the DAC meeting**, and formal approval is expected no later than 3 months after the meeting. The company is required to notify ACE once final approval is granted by HSA.

The DAC recommends whether a medicine should receive government subsidy through inclusion on the Standard Drug List (SDL) or the Medication Assistance Fund (MAF)<sup>i</sup> (Table 4.1.2). It may recommend the use of a medicine in line with the full indication under evaluation, or for a subgroup of the population, if:

- there is clear evidence that the medicine is likely to be more clinically effective and/or cost effective in the subgroup, and
- the characteristics defining the subgroup are easily identifiable or routinely measured in clinical practice.

**Table 4.1.2: Types of recommendations made by the DAC**

Decision	Type of Recommendation
Medicine provides similar or greater benefits at a lower cost than the comparator(s)	Recommended
Medicine provides less health benefit at the same or greater cost than the comparator(s) <b>OR</b> Medicine provides similar health benefits at a greater cost than the comparator(s)	Not Recommended
Medicine provides greater benefits at a greater cost than the comparator(s)	Recommended / Not Recommended depending on the magnitude of incremental benefit, clinical need for treatment and other value judgements that informed the DAC's recommendation

If the DAC considers a cancer medicine for funding, the DAC Chairman and Minister for Health will subsequently determine if it should be included on the Cancer Drug List (CDL) and its corresponding claim limits under MediShield Life and MediSave.

<sup>i</sup> Drugs on the SDL are subsidised at 50% for all Singapore citizens who are patients in a public healthcare institution. Patients from lower to middle income households can receive more subsidy up to 75%. For drugs on the MAF, eligible patients can receive 40-75% assistance based on means testing.

# Section 5 Guidance and funding implementation

---

## 5.1 Post-DAC processes

This section summarises the key steps that take place once the DAC makes a positive or negative funding decision.

### 5.1.1 Drafting ACE guidance

Following the DAC meeting, ACE will draft a guidance document to outline the recommendation(s), the rationale for the recommendation, and a summary of the key clinical and economic evidence from the company submission, clinical and patient expert advice, and the ERC commentary which informed the DAC's deliberations. Guidance documents are produced for positive and negative recommendations and are published on the ACE website before funding is implemented. A plain English summary (PES) is also produced to explain the DAC's recommendations in non-technical language for patients and the public.

**Guidance documents do not contain confidential information.** For company submissions which include a cost utility analysis, the actual base-case incremental cost-effectiveness ratio (ICER) will not be reported in the guidance due to commercial sensitivities regarding the price used in the model. Instead, an ICER range will be presented as follows:

- Dominant (i.e. cost saving and health improving);
- 0 to <SG\$15,000/QALY gained; then
- SG\$15,000 to <SG\$45,000/QALY gained; then
- SG\$45,000 to <SG\$75,000/QALY gained; then
- SG\$75,000 to <SG\$105,000/QALY gained; then
- SG\$105,000 to <SG\$135,000/QALY gained; then
- SG\$135,000 to <SG\$165,000/QALY gained; then
- SG\$40,000 increments to SG\$365,000 (i.e., SG\$165,000 to <SG\$205,000/QALY gained, SG\$205,000 to <\$245,000/QALY gained etc.); then
- >SG\$365,000/QALY gained.

The annual budget impact to the healthcare system for funding the medicine under evaluation will also be presented in ranges, such as:

- Cost saving
- <SG\$1 million
- SG\$1 million to <SG\$3million
- SG\$3 million to <SG\$5 million
- SG\$5 million to <SG\$10 million
- >SG\$10 million

Companies will receive draft ACE guidance ahead of publication and will have **7 calendar days** to respond with any factual inaccuracies and confirm that the guidance does not contain any commercial-in-confidence information.

### 5.1.2 Notification of outcome

ACE will send a **Notification of Outcome** (NOO) to the company to advise them of the DAC's recommendation. Companies that receive a positive recommendation should not distribute the information in the NOO in an indiscriminate manner until the date of funding implementation.

Companies that receive a negative recommendation may request to have a **post-decision meeting** with ACE (via teleconference or in-person) to discuss the DAC's reasons for the decision and any revised pricing proposals that the company would like the DAC to consider to address the key uncertainties in the evidence base.

### 5.1.3 Letter of Acceptance and/or Deed of Agreement

If a medicine is recommended for subsidy and/or inclusion on CDL, a **Letter of Acceptance** (LOA) and/or **Deed of Agreement** (Subsection 4.1.5) that specifies the price and conditions of listing on SDL, MAF, and/or CDL, and terms for any RSA will be issued to the company by ACE.

The LOA and Deed are legally binding agreements signed by the Permanent Secretary (Health) for and on behalf of the Government of the Republic of Singapore, represented by the Ministry of Health, whereby:

- the company undertakes to sell the medicine at a price not exceeding the negotiated price agreed upon for subsidy listing when supplying the medicine to the public healthcare institutions, and
- the company undertakes to provide rebates (if applicable) once an agreed amount of expenditure has been exceeded, and
- MOH lists the medicine on SDL or MAF (and for cancer medicines, on the CDL) in line with specific clinical criteria.

These agreements set the price and expenditure caps for listing on the SDL, MAF, and/or CDL, provide traction against price increases, and ensure budget certainty for a listed medicine. From time to time, prices and details of a listing may be subject to review, including but not limited to circumstances such as an expansion of indications, availability of new evidence that will change the original cost-effectiveness conclusions or regulatory approval of new medicines that are used in a similar population or used in combination with the original medicine that was funded.

### 5.1.4 Resubmission following a negative recommendation

During the post-decision meeting, ACE will advise the company about the type of additional information required to address the DAC's concerns that led to the negative recommendation. For medicines that were not recommended on the basis of uncertain or unacceptable cost-effectiveness or budget impact, the company may register their intent to resubmit a revised price proposal for the DAC's consideration. Companies should refer to the key processes deadlines that are published on ACE's website for the revised price proposal to be reviewed at the respective DAC meetings. Companies are responsible to pay the fees involved and avoid indiscriminate submissions of minimally improved proposals. In the event of any delay in fee payment or submission, the proposal will be considered at a later DAC meeting.

For medicines that were not recommended due to uncertainties regarding clinical effectiveness or safety, or limitations in the evidence base or economic model, the company can discuss with ACE any additional evidence, revised analyses, or RSAs that they would like to provide to address the DAC's concerns and the appropriate route for submission. If a substantial rewrite of the original submission or revision of the model

is required, the revised submission may need to go to the ERC for critique, and the company will be responsible for paying the fees involved. ACE will advise the company whether an ERC will be required to review the revised submission and the appropriate timelines for submission.

### 5.1.5 Funding implementation

Funding implementation (i.e. listing on SDL or MAF) for HSA-approved medicines, typically occurs within 4 to 6 months after each DAC meeting once financing is approved by the Ministry of Health and the LOA and/or Deed of Agreement is signed by MOH and the company. ACE communicates funding decisions to public healthcare institutions after each DAC meeting to allow sufficient time for them to prepare for implementation, including making changes to their hospital formularies, inventories and procurement processes, if necessary.

Cancer medicines recommended for inclusion on the CDL by the DAC Chairman and Minister for Health are listed at the same time as funding implementation. The CDL is also updated to include the specific clinical indications covered and the MediShield Life and MediSave claim limits for each medicine.

Public healthcare institutions are instructed to adhere to the maximum selling price (cost price plus stipulated margin) that was recommended by DAC. This ensures that the savings generated from price reductions offered by the company are passed onto the patients and selling prices are consistent across the public healthcare institutions.

Part 2:

Guidelines for preparing an  
evidence submission for funding  
consideration

# Introduction

---

Part 2 describes guidelines which have been developed to assist companies prepare a submission to ACE to inform funding decisions made by the MOH Drug Advisory Committee (DAC). They reflect best HTA practice, as far as possible, and seek to maximise the confidence of the DAC in accepting the clinical claims and value proposal presented in the submission.

The key information that should be included in the submission is highlighted as a checklist in boxes at the start of each section of the guidelines. Further explanation for each information request is provided under the numbered subheadings following these boxes. Companies are encouraged to use the text headings in the guidelines as a template for their submission.

Although the guidelines present the preferred approach to preparing an evidence submission to ACE, the approach is not prescriptive or mandatory. Alternative approaches are permitted when adequately justified and supported by data. Similarly, evidence submissions initially developed for other HTA agencies (e.g. NICE (UK), PBAC (Australia), or others) can be adapted and contextualised to the Singapore setting, at the company's discretion.

Companies should attempt to include all of the key information requested in the guidelines in their submission. Where an information request cannot be addressed or is not relevant, a clear explanation should be provided.

## *Proposed submission structure*

A submission should consist of four main sections, presented in sequential order:

- **Section 1 – Context.** Describes the proposed medicine, its intended use in Singapore, clinical need for funding and the therapies most likely to be most replaced by the medicine in clinical practice.
- **Section 2 – Clinical evaluation.** Provides the best available evidence comparing the clinical performance of the proposed medicine with that of the comparator(s) (preferably from direct randomised trials, or, if these are not available, from other suitable studies). This section should end with a therapeutic conclusion stating whether the proposed medicine is superior, non-inferior or inferior to the comparator.
- **Section 3 – Economic evaluation.** Presents an economic evaluation of the consequences of substituting the proposed medicine for the comparator in local clinical practice for the indication under evaluation. There are two alternative pathways for presenting economic evidence which are described in the following sections:
  - **3A** – guidance on presenting a cost-utility analysis
  - **3B** – guidance on presenting a cost-minimisation analysis.
- **Section 4 – Utilisation and financial impact.** Includes the expected utilisation of the proposed medicine in Singapore clinical practice and the associated financial impact to the government.

All submissions should have an executive summary (**not exceeding 10 pages**) that clearly sets out the key aspects and issues presented in the main body of the submission.

### *Preparing the submission*

The main body of the submission should be concise and **not exceed 150 pages** in length. Additional information can be included as appendices or attachments. Any information that is important for the DAC to consider during their funding deliberations should not be included in the appendices. Font size for text in the main body of the submission should not be smaller than size 11. Smaller font sizes may be used in tables.

The information presented in the submission should be **fit for purpose**. When considering a more complex analysis, companies should weigh the additional information requirements and evaluation burden against the additional confidence that such an analysis provides. Where complex methods reduce the confidence in estimates compared with simpler methods, they are unlikely to be accepted.

Companies must ensure that all confidential information in the submission is **highlighted and underlined**.

The submission should be sent to ACE electronically in Word. If an economic model is included with the submission, it must be fully executable, and all programming code must be accessible (no locked cells). Companies should also complete the [Costing template for company submissions to ACE](#) to estimate the expected utilisation and financial impact of the medicine under evaluation.

A submission checklist is provided in **Appendix 1** for companies to complete to ensure that all relevant documents are provided to ACE.



# Section 1 Context for the submission

## Introduction

In Section 1, establish the context for the submission by providing the following information:

- the scope of the evaluation (PICO framework);
- the clinical claim that the submission will address;
- the expected use of the proposed medicine in local clinical practice; and
- the regulatory status of the proposed medicine.

## 1.1 Defining the evaluation framework and clinical claim

### KEY INFORMATION REQUIRED

- Tabulate the scope of the evaluation using the PICO framework
- Define the clinical claim that the submission aims to address

### 1.1.1 Rationale for submission

Provide a brief introductory statement outlining the purpose of the submission.

### 1.1.2 Evaluation framework

In Table 1.1.2, define the scope of the evaluation by presenting the PICO elements - proposed population, intervention, comparator(s), key effectiveness and safety outcome(s) - and the overall clinical claim that the submission aims to address.

**Table 1.1.2: Key elements of the evaluation framework**

Element	Description
Population	Briefly describe the target health condition and population to be treated
Intervention	State the medicine under evaluation
Comparator(s)	State the comparator(s), which may include proprietary (branded) and non-proprietary (generic) drugs and biosimilar products
Outcomes	Briefly state the key patient-relevant clinical effectiveness and safety outcomes <sup>a</sup>
Clinical claim	State the clinical claim that the submission presents as follows: 'In [population with health condition], [intervention] is no worse than/as effective as/more effective than [main comparator] at improving/reducing [outcome(s)]'

<sup>a</sup> Outcomes should be directly related to the quality and/or length of a patient's life.

### 1.1.3 Target population and health condition

#### KEY INFORMATION REQUIRED

- Describe the target population and health condition in the Singapore setting
- Estimate the number of people in Singapore with the health condition

The target population should be in line with the HSA approved indication for the proposed medicine. A proposal for off-label use of a medicine in an unapproved population should only be presented in exceptional

circumstances<sup>ii</sup> if there is sufficient evidence to show that **all** of the following criteria are met:

- The off-label use of the medicine is considered to be standard of care for the proposed population in local clinical practice and also in line with international best practice and/or registered indications approved by US FDA or EMA; and
- There is a lack of affordable and cost-effective treatment alternatives to the off-label use of the medicine for the proposed population; and
- There is sufficient evidence available to robustly assess the safety, clinical effectiveness and cost-effectiveness of the off-label use of the medicine in the proposed population.

Provide an overview of the health condition that can be treated by the proposed medicine. Include details of the underlying course of the condition, including diagnosis, symptoms and prognosis (with and without treatment). Describe the effects of the health condition on patients and their carers, if relevant, including the morbidity and premature mortality associated with the condition.

If the medicine is proposed for use in a subgroup(s) of the population with the health condition, indicate whether the usual course of the health condition, or the available therapies for that subgroup(s), differ from that of the whole population with the health condition.

Estimate the annual incidence and prevalence of the health condition, and the number of people in Singapore affected in the total target population (and in any proposed subgroups if applicable), preferably using local data, if available. In all cases where estimates or assumptions are made, please justify your reasoning and clearly state sources used.

Describe the population who would be treated in Singapore with the proposed medicine, including their age, sex, important comorbidities and condition-related characteristics.

Where data sources involving Singapore participants are not available, discuss whether population characteristics presented in the submission are likely to be representative of the Singapore setting. Include percentages and means with estimates of uncertainty (e.g. interquartile range, standard deviation and ranges) for these data, where possible.

---

<sup>ii</sup> An example could be consideration of the use of the proposed medicine in a population with a broader age range (e.g. in children) than what is stipulated in the approved indication, if use in the broader population fills an important unmet clinical need or equity consideration and/or constitutes routine clinical practice. Another example could be when the HSA indication is narrower than the indication approved by overseas regulatory agencies and use in line with the overseas indication represents standard of care for that population in Singapore.

### 1.1.4 Intervention and comparator(s)

#### KEY INFORMATION REQUIRED

- Provide a short overview of the proposed medicine
- Provide justification for the proposed comparator(s)
- List the HSA-approved indication(s) for the proposed medicine and comparator(s)
- Indicate whether overseas regulatory approval has been obtained for the proposed medicine and provide US FDA or EMA clinical efficacy and safety reviews
- Summarise the pharmacological action and dosing requirements of the proposed medicine and comparator(s)

#### *Intervention*

Provide a general description of the proposed medicine. Describe any specific response criteria or continuation rules (if applicable) associated with the use of the proposed medicine (e.g. in line with the approved indication or clinical practice guidelines). Discuss whether the response criteria can be reasonably achieved and describe any changes required to enable them to be incorporated into routine clinical practice.

#### *Choice of comparator(s)*

Select the comparator(s) which represents the current alternative therapy routinely prescribed for the condition in Singapore (i.e. the therapy most likely to be replaced in clinical practice, including non-proprietary or biosimilar medicines) and provide justification. In some instances, ACE may advise companies to also conduct analyses which compare the medicine with the most cost-effective treatment option available. The choice of comparator(s) should not be determined based on expert clinical opinion alone, but supported by evidence from other sources such as current local utilisation patterns and evidence-based clinical practice guidelines.

Comparisons with therapies which are used off-label for the indication under evaluation are permitted only if they constitute routine clinical practice in Singapore, informed by local and/or international clinical practice guidelines, and there is sufficient evidence available to robustly assess their safety, clinical effectiveness and cost effectiveness in the proposed population.

Where there is more than one comparator, the main comparator should be the therapy that is most likely to be replaced with the proposed medicine. The following general hierarchy is intended to assist in selecting the appropriate main comparator:

- a) **An alternate mode of administration.** If the proposed medicine is already routinely used in clinical practice for the target population, but with a different mode of administration (e.g. oral, intravenous, subcutaneous injection) compared to the mode of administration presented in the submission, the main comparator would usually be the current mode of administration most commonly prescribed.
- b) **An existing pharmacological analogue.** If the proposed medicine is in a therapeutic class where pharmacological analogues are already used in clinical practice, the main comparator would usually be the analogue that is prescribed for the largest number of patients in the target population.
- c) **New therapeutic class.** If the proposed medicine is in a new therapeutic class but would be used for a target population for which there are other, routinely used medicines, the main comparator would usually be the medicine that is prescribed for the largest number of patients in the target population.

If the proposed medicine is for a target population for which there are no currently available therapies, or the proposed medicine will be used in addition to (“add-on therapy”) – rather than replace – a medicine, the comparator would usually be standard clinical management (such as best supportive care, watchful waiting, conservative management or a surgical procedure). Choice of standard clinical management as the main comparator needs to be justified and clearly defined for the Singapore context.

If the intervention and the comparator form part of a treatment sequence in the pathway of care, it may be appropriate to compare alternative treatment sequences.

### *Different comparators for subgroups*

A different comparator(s) for a subgroup(s) of the target population can be considered if:

- the proposed medicine is claimed to be significantly more effective or has significantly less adverse effects than the main alternative comparator therapy in the subgroup (but not in the remainder of the target population); or
- the main comparator therapy used to treat the overall target population cannot be used in the subgroup due to contraindication, and therefore, does not constitute an alternative therapy for that subgroup.

Sufficient evidence must be provided justifying the claim for the difference in clinical responses for different populations and therefore for the alternative comparator.

### *HSA regulatory approval*

State the indication(s) approved by HSA for the proposed medicine as described in the package insert. Any restrictions or contraindications should also be included. If HSA approval has not been finalised, provide the proposed indication and state anticipated timelines for registration.

Provide information on the overseas registration status of the proposed medicine with the US FDA and/or the EMA<sup>iii</sup>, including registration conditions or boxed warnings that may apply. Include FDA and/or EMA clinical reviews on efficacy and safety of the medicine as supporting documentation to the submission.

### *Characteristics and dosing requirements of the intervention and comparator(s)*

Present a brief description of the characteristics and dosing requirements of the intervention and the comparator(s) in Table 1.1.4.

---

<sup>iii</sup> Regulatory information from TGA (Australia) or MHRA (UK) can also be provided as supporting evidence if available.

**Table 1.1.4: Characteristics, administration and dosing of the intervention and comparator(s)**

	Intervention	Comparator(s)
International non-proprietary name (Brand)		
Available formulation(s), strength(s)		
Therapeutic class		
ATC code <sup>a</sup>		
Pharmacological action		
Route of administration		
HSA-approved dosing regimen		
Average length of treatment course		
Estimated average interval between treatment courses		
Estimated number of repeat treatment courses per patient		
Anticipated care setting		

<sup>a</sup> [www.whooc.no/atc\\_ddd\\_index](http://www.whooc.no/atc_ddd_index)

### *Subsidy/reimbursement status in overseas countries*

If the proposed medicine is already subsidised in other countries<sup>iv</sup>, provide details of the list and ex-manufacturer prices<sup>v</sup> in local currencies and the indications covered, whether RSAs are in place, including any restrictions or initiation/continuation clinical eligibility criteria. Indicate if the proposed medicine has been assessed by the respective national HTA agency in each country.

## 1.2 Clinical management

### KEY INFORMATION REQUIRED

- Present a clinical treatment algorithm for the health condition in line with current clinical practice in Singapore
- Describe the clinical need addressed by the proposed medicine
- Include any patient (and/or carer) testimonials, if relevant
- Describe how the proposed medicine will impact the current treatment algorithm
- Describe any additional tests, training or services that are required to support the use of the proposed medicine

### 1.2.1 Clinical treatment algorithm

Present a flowchart that depicts the current clinical treatment algorithm (or pathway) for the health condition in the target Singapore population. The treatment algorithm should be informed by local and international clinical practice guidelines which define current treatment practices in Singapore. A copy of any relevant guidelines should be provided as an attachment.

<sup>iv</sup> It is preferable to focus this section on countries/regions in the Asia Pacific (particularly Australia, New Zealand, South Korea and Taiwan), the UK and Canada. Examples from other countries in Europe (such as Belgium or Sweden) or Latin America can be provided as additional information if relevant to the submission.

<sup>v</sup> Ex-manufacturer price refers to the price before distributor/wholesaler and/or pharmacy mark-ups are applied. It does not take into account confidential price reductions or rebates.

Important characteristics of the target population (and/or subgroup(s)) should be stated. Include all relevant diagnostic criteria and/or tests to identify the target population, where appropriate. Ensure that the treatment algorithm captures all relevant downstream changes to patient management until the expected end of the condition, capturing all treatment options. The healthcare professional(s) who is responsible for prescribing and/or administering the medicine, and the treatment setting (primary care, inpatient/outpatient hospital setting etc.) should also be shown in the algorithm.

### 1.2.2 Clinical need

Explain the clinical need for the proposed medicine (e.g. how it fills an unmet medical need) and describe how it is expected to change current clinical practice (e.g. does the proposed medicine displace the comparator? Does it change existing treatment sequences? etc.). Explain whether it is administered as monotherapy or in combination with other treatments.

Indicate where the proposed medicine is most likely to fit into the current treatment algorithm (described in subsection 1.2.1) and explain how it is likely to change the treatment algorithm.

Ensure that the population and the use of the proposed medicine and main comparator(s) in the treatment algorithm are consistent with the evaluation framework defined in Subsection 1.1.2.

Describe any issues, if relevant, relating to current clinical management (e.g. uncertainty about standard of care, or variations in local practice).

Patient (and/or carer) testimonials may also be included to substantiate any claims made in this subsection. Present the methods used to select patients, which hospital they receive care from, and state if any fees were paid to them for their testimonials.

Expert opinion from local clinicians through an advisory panel and/or a well-designed survey should be obtained and presented as qualitative or quantitative (but not statistically analysed) information to validate the treatment algorithm and justify the positioning of the proposed medicine in the Singapore context. Present details (name, specialty, institution) of all clinical experts who informed the algorithm and include copies of administered surveys or hypothetical scenarios that were presented to experts, in addition to their responses, as an attachment.

### 1.2.3 Administration, assessment and monitoring requirements

Describe how the proposed medicine is administered. Describe any changes in requirements needed to support the use of the proposed medicine in clinical practice. This includes any tests or investigations that are necessary to determine initial patient eligibility or continuing eligibility for the proposed medicine; any training or education required by healthcare professionals to administer the proposed medicine or monitor for possible adverse reactions; or, any specialised capacity or facilities required at the public healthcare institutions (e.g. diagnostic services).

If the proposed medicine requires a specific skill that is developed over a period of time using the medicine, provide an estimate of the number of patients a healthcare professional would need to treat (as a total number or per year) in order to reach a minimum standard.

## 1.3 Clinical criteria for MAF listing

### KEY INFORMATION REQUIRED

- Define and justify any restriction(s) in the proposed clinical criteria for MAF listing

### 1.3.1 Proposed clinical criteria for MAF listing

The proposed clinical criteria for MAF listing seek to limit eligibility of the treatment to specific patient groups in whom it is clinically effective and cost-effective. State whether the proposed clinical criteria are consistent with:

- i. the (proposed) HSA-approved indication(s);
- ii. the target population and health condition that the treatment is being considered for under the submission (as provided in Subsections 1.1.2 and 1.1.3);
- iii. the clinical and economic evidence presented in Sections 2 and 3.

Where applicable, discuss the implications the MAF listing is likely to have on another MAF-listed treatment.

# Section 2 Clinical evaluation

---

## Introduction

In Section 2, demonstrate the effectiveness and safety of the proposed medicine in line with the evaluation framework (Subsection 1.1.2) by providing:

- a systematic literature search to identify relevant studies;
- an analysis and interpretation of the findings for the whole trial population from each study, including an assessment of risk of bias;
- any additional subgroup analyses, meta-analyses and/or indirect treatment comparisons required to estimate the comparative treatment effect of the proposed medicine; and
- an assessment of the applicability of the evidence to the Singapore setting.

Consideration of a comprehensive evidence base is fundamental to the evaluation process. While information from many sources may inform the evaluation, randomised controlled trials (RCTs) directly comparing the proposed medicine with the relevant comparator(s) are considered to provide the most valid evidence of relative efficacy. When RCTs are not available, data from indirect comparisons of randomised trials should be considered. When relevant, good quality non-randomised studies can be provided as supplementary evidence.

## 2.1 Literature search methods

### KEY INFORMATION REQUIRED

- Define the search terms and criteria used to retrieve the most relevant evidence
- Document the search strategies and the different sources searched

### 2.1.1 Search strategy

The primary objective of the literature search is to retrieve all randomised trials that compare the proposed medicine directly with the main comparator(s) for the target population. Literature searches should be systematic, transparent, reproducible and updated within four months of the date of evidence submission. The methodological standards defined in the *Cochrane Handbook for Systematic Reviews of Interventions*<sup>1</sup> should be followed to generate a high-quality systematic literature search to ensure the accuracy and completeness of the evidence base informing the submission.

#### Search terms

All search terms should be consistent with the population, intervention and comparator(s) defined in the evaluation framework (Subsection 1.1.2). The search terms used for the population should be broad, to avoid excluding potentially relevant studies, and only need to be applied if the proposed medicine is used for multiple indications. It is not necessary to include search terms for outcomes. Present all search terms in Table 2.1.1a.



**Table 2.1.1a: Search terms**

Category	Description	Search terms
<b>Study design</b>	[insert description of category]	[e.g. Cochrane Highly Sensitive Search Strategies for identifying randomised trials in MEDLINE, or MeSH terms and text words for non-randomised study designs]
<b>Population</b>	[insert description of category]	[include MeSH terms, text words and synonyms for the target population/health condition]
<b>Intervention</b>	[insert description of category]	[include known proprietary and non-proprietary names, MeSH terms and developmental/provisional medicine names]
<b>Comparator(s)</b>	[insert description of category]	[include known proprietary and non-proprietary names, MeSH terms and developmental/provisional medicine names]

When searching electronic databases, filters should be initially set to only include randomised trials (use [Cochrane Highly Sensitive Search Strategies](#)<sup>vi</sup>). If no direct randomised comparisons are identified, search separately for randomised trials of either the proposed medicine or the main comparator(s) that would enable an indirect comparison, and present both search strategies. If an indirect comparison is not possible, broaden the search to identify all non-randomised studies (such as cohort studies, case-control studies or quasi-experimental studies) of the proposed medicine, preferably compared with the main comparator(s).

Non-randomised studies may provide useful supplementary evidence to randomised trials about long-term outcomes, rare events and populations that are typical of real-world practice. Examples of when non-randomised studies may inform a submission include:

- when randomised trials are not feasible (e.g. when the health condition is rare);
- when it is unethical to conduct randomised trials (i.e. when the treatment effect is extraordinarily large in observational studies and so equipoise is not achieved);
- when the duration of a randomised trial is insufficient to quantify the effect of treatment over the course of the disease;
- when rare adverse events cannot be feasibly captured within the duration of a randomised trial (in this circumstance provide non-randomised data to supplement randomised trial data);
- when eligibility criteria for the trial are very restrictive, and the applicability of the treatment effect to the target population is unknown (in this circumstance provide non-randomised data to supplement randomised trial data).

Searches in study registries (such as ClinicalTrials.gov) should be simple, highly sensitive, and ideally limited to one search term (e.g. intervention or indication). Due to the varying quality of individual registry entries, it is not advisable to apply additional limitations (e.g. study status or phase).

### Evidence sources

The following sources should be prioritised for searching:

- published literature in electronic databases (MEDLINE [via PubMed], EMBASE, International [Health Technology Assessment database](#) and the [Cochrane Library](#) [which includes the Cochrane Database of Systematic Reviews (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL)])
- registers of randomised trials ([ClinicalTrials.gov](#), [WHO International Clinical Trials Registry Platform](#))
- reference lists of all relevant articles that are obtained.

<sup>vi</sup> <https://training.cochrane.org/handbook/current/chapter-04#section-4-4-7>

Present the full search strategy for PubMed (MEDLINE) in an attachment. The search strategy for EMBASE does not need to be presented but should be available upon request. Summarise the search strategy for each data source in Table 2.1.1b (add rows as needed). Where additional databases are relevant (e.g. PsycINFO for psychology and psychiatry literature), include these in the table.

If relevant evidence is likely to be published in non-journal sources, it may be appropriate to search for grey literature (e.g. institutional reports). Useful sources of grey literature include websites of professional bodies or other organisations relevant to the topic (e.g. US FDA, EMA), [OpenGrey](#), [OpenDOAR](#), [Trip Medical Database](#), and [Grey Matters \(CADTH\)](#)<sup>vii</sup>. This list is not exhaustive, and companies may choose to search other sources as well to inform their submission.

To reduce publication and outcome reporting bias, unpublished data (e.g. in clinical study reports [CSRs]) and/or studies that are pending publication should also be identified. Reasons why each trial has not been published, and expected dates of publication (if applicable) should be provided. Copies of all relevant CSRs and pending publications should be provided as an attachment, where available. Sufficient justification should be provided if CSRs are not available.

**Table 2.1.1b: Details of search strategy for each source**

Source	Date searched	Date span of search	Details of search
MEDLINE (via PubMed)	[insert date]	[insert dates]	State where the complete search strategy (search terms, indexing terms, filters, Boolean operators) has been provided in the submission
EMBASE (e.g. Embase.com)	[insert date]	[insert dates]	State any key differences from the complete search strategy provided for the PubMed search
Cochrane Library <sup>a</sup>	[insert date]	[insert dates]	State any key differences from the complete search strategy provided for the PubMed search
ClinicalTrials.gov <sup>b</sup>	[insert date]	[insert dates]	State any key differences from the complete search strategy provided for the PubMed search
WHO International Clinical Trials Registry Platform <sup>c</sup>	[insert date]	[insert dates]	State any key differences from the complete search strategy provided for the PubMed search
International HTA database <sup>d</sup>	[insert date]	[insert dates]	State any key differences from the complete search strategy provided for the PubMed search
Other sources <sup>e</sup>	[insert date]	[insert dates]	Not applicable

<sup>a</sup> <https://www.cochranelibrary.com/>; <sup>b</sup> <https://clinicaltrials.gov/>; <sup>c</sup> <https://www.who.int/ictrp/en/>; <sup>d</sup> <https://database.inahta.org/>; <sup>e</sup> Report details of supplementary searches, including manual checking of the references in retrieved papers, searches of regulatory dossiers from HSA, US FDA, EMA etc., internal (company) registries, unpublished studies (CSRs) and grey literature.

<sup>vii</sup> OpenGrey: <http://www.opengrey.eu/>; OpenDOAR: <http://v2.sherpa.ac.uk/opendoar/>; Trip: <https://www.tripdatabase.com/>; Grey Matters: <https://www.cadth.ca/resources/finding-evidence/grey-matters>

## 2.2 Identifying and selecting relevant studies

### KEY INFORMATION REQUIRED

- Describe the inclusion and exclusion criteria used to select studies
- Present search results using a PRISMA flowchart
- Create a list of relevant included studies
- Attach copies of included trials
- Identify trials used in an indirect comparison (if applicable)

### 2.2.1 Study selection

Describe the inclusion and exclusion criteria used to select studies in Table 2.2.1 (add rows as necessary).

**Table 2.2.1: Inclusion/exclusion criteria used in the search strategy**


	Inclusion criteria	Exclusion criteria
Population		
Intervention		
Comparator(s)		
Study design		
Language restrictions		

Use a PRISMA flowchart<sup>2,3</sup> (Figure 2.2.1) to indicate the number of studies screened and selected for each search. Extract individual studies from published systematic reviews or meta-analyses and exclude any that do not meet the inclusion criteria.

Direct randomised trials that are selected should form the basis of the submission. If no direct randomised trials are identified that compare the proposed medicine with the main comparator(s), present PRISMA flowcharts separately for the proposed medicine and for the main comparator(s), without excluding studies on the basis of comparator, to enable an indirect comparison of randomised trials. If no randomised trials are identified that would enable an indirect comparison to be conducted, present a third PRISMA flowchart depicting screening for non-randomised studies.

Record all identified studies (with complete references) in an Excel spreadsheet and indicate any excluded studies and the reason for exclusion. Provide the spreadsheet as an attachment.

**Figure 2.2.1: PRISMA flowchart showing screening and selection of studies**



### 2.2.2 List of selected studies

Tabulate all selected studies and relevant systematic reviews or meta-analyses that meet the inclusion criteria in Table 2.2.2. Indicate if any studies had sites in Singapore, and the number of local patients included, if applicable.

**Table 2.2.2: Studies and associated references used in the submission**

Study identifier (ID)	Date of study (start and [expected] completion date)	Status (ongoing/complete)	Source of identification	References
<b>Randomised controlled trials</b>				
Unique (ID) of study used in submission			[e.g. trial registry, electronic database]	•
Study 2				•
<b>Non-randomised studies</b>				
Unique (ID) of study used in submission				•
Study 2				•

Note: add rows and convert to landscape format if required

When data from a single study has been identified in more than one source (e.g. a poster and a published report), or when studies are linked (e.g. an open-label extension to a randomised trial), this should be clearly stated. Ensure that all relevant studies identified outside database searches (e.g. regulatory dossiers, CSRs) are also included.

### 2.2.3 Ongoing studies

List all ongoing studies (including post-marketing surveillance) of the proposed medicine for the indication under evaluation, and their anticipated date of completion.

### 2.2.4 Copies of included studies

Provide copies of all included studies (key publications, supplementary data, CSRs) as attachments to the submission. Provide reputable translations of studies that are not published in English.

Where there is more than one report of a randomised trial, provide the published paper(s) and the complete CSR(s). If the results vary between reports of the same randomised trial, discuss and justify these differences. For any included trial identified from a meta-analysis, provide a copy of the individual trial report or publication(s).

### 2.2.5 Selecting studies for an indirect comparison

If the proposed medicine and the main comparator(s) can be compared using one or more direct randomised trials, an indirect comparison is not required. When direct randomised trials are not available, an indirect comparison of randomised trials should be conducted using established methodology<sup>4,5</sup> (see Subsection 2.6.3).

Justify the exclusion of studies (from Table 2.2.2) that are unsuitable for use in the indirect comparison (e.g. no common reference is available). Do not exclude studies on the basis of heterogeneous characteristics when these are unlikely to modify the treatment effect (or unlikely to affect the assumption of transitivity). Instead, the impact of these studies can be examined by removing them in sensitivity analyses.<sup>viii</sup>

List all indirect comparisons that are possible using the randomised trials within Table 2.2.2. Indirect comparisons using non-randomised studies should be avoided, unless there are no suitable randomised trials available. If there are two or more common reference arms, or if more than one indirect comparison is possible, present a network diagram for each relevant outcome. When a network meta-analysis (NMA) is presented, describe the search strategy required to capture the complete range of studies eligible for the network and any limitations of the search. Any NMAs presented should be based on simple networks (without complex loops and numerous edges<sup>ix</sup>).

Compare the event rates in the common reference groups within trial sets (e.g. A vs C, B vs C). Justify the exclusion of trials with markedly different event rates or treatment effects in the common reference arms,

---

<sup>viii</sup> Framework to improve confidence in the results of an indirect comparison (ITC) by justifying trial selections and presenting sensitivity analyses to demonstrate the impact of trial selection on the ITC results is available in *Report of the Indirect Comparisons Working Group to the Pharmaceutical Benefits Advisory Committee: assessing indirect comparisons* (2008). Available at [www.pbs.gov.au/info/industry/useful-resources/pbac-feedback](http://www.pbs.gov.au/info/industry/useful-resources/pbac-feedback)

<sup>ix</sup> A loop of evidence exists when two or more direct comparisons contribute to an indirect estimate (e.g. A-B and A-C contribute to B-C – this loop is considered closed if direct evidence exists between B-C, and open when direct evidence for this comparison does not exist). An “edge” in an NMA represents a direct (head-to-head) comparison between pairs of interventions.

both within the trial sets and across the indirect comparison. Care should be taken when excluding trials because of differences in event rates in the common reference arms when there is evidence of a constant treatment effect across the event rates. Include any excluded trials in a sensitivity analysis (in Subsection 2.6.3).

Present a list of the studies included in the indirect comparison or sensitivity analyses, and the trials excluded from all analyses in Table 2.2.5.

**Table 2.2.5: Example table of studies included/excluded in the indirect comparison**

Study identifier*	Included/sensitivity analysis/excluded	Justification
Study 1	Included	Not applicable
Study 2	Included	Not applicable
Study 3	Sensitivity analysis	Includes patients with earlier stage of disease than study 1 and study 2
Study 4	Excluded	Common reference arm uses different dosing, reducing likelihood of transitivity

\*Study identifier (ID) should be consistent with the IDs in Table 2.2.2.

## 2.3 Assessing risk of bias in included studies

### KEY INFORMATION REQUIRED

- Assess risk of bias (internal validity) in the included randomised and non-randomised studies
- Present the flow of participants through the included randomised trials

### Internal validity

The reliability of the results from the included studies will depend on the extent to which potential sources of bias have been avoided. Information required to assess the risk of bias for randomised trials and non-randomised studies is described below in subsections 2.3.1 to 2.3.4.

#### 2.3.1 Risk of bias assessment for randomised trials

The preferred approach for assessing the risk of bias for randomised trials is described in [Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions<sup>x</sup>](#).<sup>6</sup> Complete Table 2.3.1 for each included trial (add rows as needed). Provide additional information about the following aspects that may influence an assessment of risk of bias for each trial (state if this information is not relevant or not available):

- **Unmasking.** Discuss whether the proposed medicine or comparator has any effects (such as adverse events) that may result in the participant, the investigator or the outcome assessor ‘guessing’ the treatment allocation of the participant.
- **Treatment decisions.** Describe how decisions such as either stopping treatment or starting a new or concomitant treatment in response to adverse events, treatment failure or inadequate treatment response were made (including responsible personnel). Discuss whether these decisions could affect the measurement of any of the key outcomes.
- **Testing decisions.** Discuss whether the investigator can request tests that are not part of the protocol or that occur at different times than prescribed in the protocol, and whether these tests may affect the measurement of key outcomes or adverse events.

<sup>x</sup> <https://training.cochrane.org/handbook/current/chapter-08>

- **Nature of outcomes.** Regardless of whether the trial is blinded or open-label, discuss whether any of the key outcomes could be affected by a participant’s, investigator’s or outcome assessor’s knowledge of treatment allocation.
- **Missing data.** Discuss the reasons for any loss to follow-up or missing data. Discuss whether the characteristics of the participants who were lost to follow-up are similar to, or different from, those remaining in the trial, and state whether there is a differential loss to follow-up or discontinuation across the arms. Discuss whether missing data are expected to affect the treatment effect, and if the effect is likely to be overestimated or underestimated.

**Table 2.3.1: Risk of bias assessment for randomised trials**

Bias domain	Study ID	Description	Source	Risk categorisation	Effect of bias
Bias arising from the randomisation process	Study 1	[Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. Describe the method used to conceal the allocation sequence in sufficient detail to allow an assessment of whether intervention allocations could have been foreseen in advance of, or during participant enrolment]	[insert source/page number]	[low risk/high risk/some concerns]	[likely effect the bias may have on the direction of the comparative treatment effect]
	Study 2				
Bias due to deviations from intended interventions	Study 1	[Describe all measures used, if any, to blind trial participants and study personnel from knowing which intervention a participant received. Provide any information relating to whether the intended blinding was effective]	[insert source/page number]	[low risk/high risk/some concern]	[likely effect the bias may have on the direction of the comparative treatment effect]
	Study 2				
Bias in measurement of the outcome	Study 1	[Describe all measures used, if any, to blind outcome assessors from knowing which intervention a participant received. Provide any information relating to whether the intended blinding was effective]	[insert source/page number]	[low risk/high risk/some concern]	[likely effect the bias may have on the direction of the comparative treatment effect]
	Study 2				
Bias due to missing outcome data	Study 1	[Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), and the reasons for attrition/exclusions, where reported]	[insert source/page number]	[low risk/high risk/some concern]	[likely effect the bias may have on the direction of the comparative treatment effect]
	Study 2				
Bias in selection of the reported result	Study 1	[State how the possibility of selective outcome reporting was examined, and what was found]	[insert source/page number]	[low risk/high risk/some concern]	[likely effect the bias may have on the direction of the comparative treatment effect]
	Study 2				

Other sources of bias*	Study 1	[State any important concerns about the study design that are not addressed elsewhere in this table]	[insert source/page number]	[low risk/high risk/some concern]	[likely effect the bias may have on the direction of the comparative treatment effect]
	Study 2				

Note: Adapted from the [Cochrane Collaboration's tool for assessing risk of bias RoB 2](#)<sup>6</sup>

\* Some examples include use of non-validated or insensitive measurement instruments, selective reporting of subgroups, and inappropriate administration of an intervention

### 2.3.2 Flow of participants

Present the flow of participants through each stage (enrolment, intervention allocation, follow-up and data analysis) of each randomised trial in Table 2.3.2 (adapt as necessary to record participants who crossed over treatment groups etc.).

**Table 2.3.2: Flow of participants through the included randomised trials**

Study ID	Intervention arm	No. randomised	Did not receive intervention	Lost to follow-up	Discontinued	Analysed	Median duration of follow-up	Source of information
Study 1	Proposed medicine	<i>N</i>	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> months (range)	[Reference]
	Comparator	<i>N</i>	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> months (range)	[Reference]
Study 2								

### 2.3.3 Risk of bias assessment for systematic reviews and meta-analyses

Assess the risk of bias for included individual trials within a systematic review or meta-analysis. Where individual trials are not able to be retrieved and the submission relies on a pooled treatment effect from the published systematic review or meta-analysis, clearly report the risk of bias assessment undertaken by the authors and assess the methodological quality of the systematic review using a validated tool (e.g. AMSTAR<sup>7</sup> or Oxman and Guyatt index<sup>8</sup>).

### 2.3.4 Risk of bias assessment for non-randomised studies

Due to the large variety of non-randomised study designs and their varying susceptibility to different biases, it is complex to assess risk of bias for this type of evidence.

The internal validity of a non-randomised study can be elicited by reference to how the study design or conduct differs from that of a well-designed, double-blind randomised controlled trial. A risk of bias assessment for a non-randomised study should cover the following types of bias: selection bias (including bias due to confounding), performance bias, detection bias, attrition bias, and reporting bias.

Potential sources of bias include (but are not limited to):

- imbalances in baseline or post-baseline characteristics that are potential confounders;
- treatment switching or imbalances in the use of later-line or concomitant therapies;
- patients who are selected into the study and are already receiving the intervention (or comparator), where these patients are different to those who are not already receiving treatment, or have started then stopped treatment, and where these two groups may have different expected outcomes;



- a definition of the intervention or comparator (doses, duration, setting) that is too broad or ambiguous, and where allocation of intervention status may be influenced by the knowledge of outcomes;
- missing data that affect the estimate of the outcome;
- outcome measures that are subjective, or outcome assessors who are not blinded to treatment allocation;
- timing of measurement of outcomes, or the method of determining outcomes, that differs between study arms;
- reporting of outcomes, time points or subgroups that were not pre-defined in the protocol.

Several risk of bias tools have been developed to identify and report study characteristics that may impact on the comparative treatment effect in non-randomised studies (e.g. ROBINS-I<sup>9</sup> [previously called ACROBAT-NRSI] and RoBANS<sup>10</sup>). Use the domains defined in a validated tool to describe whether there is a risk of bias for each non-randomised study, and any measures taken to mitigate the risk. Provide references to support the information. It is not necessary to complete the chosen tool.

## 2.4 Characteristics of included studies

### KEY INFORMATION REQUIRED

- Present the trial design and eligibility criteria for participants in each study
- Present the baseline demographic and clinical characteristics of participants and relevant subgroups in each study
- Provide details of the treatments in each study and for relevant subgroups
- Describe the primary outcome and important patient-relevant outcomes in each study
- Define the minimal clinically important difference (MCID) for the primary outcome and key patient-relevant outcomes
- Specify the non-inferiority margin for the primary outcome, if appropriate

### 2.4.1 Characteristics of included randomised trials

In Table 2.4.1, describe the trial design and provide details about the eligibility criteria for participants and the treatments administered in each included randomised trial, in line with the requirements of the [CONSORT 2010 checklist](#)<sup>xi</sup> (items 3 to 5).<sup>11</sup> The table should include the following:

- **Trial design.** A brief description of the trial design (e.g. parallel group, multi-arm parallel, crossover, factorial) including details of randomisation and whether the trial was designed to assess superiority or non-inferiority.
- **Eligibility criteria.** Comprehensive description of the eligibility criteria used to recruit trial participants, including any assessments used to select participants.
- **Settings and locations where the data were collected.** Describe the locations where the trial was conducted, including the country and care setting (if applicable).
- **Trial interventions.** Provide the intended treatment regimens (for intervention and comparators) outlined in the trial protocol. Include dosing information (when/how treatments were administered), duration of treatment, continuation or stopping criteria, and titration schedules, if appropriate. Include concomitant medications permitted and disallowed during the trial.

<sup>xi</sup> <https://www.equator-network.org/reporting-guidelines/consort/>

**Table 2.4.1: Comparative summary of trial design, eligibility criteria and treatments for included randomised trials**

Study ID	Study 1	Study 2
Trial design		
Eligibility criteria for participants		
Settings and locations where data were collected		
Trial interventions for each group		

Note: add columns as necessary

### 2.4.2 Participants

Describe the baseline demographic and clinical characteristics of the participants (e.g. age, sex, disease severity, duration of previous treatments etc.) in each randomised group or study arm in Table 2.4.2. Information should be provided for the whole trial population as well as any subgroups (and their complements) to confirm whether there are imbalances in important prognostic factors or effect modifiers across arms, or between a subgroup and its complement. Where baseline characteristics are unavailable for a subgroup(s), state why and provide any relevant details to reduce the uncertainty related to an imbalance of patient characteristics within the subgroup analysis.

**Table 2.4.2: Characteristics of participants in the randomised trials across treatment groups**

Baseline characteristic	Treatment group X (n=)	Treatment group Y (n=)
Study ID (N=)		
Mean (SD) age		
Proportion of males (%)		
[Add more rows as required]		
Study ID (N=)		
Mean (SD) age		
Proportion of males (%)		
[add more rows as needed]		

Note: add columns and rows as necessary; SD = standard deviation

Report differences in the baseline demographic or clinical characteristics across arms in the trials or across trials and indicate whether differences are clinically important and/or statistically significant. For each identified difference, discuss the likely impact on the magnitude and direction of the treatment effect.

Where there are differences between treatment arms (or trials) in terms of the extent or timing of patients lost to follow-up, patient withdrawals, or missed or refused assessments (as described in 2.3.2), present the baseline demographic and clinical characteristics for the following groups (as an attachment):

- patients who were lost to follow-up compared with those who were not;
- patients who withdrew from the trial compared with those who did not;
- patients who missed an assessment compared with those who were assessed.

### 2.4.3 Treatment details

State whether the dose or treatment regimen (including the use of concomitant treatments) in each trial is in line with the approved dosage, and/or supported by clinical practice guidelines. Justify where the protocol's specified dose (or the actual dose in the trial) differs from recommended dosing<sup>xii</sup>.

<sup>xii</sup> Recommended dosing refers to regimens that are in line with HSA approved dosing, or recommended dosing regimens in clinical practice guidelines that inform treatment decisions in Singapore.

Provide the average dose of each treatment administered in each trial, taking the dosing frequency (and/or proportion of participants taking particular doses) and average duration of treatment into consideration. Indicate if different treatment regimens were administered for subgroups (if applicable). Discuss differences of treatment duration across arms and across trials and explain any differences observed.

If participants received active treatments following cessation of the proposed medicine or comparator, provide details on dose and duration of these treatments across the trial arms.

#### 2.4.4 Outcomes

For each trial, present the primary outcome specified in the trial protocol and any secondary outcomes that are patient-relevant ([CONSORT 2010 checklist](#) items 6a, 6b, 12a and 12b) in Table 2.4.4. For each outcome:

- state whether it was the primary outcome;
- describe the instrument used to measure the outcome (e.g. questionnaire, blood test) and the personnel who administered the instrument (e.g. investigator, study nurse);
- describe the threshold for categorisation as an outcome, if applicable;
- describe the timing of the outcome assessment;
- describe the personnel who determined whether the outcome had been achieved;
- describe the methods of statistical analysis;
- describe the population in which the analysis is performed (i.e. intention to treat (ITT), per protocol);
- describe how the sample size was determined;
- summarise the power calculations for outcomes for which the trial was designed to detect a change.

For each instrument, state whether the instrument is validated in the population and the circumstances in which it is applied in the study, and provide a reference(s) for its validation.

**Table 2.4.4: Differences in outcomes or analyses for included studies**

Outcome	Study ID	Measurement of outcome and timing of assessment	Method of analysis	Sample size, power calculation
Example: overall survival [primary outcome]	Study 1	[description of outcome, instrument used to measure outcome, units of measurement, personnel who determined if outcome was achieved, timing of assessment]	[name of statistical test and sufficient details about how the analysis was performed and the population [ITT etc.] in which the analysis was performed]	[describe how sample size was determined and summarise power calculations]
	Study 2			
	Study 3			
Example: progression-free survival [secondary outcome]	Study 1			
	Study 2			

Note: add columns and rows as necessary (landscape format is recommended)

#### Composite outcomes

A composite outcome is one in which two or more distinct clinical endpoints (called component endpoints) are combined. A composite endpoint is usually considered to have been experienced when the first of any of the individual component endpoints occurs, even though subsequent component endpoints may also occur.

If one or more of the reported outcomes is a composite, discuss and compare the clinical importance of each

of the components of the composite. Disaggregate the composite outcome and present the results of each component as a secondary outcome.

### *Surrogate outcomes*

A surrogate outcome is an endpoint (either a biomarker<sup>xiii</sup> or intermediate endpoint<sup>xiv</sup>) that is intended to provide an indirect measurement of a clinical effect in situations where direct measurement is not feasible or practical.<sup>13</sup> Submissions that do not rely on proposed surrogate measures (PSM) to inform effectiveness in terms of patient-relevant or clinically relevant outcomes are preferred, given few PSMs to date have been robustly shown to be true measures of tangible clinical benefit.

Final clinical endpoints are preferred for measures of effectiveness. Only present a surrogate outcome (that is not the primary outcome) when it is critical to the therapeutic conclusion or economic evaluation. State the target clinical (patient-relevant) outcome (TCO) which the surrogate outcome intends to measure and present evidence<sup>xv</sup> to establish the biological plausibility for the link between the PSM and the TCO, including the role of the PSM in the causal pathway to the clinical outcome, and any limitations of the evidence or contradictory findings. Present any statistical associations (including the strength of the association and the precision) and include relevant statistical outputs (e.g. regression coefficients and R-squared) as an attachment.

Establish the PSM-TCO comparative treatment effect relationship using empirical evidence (preferably from RCTs that measure both the PSM and TCO). Present the characteristics (e.g. patient and condition characteristics, treatment settings, measurement of PSM and TCO) and results of each trial in a table. Where multiple trials exist for a class of medicine, present results of a meta-analysis for individual studies. Provide any meta-regression outputs, the R-squared for trials, and the surrogate threshold effect.

Discuss the PSM-TCO comparative treatment effect relationship, including details of the shape of the relationship (e.g. linear, exponential) and whether there is any evidence of a floor or ceiling effect, below or above which the comparative treatment effect on the PSM no longer predicts a comparative treatment effect on the TCO.<sup>xvi</sup>

Discuss where the PSM-TCO comparative treatment effect relationship differs across trials, medicines or mechanisms of action.<sup>xvii</sup> Where trials are removed, for example, that have medicines of different mechanisms of action or populations that do not reflect the evaluation framework (Subsection 1.1.2), present the estimate of the PSM-TCO comparative treatment effect relationship with all trials included as the base case and only remove less-relevant trials in a sensitivity analysis. Where more than one estimate of the PSM-TCO comparative treatment effect relationship has been established, justify the selection of one estimate for the base case, and present the remainder as sensitivity analyses.

---

<sup>xiii</sup> A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to an intervention (e.g. cholesterol level, HbA1c). A biomarker must lie on the pathophysiologic causal pathway of the disease; must be correlated with a clinical endpoint to be useful in detecting disease and assessing prognosis, and validated.<sup>12</sup>

<sup>xiv</sup> An intermediate endpoint measures a function or a symptom (e.g. disease-free survival, exercise tolerance, angina frequency) but is not the ultimate endpoint of the disease, such as survival or the rate of irreversible morbidity (stroke, myocardial infarction).

<sup>xv</sup> Evidence may include in vitro studies, animal studies, case reports, cross-sectional observational studies, ecological association studies, retrospective observational cohort studies, non-population based prospective observational cohort studies, or population-based prospective observational cohort studies.

<sup>xvi</sup> Further information on methods to validate the PSM-TCO comparative treatment effectiveness relationship is available in a report by the PBAC Surrogate to Final Outcomes Working Group: [www.pbs.gov.au/info/industry/useful-resources/pbac-feedback](http://www.pbs.gov.au/info/industry/useful-resources/pbac-feedback)

<sup>xvii</sup> Possible causes of heterogeneity include, but are not limited to mechanism of action, population and disease characteristics, definition or measurement of the PSM or TCO, quality of the trial and treatment settings.

The PSM-TCO comparative treatment effect relationship is usually only considered valid if it is:

- **Condition-specific.** Validity of the relationship should be demonstrated for different stages of a condition;
- **Population-specific.** Validity of the relationship should be justified for populations with a condition who have different characteristics (age, gender, co-morbidities);
- **Pharmacological class-specific.** The relationship should be validated for each pharmacological class separately (e.g. LDL-C as a surrogate of CHD event risk is validated for statins but not for fibrates). An attempt to extrapolate the validity of the PSM-TCO relationship to other pharmacological classes within an indication should be justified and substantiated with supporting evidence.

When applying the PSM-TCO comparative treatment effect relationship to the trial evidence for the proposed medicine, it is critical that both the proposed medicine and the main comparator have the same mechanism(s) of action as medicines for which the PSM-TCO comparative treatment effect has been established, otherwise the transformation of the PSM to the TCO will be uncertain. In such instances, explain how any differences will not result in a different measurement of the PSM-TCO comparative treatment effect relationship.

It is not necessary to describe the transformation of a PSM to TCO in detail if the surrogate outcome has previously been accepted as valid by one of ACE's decision-making committees or an international HTA agency (e.g. PBAC, NICE or CADTH) and:

- The proposed treatment effect is within the range of the comparative treatment effect identified in the clinical evidence associated with the transformation that was previously accepted;
- The proposed medicine will be used in the same population as the previously accepted transformation; and
- The treatments in the evidence used to previously validate the surrogate, the main comparator and the proposed medicine are all in the same class or have a similar mechanism of action.

If available, provide a summary of previous decisions about the PSM-TCO comparative treatment effect relationship reported by international HTA agencies (e.g. NICE, PBAC, CADTH) as supporting evidence.

### *Patient-reported outcome measures*

Patient-reported outcomes describe any outcomes evaluated directly by a patient (or their carer/family), based on their perception of their current health state. They are reported using generic (e.g. Short Form-36 [SF-36]), condition-specific (e.g. St George's respiratory questionnaire) or population-specific questionnaires (e.g. Child health questionnaire), that measure quality of life, health status, symptoms or function.

Patient-reported outcome measures may also include multi-attribute utility instruments (MAUIs), in which the scoring method for the instrument is anchored on a quality-adjusted life year scale of 0 (death) to 1 (full health). Several commonly used MAUIs which can be used in submissions without a detailed discussion of their validity or reliability, are the Health Utilities Index (HUI2 or HUI3), the EQ5D-3L ('EuroQol'), the SF-6D (a preference-based single index measure derived from a selection of SF-36 items), the Assessment of Quality of Life (AQoL) instruments, and the Child Health Utility 9D (CHU9D) index for children and adolescents.

Where a less common patient-reported outcome measure or MAUI is used in the submission, provide a reference (as an attachment) that describes:

- domains of quality of life, symptoms or function that are covered by the instrument;
- scoring method of the instrument;
- validity and reliability of the instrument;

- responsiveness of the instrument to differences in health states between individuals and to changes in health states over time experienced by an individual;
- clinical importance (MCID) of any differences detected by the instrument.

For all patient-reported outcome measures, explain how they are used within the study, including

- the timing of assessments (frequency and at what points in the study the instruments were administered);
- who administered the questionnaire and in what setting; and
- why assessments were missed and how missed assessments were dealt with.

Provide the characteristics of the patients who missed or refused to complete the relevant questionnaires, and compare them with those patients who completed the questionnaires. Describe any methods that were used to adjust for response bias, or describe the effect of missed assessments on the comparison of patient-reported outcome measures across the arms of the study.

### 2.4.5 Minimal clinically important difference (MCID)

An MCID is the smallest difference in a particular outcome that patients perceive as important (beneficial or detrimental). An MCID should be specified for the primary outcome and the main patient-relevant outcome (where this is not the primary outcome).

In Table 2.4.5, describe the proposed MCIDs for the key outcomes in the included studies. Sources of MCIDs are variable and can include:

- the study protocol;
- a MCID previously accepted by one of ACE’s decision-makers (e.g. MOH Drug Advisory Committee [DAC]), or by another reference HTA agency (e.g. PBAC, PHARMAC, NICE or CADTH), that is relevant to both the trial population and the indication under evaluation;
- a commonly accepted MCID in the literature, relevant to the population/indication under evaluation;
- expert consensus elicited through an internal study.

If alternative MCIDs for the same outcome are available, discuss any differences and justify the choice of MCID for the purpose of this submission.

**Table 2.4.5: Details of MCIDs for key outcomes in the included trials**

Proposed MCID (value)	[Present this as an absolute change in units]
Source of MCID	[Provide source]
Method of derivation of the MCID	[e.g. anchor-based assessment, expert consensus, statistical methods]
Comparison of the derivation of the MCID and the studies included in the submission	[Describe]
Population	[Describe any differences in the population or indication]
Outcome definition	[Describe any differences in the outcome definition]
Baseline value for measurement	[Describe any differences in the baseline value from which change was measured]

Where the primary outcome is a surrogate for another endpoint (e.g. cholesterol levels for cardiovascular events), the justification of an MCID should be the change in the surrogate required to result in a meaningful

change in the target outcome.

For patient-relevant outcomes that are measured on a scale (e.g. a patient-reported outcome measure, a quality-of-life instrument, the Visual Analogue Scale, the 6-Minute Walk Distance test), the MCID should preferably be established using an anchor approach.<sup>14,15</sup> For these types of outcomes, the MCID can be used as a threshold, beyond which a patient would be regarded as a 'responder'.

#### 2.4.6 Non-inferiority margin

A claim of non-inferiority implies that the proposed medicine is no worse than the main comparator in terms of effectiveness and safety. However, a lack of a statistically significant difference between the proposed medicine and the comparator does not adequately establish non-inferiority. It is common practice to require that the confidence limits of the difference in treatment effect do not include an *a priori* stated clinically meaningful difference favouring the comparator.

Establish a non-inferiority margin for the primary outcome and the most important patient-relevant outcome (where this is not the primary outcome) based on statistical reasoning and clinical judgement to assure that the proposed medicine is not inferior to the main comparator by an important difference. Propose a magnitude of difference in each outcome that would be regarded as unimportant (e.g. less than a minimal clinically important difference) and can be used as the non-inferiority margin, indicating whether there is agreement across multiple sources.

Where the included trial has pre-specified a non-inferiority margin, present and justify the choice of the margin (referring to the trial protocol and/or additional supporting evidence).

Often non-inferiority margins are defined post hoc (not pre-specified) when there are:

- failed superiority trials of the proposed medicine versus comparator;
- indirect comparisons of the proposed medicine versus the comparator via a common reference; and
- outcomes that did not have a pre-specified non-inferiority margin.

When selecting post hoc non-inferiority margins, demonstrate that an exhaustive search has been conducted to identify relevant information, which justifies a similar proposed margin that represents an unimportant loss of treatment effect. Justify the selection of one particular estimate as the proposed non-inferiority margin.

## 2.5 Results: whole trial population

### KEY INFORMATION REQUIRED

- Present the results from each included study for all relevant outcomes for the whole trial population
- Present adverse event data

Report the results from the studies for the whole trial population in this subsection. Additional analyses, such as subgroup analyses, meta-analyses, indirect comparisons or adjustments for treatment switching, are presented in Subsection 2.6.

## 2.5.1 Clinical effectiveness

Present results for all relevant outcomes defined in Subsection 2.4.4 for the whole trial population in each included study. Cross-reference the results to the relevant pages of the CSRs or trial publications.

Examples of how to present the different types of data are shown in Tables 2.5.1a-2.5.1c (adapt tables as required). Where possible, the following information should be presented for each outcome:

- the timing of the outcome assessment (e.g. FEV<sub>1</sub> at week 12);
- the number of patients at risk or providing data to the results;
- the number of patients experiencing the event (if appropriate);
- the percentage of patients with the event, and means (standard deviation) or medians (interquartile range) within groups as appropriate;
- the size of the treatment effect (both relative and absolute differences between groups, and CIs);
- an interpretation of the results;
- a discussion of any clinically important differences in the results between the arms of the trial and between trials, in the context of the nominated MCID.

### Dichotomous data

**Table 2.5.1a: Results of [outcome] across the studies: dichotomous data**

Study ID	n/N with event (%) for proposed medicine	n/N with event (%) for main comparator	Relative risk (95% CI) (p value)	Risk difference (95% CI) (p value)
Study 1	[add]	[add]	[add]	[add]
Study 2	[add]	[add]	[add]	[add]
[etc]	[etc]	[etc]	[etc]	[etc]

CI = confidence interval; n = number of participants with event; N = total participants in group

### Continuous data

Many trials measure a continuous variable at baseline and again at a pre-specified time point. Analysis of covariance (ANCOVA) is the most commonly used approach to measure treatment effectiveness from such trials. It is usually presented as the difference in mean change scores, adjusted for baseline scores (as per Table 2.5.1b).

In addition to the information reported in Table 2.5.1b, report and justify the covariates used in the ANCOVA (and how they were tested) and discuss the effect of controlling for covariates on the estimated comparative treatment effect.

**Table 2.5.1b: Results of [outcome] across the studies: continuous data**

Study ID	Mean (SD) [Proposed medicine]			Mean (SD) [Main comparator]			Mean difference (95% CI)	ANCOVA (95% CI)
	Baseline	End point	Change	Baseline	End point	Change		
Study 1 <sup>a</sup>	[add]	[add]	[add]	[add]	[add]	[add]	[add]	[add]
Study 2 <sup>a</sup>	[add]	[add]	[add]	[add]	[add]	[add]	[add]	[add]
[etc]	[etc]	[etc]	[etc]	[etc]	[etc]	[etc]	[etc]	[etc]

ANCOVA = analysis of covariance; CI = confidence interval; SD = standard deviation

<sup>a</sup> For each study, state the number of participants in the group and the number reporting data for each time point.

If the outcome was measured at more than one time-point, justify why a specific end point was selected and discuss whether the treatment effect differs across other time points (indicate where relevant data supporting the time-point selected are located in the CSR). Where continuous data are translated to dichotomous data in



the economic evaluation or to support the clinical claim, justify the use of the threshold to convert the data. If the threshold is not well supported by the literature, present sensitivity analyses using different thresholds, or present a cumulative distribution function of the continuous outcome separated by treatment arm. Clearly show the effect of the choice of threshold to determine the dichotomous outcome on the comparative treatment effect.

### Time-to-event data

Present relevant Kaplan–Meier curves for each included study. The numbers at risk at regular time intervals should also be provided below the Kaplan-Meier curve. Provide sufficient justification if curves cannot be provided.

**Table 2.5.1c: Results of [outcome] across the studies: time-to-event data**

Study ID	Proposed medicine		Main comparator		Difference in median	P value (log rank test)	Hazard ratio (95% CI)
	n/N with event (%)	Median time to event (95% CI)	n/N with event (%)	Median time to event (95% CI)			
Study 1	[add]	[add]	[add]	[add]	[add]	[add]	[add]
Study 2	[add]	[add]	[add]	[add]	[add]	[add]	[add]
[etc]	[etc]	[etc]	[etc]	[etc]	[etc]	[etc]	[etc]

CI = confidence interval; n = number of participants reporting data; N = total participants in group

Describe the method for analysing the time-to-event data, including any assumptions and how they have been tested. Discuss whether the results are consistent with the assumption of constant proportional hazards. Where the assumption of constant proportional hazards is not reasonable, present alternative methods for estimating comparative effectiveness.

### Multi-attribute utility instrument (MAUI) data

Report MAUI results (with 95% CI) for each time point and each arm within the trial. Report the number of patients eligible for the questionnaire and the number of patients who responded for each time point. Report the difference between the arms (with 95% CI) as the integrals between the mean utility weights obtained over time up to the median (or other relevant time point) follow-up in the trial. If an alternative approach for comparing MAUIs was used, explain how this was done. Discuss the interpretation of these results.

If the proposed medicine has already been appraised by NICE, use the scoring algorithm derived from the UK population which informed the submission, then present a sensitivity analysis using a scoring algorithm derived from the general population in Singapore (if available). If more than one MAUI has been used in the included study, compare the results from the two MAUIs.

### Effectiveness in the context of minimal clinically important difference

Discuss the results of the primary outcome and main patient-relevant outcome with reference to the MCID. State whether the intervention group has achieved a difference as large as or larger than the proposed MCID when compared with the comparator group. Comment on the extent to which the confidence interval for the comparison includes differences smaller than the proposed MCID.

### Applying a non-inferiority margin

Compare the least favourable tail of a 95% CI with the non-inferiority margin (defined in Subsection 2.4.6) and determine whether the ‘worst’ result would be regarded as non-inferior. Assess this using both intention-to-

treat and per-protocol approaches, when available, and discuss any discrepancies between both approaches.

Discuss other considerations that may support the conclusion of non-inferiority (e.g. whether the medicines are from the same class, the point estimate favours the proposed medicine, whether there are safety or tolerability advantages of the proposed medicine).

Explain and justify all approaches undertaken to establish non-inferiority and demonstrate that the proposed medicine is superior to placebo and is not inferior to the proposed comparator by an important extent.

### 2.5.2 Adverse events

Report the following categories of adverse events in Table 2.5.2a for each study:

- any adverse event;
- any adverse event resulting in discontinuation of the randomised treatment;
- any serious adverse event;
- any adverse event resulting in death;
- any other adverse events (e.g. treatment-emergent adverse events) where the frequency or severity differs substantially across treatment groups in the included studies, if applicable.

**Table 2.5.2a: Summary of adverse events in included studies**

	Study 1				Study 2			
	Intervention (n = x)	Comparator (n = x)	RR (95% CI)	RD (95% CI)	Intervention (n = x)	Comparator (n = x)	RR (95% CI)	RD (95% CI)
Total number of adverse events**	n (%)	n (%)			n (%)	n (%)		
Total number of serious adverse events**	n (%)	n (%)			n (%)	n (%)		
Total number of deaths due to adverse events	n (%)	n (%)			n (%)	n (%)		
Total number of adverse events leading to treatment discontinuation	n (%)	n (%)			n (%)	n (%)		
[Add rows as necessary]								

\*For non-comparative studies, only complete the column for the intervention.

\*\* If trials report number of patients who experienced an adverse event or serious adverse event, rather than total number of adverse events (or serious adverse events), amend description in first column.

For specific adverse events, consider presenting a more detailed summary table (e.g. Table 2.5.2b) to compare their frequency and severity across treatment arms. Analyse the relative adverse event rates (events per period at risk). Present the assumptions associated with any statistical analyses and describe how they were tested.

**Table 2.5.2b: Frequency and severity of adverse events in included studies**

Study ID								
System organ/ class/adverse events	All grades				Serious adverse events			
	Intervention (n = x)	Comparator (n = x)	RR (95% CI)	RD (95% CI)	Intervention (n = x)	Comparator (n = x)	RR (95% CI)	RD (95% CI)
Class 1 (for example, nervous system disorders)								
Adverse event 1	n (%)	n (%)			n (%)	n (%)		
Adverse event 2	n (%)	n (%)			n (%)	n (%)		
Class 2 (for example, vascular disorders)								
Adverse event 3	n (%)	n (%)			n (%)	n (%)		
Adverse event 4	n (%)	n (%)			n (%)	n (%)		
CI, confidence interval; RR, relative risk; RD, risk difference Adapted from European Public Assessment Reports published by the European Medicines Agency								

## 2.6 Results: additional analyses

### KEY INFORMATION REQUIRED

Present the results of any additional relevant analyses including:

- subgroup analyses
- meta-analyses
- indirect comparisons
- adjustments for treatment switching

### 2.6.1 Subgroup analyses

Submissions based on the whole population of a randomised trial are preferred. If only some of the participants from the whole trial population are likely to be eligible for treatment according to the evaluation framework, present a subgroup analysis to show the relative effectiveness of the proposed medicine in eligible participants.

Indicate which subgroup analyses were pre-specified in the trial protocol and whether randomisation was stratified by the subgroup. If any subgroup analyses were performed post hoc, provide justification for consideration of these subgroups.

Clarify why the trial(s) enrolled a broader population than the subgroup, and why the proposed medicine should not be funded for patients in the complement of the subgroup (e.g. is it not effective in the complement, or does it work in the complement but is not cost effective? etc.).

For each outcome relevant to the submission, present the relative and absolute treatment effect measures for the whole trial population, the subgroup and the complement (Table 2.6.1)<sup>xviii</sup>. Discuss whether the differences between subgroups are clinically plausible and whether the magnitude of the differences is practically important.

Test for interaction between the subgroup and its complement to support and quantify the association between the treatment effect and the covariate defining the subgroup. If the subgroup is defined by a

<sup>xviii</sup> Where the whole trial population for each trial is adequately captured in Table 2.6.1, there is no need to present extensive tables in Section 2.5.

continuous variable, present a sensitivity analysis on the threshold value chosen to define the subgroup for different thresholds.

Present adverse event data for each subgroup in a table. Take care when testing for interaction where the average period at risk per participant varies substantially between the relevant subgroup and its complement.

**Table 2.6.1: Results of [outcome] within the studies: dichotomous data\***

Population	Study ID	Proposed medicine [n with event/N (%)]	Main comparator [n with event/N (%)]	RR (95% CI)	RD (95% CI)
Whole trial population	Study 1	[add]	[add]	[add]	[add]
	Study 2	[add]	[add]	[add]	[add]
	Meta-analysis of overall trial results	[add]	[add]	RR (95% CI) (k = )	RD (95% CI) (k = )
	I <sup>2</sup> statistic with 95% uncertainty interval	–	–	[add]	[add]
Identified subgroup	Study 1	[add]	[add]	[add]	[add]
	Study 2	[add]	[add]	[add]	[add]
	Meta-analysis of identified subgroup	[add]	[add]	RR (95% CI) (k = )	RD (95% CI) (k = )
	I <sup>2</sup> statistic with 95% uncertainty interval	–	–	[add]	[add]
Complement of subgroup	Study 1	[add]	[add]	[add]	[add]
	Study 2	[add]	[add]	[add]	[add]
	Meta-analysis of complement of subgroup	[add]	[add]	RR (95% CI) (k = )	RD (95% CI) (k = )
	I <sup>2</sup> statistic with 95% uncertainty interval	–	–	[add]	[add]
Test for treatment effect variation	–	–	–	P =	P =

\*Adapt the table to include continuous or time-series data if required

– = not required; CI = confidence interval; k = number of studies contributing to the pooled estimate of effect; n = number of participants with event; N = total participants in group; P = probability; RD = risk difference; RR = relative risk

## 2.6.2 Meta-analyses

If more than one study reports a relevant outcome, where feasible, present a meta-analysis<sup>xix</sup> of the aggregated results of each study that reported the outcome, and state the software used for the analysis (e.g. RevMan,<sup>16</sup> Stata<sup>17</sup>). Justify any decision to not present a pooled result for any relevant outcomes (e.g. because there is significant clinical heterogeneity between studies).

Use a random effects model<sup>18</sup> to pool group-level trial data. Explain and justify any other method used (e.g. fixed effects). Provide adequate detail of the methods used, and all references which informed the meta-analyses, so that the results are verifiable and can be independently reproduced, if required.

### Presenting the results

Present the pooled estimates with their 95% CIs in Table 2.6.2. Report results for the extent of statistical heterogeneity observed using a chi-square (Cochran’s Q test) statistic, degrees of freedom, and the I-squared

<sup>xix</sup> Standardised methods to conduct a meta-analysis are described [Chapter 10 of the Cochrane handbook](#).

(I<sup>2</sup>) statistic with its 95% uncertainty interval.

Comment on the consistency of treatment effects across the trials. Include a forest plot of relative and absolute treatment effects and discuss the results for each outcome.

**Table 2.6.2: Example of tables to include relevant information on pooled (dichotomous\*) results**

Measurement	Outcome	Chi-square (Q) for heterogeneity, df and P value	I <sup>2</sup> statistic with 95% uncertainty interval
Pooled result from random effects model (RR, 95% CI, k)	[add]	[add]	[add]
Pooled result from random effects model (OR, 95% CI, k)	[add]	[add]	[add]
Pooled result from random effects model (RD, 95% CI, k)	[add]	[add]	[add]

**\*Adapt the table as necessary to report results for continuous outcomes or time-series data**

CI = confidence interval; df = degrees of freedom; k = number of studies contributing to the pooled estimate of effect; OR = odds ratio; P = probability; RD = risk difference; RR = relative risk

Discuss and explain any heterogeneity of treatment effect across trials and the I<sup>2</sup> statistic. There are several confounding factors that can cause heterogeneity such as variations in study design, study participants, treatments, setting, geographic location and outcome measures. Where there are strong biological or methodological grounds for heterogeneity, consider presenting sensitivity analyses that explore the impact of these factors. Discuss any implications of factors that may cause heterogeneity of treatment effect with regard to the proposed target population.

If there is a risk of heterogeneity because the trials have different follow-up periods, present the pooled incidence rate differences.

### Adverse event data

Present a meta-analysis of adverse event data in line with the specifications in Table 2.6.2. Report the duration over which adverse events were recorded for each trial.

### 2.6.3 Indirect comparisons

Indirect comparisons refer to the synthesis of data from studies in which the interventions of interest have not been compared directly (head-to-head) with each other but have been compared indirectly using a common comparator. There are several methods that can be used, such as the Bucher single pairwise method,<sup>19</sup> matching-adjusted indirect comparison,<sup>20</sup> simulated treatment comparison,<sup>21</sup> network meta-analysis (NMA) or mixed treatment comparison (MTC). All methods chosen to conduct an indirect comparison to inform the submission should be described in sufficient detail and justified. An indirect comparison should not be conducted if the transitivity assumption<sup>xx</sup> is not met.

Where there are multiple common reference arms, it is preferable to perform pairwise indirect comparisons using the Bucher method<sup>xxi</sup> for each possible evidence loop and discuss any differences.

<sup>xx</sup> Transitivity assumption requires that the treatment comparisons within the indirect comparison do not differ with respect to the distribution of known effect modifiers.

<sup>xxi</sup> The Bucher method is commonly used to indirectly compare the odds ratios from randomised trials that share a common reference arm. However, this method has been extended to include other treatment effect measures, such as relative risk, absolute risk and hazard ratio.<sup>22</sup>

More complex methods, such as network meta-analyses, may be presented as supplementary analyses. For network meta-analyses, present the results of pairwise comparisons for each link in the network. It is preferable that non-randomised studies are not included in any network meta-analyses. Where non-randomised studies must be included, present the results of the network meta-analysis both with and without the non-randomised studies.

Unadjusted indirect comparisons (such as a naive comparison between single arms), or indirect comparisons where differences in trial characteristics may affect the transitivity of the trials in the comparison, should be avoided. Where patient-level data are available for at least one study in the comparison, use matching-adjusted indirect comparisons or simulated treatment comparisons to correct for trial differences to improve the transitivity of the comparison.

For all analyses, provide sufficient detail of the methods used, to enable them to be independently replicated, if required, and provide all programming code for statistical software (e.g. Stata or WinBUGS) as an attachment. For methods that require individual patient data (matching-adjusted indirect comparison or simulated treatment comparison), attach the individual patient dataset in a spreadsheet.

Assess the heterogeneity between results of pairwise comparisons and any disagreement or inconsistencies between the direct and indirect evidence. If inconsistency within a network meta-analysis is found, attempts should be made to explain and resolve these inconsistencies.

If an indirect comparison includes confounders, adjustment using a meta-regression, a matching-adjusted indirect comparison or a simulated treatment comparison may be appropriate, in addition to the pairwise comparisons. Describe all methods undertaken in sufficient detail, to enable the approach to be independently verified, if required.

### *Presenting the results*

Report all results from the indirect comparison in tables:

- For dichotomous outcomes, present the results of each individual randomised trial as the odds ratio, relative risk and absolute risk difference with 95% CIs between the common reference, and the proposed medicine and the main comparator (three separate tables may be required).
- For time-to-event outcomes, present the results of each individual randomised trial as the hazard ratio with its 95% CI between the common reference, and the proposed medicine and the main comparator. Also report the median event-free survival in each arm of the common reference, proposed medicine and main comparator.
- Where there is more than one randomised trial in a set, separately pool the treatment effect results between the common reference and the proposed medicine, and between the common reference and the main comparator. Present the relevant outcome measures with 95% CIs using the random effects model.
- Calculate the indirect estimate of effect, and present the estimate as a relative risk and odds ratio (or the ratio of hazard ratios) with its 95% CI (and example table is shown below, Table 2.6.3).

**Table 2.6.3: Example summary table of results of the indirect comparison (for a dichotomous outcome)\***

Study type or estimate	Study ID	<i>n</i> with event/ <i>N</i> (%)	Common reference <i>n</i> with event/ <i>N</i> (%)	Treatment effect (OR)	Treatment effect (RR)
Proposed medicine vs common reference studies	Study 1	<i>n</i> / <i>N</i> (%)	<i>n</i> / <i>N</i> (%)	OR (95% CI)	RR (95% CI)
	Study 2	<i>n</i> / <i>N</i> (%)	<i>n</i> / <i>N</i> (%)	OR (95% CI)	RR (95% CI)
	Pooled	total <i>n</i> /total <i>N</i> (%)	total <i>n</i> /total <i>N</i> (%)	Pooled OR (95% CI)	Pooled RR (95% CI)
Comparator vs common reference studies	Study 3	<i>n</i> / <i>N</i> (%)	<i>n</i> / <i>N</i> (%)	OR (95% CI)	RR (95% CI)
	Study 4	<i>n</i> / <i>N</i> (%)	<i>n</i> / <i>N</i> (%)	OR (95% CI)	RR (95% CI)
	Pooled	total <i>n</i> /total <i>N</i> (%)	total <i>n</i> /total <i>N</i> (%)	Pooled OR (95% CI)	Pooled RR (95% CI)
Indirect estimate of effect adjusted for the common reference	–	–	–	OR (95% CI)	RR (95% CI)

\*Adapt the table as necessary to include continuous or time-to-event outcomes

– = not required; CI = confidence interval; *n* = number of participants with event; *N* = total number of participants in group; OR = odds ratio; RR = relative risk

#### 2.6.4 Adjustment for treatment switching

Where one or more of the included studies has participants that switched treatments, check whether the pattern of switching is similar to current clinical practice for the comparator arm and/or future clinical practice for the proposed medicine. If so, adjustment is not needed. Otherwise, the observed comparative treatment effect may not reflect the expected treatment effect in the Singapore population, and adjustment may be appropriate.

##### *Preferred approach for adjusting the treatment effect for treatment switching*

For each arm of each relevant study, explain:

- the extent of the switching and which medicines were involved;
- whether the treatment switching from the comparator arm reflects or differs from current clinical practice; and
- whether the treatment switching from the intervention arm is likely to reflect future clinical practice.

If switching (or the extent of switching) does not reflect clinical practice, describe the differences and address the following issues:

- Provide the reasons for switching (e.g. progression of condition, or toxicity) and the patient numbers for each category;
- Indicate whether treatment switching and/or specific analyses to adjust for treatment switching were pre-specified in the trial protocol (provide references where applicable);
- Present the baseline characteristics of switchers and non-switchers, as well as the characteristics of participants just before switching and summarise any differences between the different groups. If participants switched primarily as a result of progression of their condition, present the characteristics of the participants who were at risk of switching (progressed) but did not switch and compare them with those who did switch;
- Report the extent and timing of treatment switching in Table 2.6.4.

**Table 2.6.4: Extent of treatment switching in the randomised trials**

Trial arm	Characteristic	Time point 1	Time point 2	Time point 3
Proposed medicine arm ( <i>N</i> )	Number at risk of switching <sup>a</sup>	<i>s</i> 1	<i>s</i> 1 + <i>s</i> 2	[etc]
	Number of treatment switches to the comparator arm [percentage of randomised that have switched]	<i>c</i> 1 [ <i>c</i> 1/ <i>N</i> ]%	<i>c</i> 1 + <i>c</i> 2 [ <i>(c</i> 1 + <i>c</i> 2)/ <i>N</i> ]%	[etc]
	Number of treatment switches to any subsequent active treatments (comparator or non-study therapies) [percentage of randomised that have switched]	<i>t</i> 1 [ <i>t</i> 1/ <i>N</i> ]%	<i>t</i> 1 + <i>t</i> 2 [ <i>(t</i> 1 + <i>t</i> 2)/ <i>N</i> ]%	[etc]
	Proportion of patients at risk of switching who actually switched to the comparator arm (%)	<i>c</i> 1/ <i>s</i> 1	<i>(c</i> 1 + <i>c</i> 2)/( <i>s</i> 1 + <i>s</i> 2)	[etc]
	Proportion of patients at risk of switching who actually switched to any subsequent treatments (comparator or non-study therapies) (%)	<i>t</i> 1/ <i>s</i> 1	<i>(t</i> 1 + <i>t</i> 2)/( <i>s</i> 1 + <i>s</i> 2)	[etc]
Comparator arm ( <i>N</i> )	[As for proposed medicine arm]	[As for proposed medicine arm]	[As for proposed medicine arm]	[etc]

*c*<sub>*x*</sub> = number switched from the medicine to the comparator at time point *x*; *N* = number randomised; *s*<sub>*x*</sub> = number at risk of switching at time point *x*; *t*<sub>*x*</sub> = number switched from the medicine to any subsequent therapy at time point *x*

<sup>a</sup> Patients at risk of switching are usually those who stop the assigned treatment and remain alive (e.g. progression of condition, or medicine intolerance).

Several methods can be used to adjust survival estimates for treatment switching.<sup>23</sup> Provide details on the approach taken (as an attachment), including the assumptions and how they have been tested. Demonstrate that the results would be similar if different approaches to adjusting for treatment switching were undertaken. Discuss the risk of adjustment on overstating the true comparative treatment effect. Provide any additional evidence available that will reduce the uncertainty associated with the estimate of the treatment effect following adjustment.

### Results of adjustment for treatment switching

For each of the methods used to adjust the treatment effect for treatment switching, present the adjusted treatment effect and the 95% CI. Explain any heterogeneity of treatment effects across the different methods for adjustment. Present the treatment effect and the 95% CI in the absence of switching, for comparison.

Where possible, present a Kaplan–Meier graph with curves for each treatment arm with adjustments for treatment switching. Display 95% CIs for each arm, and include a risk table with the graph to display the numbers of censored patients and patients still at risk in each arm across regular time points for the study’s follow-up period.

If possible, use a number of different statistical approaches to adjust for switching. A similar result from a number of analyses will reduce uncertainty and increase confidence in the result. Comparison with historical controls will also improve confidence in the statistical approaches.

There is a risk of bias associated with the use of subgroups, indirect comparisons and adjustment methods for treatment switching. These approaches should not be combined, as they will be regarded as poor-quality evidence.



## 2.7 Applicability of study results to the Singapore setting

### KEY INFORMATION REQUIRED

- Identify characteristics of the included studies that may affect the applicability of the results to the Singapore setting
- Explore important differences between the trial setting and the Singapore setting, and estimate the likely impact on treatment effects

Applicability, also known as external validity, generalisability or transposability, is the extent to which the effects observed in clinical studies are likely to reflect the expected results when an intervention is applied to the population of interest. In this section, explore possible differences between the observed comparative benefits and harms in the trial setting, and the benefits and harms that are likely to occur in the Singapore setting. The PICO elements in the evaluation framework (Subsection 1.1.2) are useful to identify factors that may affect the applicability of the included studies to the local context (Table 2.7).

**Table 2.7: Characteristics of individual studies that may affect applicability to the local context**

Domain	Description of applicability of evidence
<b>Population</b>	[Describe the general characteristics of enrolled participants, how they may differ from the Singapore population]. Factors that may limit applicability include: <ul style="list-style-type: none"> <li>▪ Narrow eligibility criteria (that require specific tests) and exclusion of participants with comorbidities or concomitant medicines</li> <li>▪ Large differences between demographics of study population and Singapore patients</li> <li>▪ Narrow or unrepresentative severity, stage of illness, or comorbidities</li> <li>▪ Long run-in period with high exclusion rate for non-adherence or side effects</li> <li>▪ Event rates much higher or lower than observed in population-based studies</li> </ul>
<b>Intervention</b>	[Describe any differences in the general characteristics of the intervention (e.g. how it is administered) between the trial and local clinical practice in Singapore]. Factors that may limit applicability include: <ul style="list-style-type: none"> <li>▪ Doses or schedules used in trials not reflected in Singapore clinical practice</li> <li>▪ Monitoring practices or visit frequency in trials not used in Singapore clinical practice</li> <li>▪ Older versions of an intervention used in trial no longer in common use in Singapore</li> <li>▪ Level of training/proficiency with intervention required for the trial setting not widely available in Singapore</li> </ul>
<b>Comparator(s)</b>	[Describe whether the comparator(s) reflect best alternative treatment in Singapore clinical practice and how this may influence treatment effect size]. Factors that may limit applicability include: <ul style="list-style-type: none"> <li>▪ Inadequate dose of comparator</li> <li>▪ Use of substandard alternative therapy</li> </ul>
<b>Outcomes</b>	[Describe whether the measured outcomes and timing of assessments reflect the most important clinical benefits and harms]. Factors that may limit applicability include: <ul style="list-style-type: none"> <li>▪ Short-term or surrogate outcomes</li> <li>▪ Composite outcomes that mix outcomes of different significance</li> </ul>
<b>Setting</b>	[Describe geographic and clinical setting of studies and whether or not they reflect the settings in which the intervention will be typically used in Singapore]. Factors that may limit applicability include: <ul style="list-style-type: none"> <li>▪ Standards of care in Singapore differ markedly from trial setting</li> <li>▪ Intervention is administered in a different care setting in trial compared to how it will be used in Singapore (e.g. inpatient vs outpatient setting)</li> </ul>

Adapted from Atkins et al (2011)<sup>24</sup>

### 2.7.1 Identification of important differences across settings

Tabulate important differences between the trial setting and the Singapore setting in Table 2.7.1 and discuss the likely effect the differences will have on estimates of clinical effectiveness.

**Table 2.7.1: Example differences between the trial setting and the Singapore setting**

Characteristic	Trial setting	Singapore setting	Conclusion
Disease or condition severity	42% stage I or II, 58% stage III or IV	65% stage I or II, 35% stage III or IV	Requires further investigation [May have an effect on comparative treatment effect]
Comparator chemotherapy regimens	31% participants received 4-6 cycles of platinum-doublet chemotherapy followed by maintenance pemetrexed	~70% patients receive 4-6 cycles of platinum-doublet chemotherapy followed by maintenance pemetrexed	Requires further investigation [May have an effect on comparative treatment effect]
Location of enrolment/treatment	13% East Asian settings	Singapore	Requires further investigation [May have an effect on comparative treatment effect, and resource use]
Age	Median age 64.5 to 66 years	80% diagnosed at 70 years or older	Unknown

Discuss whether any differences between the settings (identified in Table 2.7.1) may affect the comparative safety of the proposed medicine if it is used in the Singapore setting. Possible factors to consider include:

- the prevalence and severity of the adverse event, and whether it is likely to be related to the medicine;
- any difference in the rate of the serious adverse events between the patients receiving the proposed medicine and the main comparator(s);
- factors for which the trial setting differs from the Singapore setting that may affect the expected rate of the serious adverse event.

Real world data (RWD)<sup>xxii</sup>, ideally derived from patients in Singapore, can be presented **as supplementary information** to substantiate claims regarding the likely effect of the proposed medicine when used in Singapore clinical practice. This type of information may be useful to:

- provide evidence with higher external validity compared to clinical studies;
- provide more certainty about the safety and effectiveness of the proposed medicine in the local setting and/or in an Asian population (which may be underrepresented in the clinical trials);
- explain patients' treatment expectations and preferences; or
- fill any information gaps in the absence of clinical trials (e.g. when it is not feasible or ethical to conduct an RCT).

RWD may also be required if there are any significant biological variations in Singapore patients compared to the trial populations (e.g. differences in body weight, pharmacokinetics and/or pharmacodynamics due to different genetic makeups between Caucasians and Asians) which may impact dosing regimens and/or the effect of the proposed medicine.

If real world evidence is included, state the source of the RWD and the sample size. Describe the methods

<sup>xxii</sup> Real world data is defined as data collected during routine delivery of healthcare (e.g. from observational studies, electronic medical records, claims and billing activities, product and disease registries, and patient-generated data). Real world evidence is defined as evidence that is derived from real world data.

used to collect and analyse any RWD and provide a summary of the reliability and quality of the data collected. Conduct a risk of bias assessment in line with the methods described in Subsection 2.3.4.

## 2.8 Interpretation of the clinical evidence

Provide a brief summary of the clinical evidence presented in the submission which considers:

- the level of the evidence;
- the quality of the evidence;
- the clinical importance and patient relevance of the effectiveness and safety outcomes;
- the statistical precision of the evidence;
- the size of the effect;
- any uncertainties in the evidence that may affect the overall clinical claim;
- the consistency of the results across the clinical trials presented and their applicability to the Singapore setting; and
- any other relevant factors.

State the therapeutic conclusion for the effectiveness and safety of the proposed medicine in relation to its main comparator(s) (i.e. whether it is therapeutically superior, inferior or non-inferior to the comparator).

**Example:**

*[Proposed medicine administered until disease progression for a maximum of 12 cycles] is superior/non-inferior/inferior in terms of effectiveness compared with [comparator administered until disease progression].*

*[Proposed medicine] is superior/non-inferior/inferior in terms of safety compared with [comparator].*

## Section 3 Economic Evaluation

---

### Introduction

In Section 3, present an economic evaluation comparing the proposed medicine with the main comparator(s) in line with the evaluation framework (Subsection 1.1.2) and ACE's reference case (Table 3). The economic evaluation may be a cost-utility analysis (CUA) (Section 3A) or a cost-minimisation analysis (CMA) (Section 3B).

**A cost-utility analysis** requires consideration of both the incremental **direct** health-related costs and health outcomes associated with the proposed medicine, to generate an incremental cost-effectiveness ratio (ICER). This type of analysis is appropriate where the clinical evaluation (Section 2) has concluded that the proposed medicine is:

- therapeutically superior to the main comparator(s), but is likely to result in additional costs to the healthcare system; or
- therapeutically inferior to the main comparator, but likely to result in lower costs to the healthcare system.

**A cost-minimisation approach** is appropriate where there is a therapeutic claim of non-inferiority (i.e. the proposed medicine and the main comparator(s) are considered to be clinically equivalent), the safety profile of the proposed medicine is equivalent or superior (in both nature and magnitude) to the main comparator(s), and use of the proposed medicine is anticipated to result in equivalent or lower costs to the healthcare system compared to the main comparator(s).

Other economic evaluations (e.g. cost-benefit analyses or cost-consequences analyses) **should not be presented** unless previously agreed by ACE during the pre-submission meeting.

Refer to the following sections for guidance on conducting specific types of economic evaluations:

- Section 3A – guidance for conducting a CUA
- Section 3B – guidance for presenting a CMA

**Table 3: Summary of ACE’s reference case for economic evaluations submitted for funding consideration**

Component of evaluation	Reference Case
<b>Perspective</b>	<ul style="list-style-type: none"> <li>▪ Singapore healthcare system including payments out of the government’s healthcare or insurance (MediShield Life) budgets as well as patients’ co-payments including MediSave and out of pocket expenses</li> </ul>
<b>Target population</b>	<ul style="list-style-type: none"> <li>▪ Consistent with the patient population defined in the evaluation framework</li> <li>▪ Epidemiological data for Singapore presented for the entire target population and relevant subgroups</li> </ul>
<b>Comparator(s)</b>	<ul style="list-style-type: none"> <li>▪ Consistent with the comparator(s) defined in the evaluation framework</li> <li>▪ Comparator(s) should either reflect the current treatment that is most likely to be replaced by the proposed medicine in routine local clinical practice, or in the case of add-on treatments, the current treatment without the proposed medicine added on</li> </ul>
<b>Outcomes</b>	<ul style="list-style-type: none"> <li>▪ Consistent with the outcomes defined in the evaluation framework</li> <li>▪ Health outcomes should be patient-relevant and valued from a Singapore healthcare system perspective</li> </ul>
<b>Economic evaluation</b>	<ul style="list-style-type: none"> <li>▪ CMA or CUA may be undertaken</li> <li>▪ Justification of model structural assumptions and data inputs should be provided. When there are alternative plausible assumptions and inputs, sensitivity analyses of their effects on model outputs should be undertaken.</li> <li>▪ Results for CUA expressed as incremental cost-effectiveness ratios (ICER)</li> </ul>
<b>Calculation of costs</b>	<ul style="list-style-type: none"> <li>▪ Only direct healthcare costs should be included</li> <li>▪ Identification, measurement and valuation of costs should be consistent with the perspective of the Singapore healthcare system (government, insurance provider and patient healthcare costs)</li> <li>▪ Indirect healthcare costs or non-healthcare costs should not be included</li> </ul>
<b>Measuring and valuing health effects</b>	<ul style="list-style-type: none"> <li>▪ Final, clearly defined, clinically meaningful outcomes should be presented</li> <li>▪ CUA: quality-adjusted life years (QALYs) gained<sup>a</sup></li> <li>▪ Life expectancy estimates based on recent Singapore age-specific and gender-specific life tables</li> <li>▪ EQ-5D-3L utility weights estimated based on the general population in the UK (which ideally have been accepted by NICE) should be used in the scoring algorithm.</li> <li>▪ Singapore-based preference weights can be used in sensitivity analyses</li> <li>▪ Quality of life weights derived from a validated instrument</li> </ul>
<b>Time horizon</b>	<ul style="list-style-type: none"> <li>▪ The time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect all important differences in costs or outcomes between the treatments being compared</li> </ul>
<b>Discount rate</b>	<ul style="list-style-type: none"> <li>▪ Costs and health outcomes are discounted at an annual rate of 3%</li> </ul>
<b>Handling uncertainty</b>	<ul style="list-style-type: none"> <li>▪ Explore all relevant structural, parameter source, and parameter precision uncertainty</li> <li>▪ One-way deterministic sensitivity analysis should be presented for all uncertain parameters</li> <li>▪ Multivariate probabilistic sensitivity analysis may also be performed to address simultaneous impact of all uncertain parameters</li> </ul>

<sup>a</sup> The QALY is considered to be the most appropriate generic measure of health benefit that reflects both mortality and health-related quality of life effects.

Although the reference case specifies the preferred methods for economic evaluations submitted for funding consideration, it does not preclude decision-making committees from considering non-reference case analyses (presented as supplementary analyses) if appropriate, and well justified.

## 3.1 Published economic evaluations

Review the literature for relevant published economic evaluations involving the proposed medicine and/or comparator treatments. This should include published HTA reports and models considered by national HTA agencies (e.g. PBAC, NICE, CADTH, PHARMAC etc.). Provide a brief overview of each identified study in Table 3.1.

**Table 3.1: Summary of published economic evaluations**

Study	Year of publication	Type of economic evaluation	Perspective and country	Strategies compared	Time horizon	Patient population	LYG/QALYs (intervention, comparator)	Costs (currency) (intervention, comparator)	ICER (cost per LYG/QALY gained)
Study 1									
[add rows as needed]									

LYG= life years gained; QALY= quality-adjusted life year; ICER= incremental cost-effectiveness ratio. **Convert table to landscape.**

## Section 3A Cost-effectiveness analysis

### 3A.1 Overview of the economic evaluation

#### KEY INFORMATION REQUIRED

- Describe the economic evaluation presented and outcome measures used
- Use a Singapore healthcare system perspective to inform analyses
- Apply an annual discount rate of 3% to costs and outcomes in base case analyses
- Describe the model structure and modelling technique used
- Justify the time horizon used
- Describe the sources of the model input parameters
- Provide an executable electronic copy of the economic model

#### 3A.1.1 Summary of the economic evaluation

Summarise the key components of the economic evaluation in Table 3A.1.1.

**Table 3A.1.1: Summary of the key components of the economic evaluation**

Component	Description
Type of analysis	[e.g. CUA]
Outcomes presented	[e.g. LYG, QALYs]
Type of model	[e.g. Markov model, microsimulation]
Time horizon	[x] months/years in the base case [x]-[y] months/years modelled in sensitivity analysis
Health states	[If applicable, present a brief description of all health states]
Cycle length	[x] days/weeks/months/years
Software	[e.g. Excel, TreeAge Pro]

CUA = cost utility analysis; LYG = life years gained; QALY = quality-adjusted life year

### 3A.1.2 Type of economic evaluation

A cost utility analysis (CUA) should be presented. Differences in costs and outcomes that occur when the proposed medicine or its main comparator(s) are used should be expressed as incremental costs and incremental outcomes between these alternatives in the Singapore setting. Identify the incremental patient-relevant health outcomes (i.e. quality-adjusted life years [QALYs]) and incremental health costs.

### 3A.1.3 Perspective of the economic evaluation

The economic evaluation should be presented from the perspective of the Singapore healthcare system, including payments out of the government's healthcare or insurance (MediShield Life) budgets as well as patients' co-payments including MediSave and out of pocket expenses. Only direct health-related costs and patient-relevant health outcomes valued from the healthcare system perspective should be presented.

Supplementary analyses which include non-health benefits may be appropriate where the proposed medicine has important societal implications extending beyond the health outcomes of the patient receiving treatment, and beyond the health care system (e.g. economic productivity impact).

### 3A.1.4 Discounting

The values of costs and benefits incurred or received in the future should be discounted to reflect the present value. In the base-case analysis, discount all costs and health outcomes that occur or extend beyond one year at an annual (compounding) rate of 3%.

Present sensitivity analyses using fixed discount rates of 0% and 5% per year (applied to both costs and outcomes) to test the impact of the chosen discount rate on the ICER.

### 3A.1.5 Structure of the economic model

Present a diagram that provides a conceptual overview of the model structure. Descriptions of the health states in the diagram should also be provided. Ensure that the model structure captures all relevant health states or clinical events along the pathway of the condition, and that it is consistent with the treatment algorithm(s) presented in Subsection 1.2.1. The model structure should also be informed using the results of the literature review of economic evaluations (Section 3.1), and other relevant literature, including clinical trials, clinical guidelines and burden of disease studies. Provide copies of the original sources of all data not already presented in Section 2 which have been used to inform the model, in an attachment.

Disaggregate patient-relevant events if there are important differences in mortality, disease/condition progression, associated costs, or quality-of-life effects, and if the distribution differs between the proposed medicine and comparator(s).

Assess the model structure(s) to establish face validity. Justify the exclusion of any potentially relevant health states or events identified in the literature (or proposed by local clinical experts) and discuss the potential impact of any exclusions on the model outputs. Where the model structure differs from existing models, explain the basis for the selected approach.

If adequate data are not available to inform the model according to the initially defined structure, consider restructuring the model according to the available data and assess the face validity of alternate model structures. If a valid alternative model structure can be constructed, describe the revisions to the initial model

and discuss the potential impact on the model outputs.

### 3A.1.6 Model types

Models should avoid unnecessary complexity and should be transparent, well described and reproducible. If a trial-based economic evaluation is being undertaken using individual patient data for costs and outcomes from a clinical trial(s), describe the methods used to do this and provide the statistical plan and statistical outputs as an attachment. This type of evaluation should only be considered if the patients in the trial are directly representative of individuals in Singapore who are likely to use the proposed medicine, and all patient-relevant endpoints were directly measured in the trial over an appropriate time horizon.

If the trial(s) do not provide evidence that sufficiently measures the full clinical and economic consequences of the proposed medicine compared with its main comparator(s) in the Singapore setting, a model-based economic evaluation is required.

For model-based economic evaluations, identify the most appropriate (and least complicated) modelling technique which is feasible to implement the specified model structure (described in 3A.1.5). Decision trees, cohort-based state transition models (Markov models) or partitioned survival analysis models are preferred to assess the cost-effectiveness of medicines.

#### *Decision trees*

Simple decision trees can be used for models with short time horizons, and/or where an event is expected to only occur once during a discrete period. Decision trees should be developed following good practice guidelines.<sup>25</sup>

#### *Cohort-based state transition (or Markov) models*

Cohort-based state transition (Markov) models can be used to represent longer time horizons (for models that can be represented using a manageable number of health states under the constraints of the Markovian [“memoryless”] assumption) and/or when events are expected to reoccur during a discrete period. Markov models assume that a person is always in one of a finite number of health states. The model cohort is usually assigned to an initial health state and then individuals can move between health states at defined recurring intervals (Markov cycles) which are determined by transition probabilities. The model is usually run until all of the cohort moves through to the absorbing state (e.g. “dead” state).

Markov models should be developed following good practice guidelines.<sup>26</sup> The cycle length chosen should be justified and should reflect the minimum time period over which the pathology or symptoms are expected to change in line with the nature of the condition. If clinical events are likely to occur frequently, then a short cycle length should be used. In designing a Markov model, assess if transition probabilities are dependent on time spent in a health state or previous occupancy of associated states. In the cases where there are such deviations from the Markovian assumption, tunnel or intermediary states could be used to circumvent this limitation.

A half-cycle correction is the default approach to represent the time of transition between states. An alternative correction factor may be proposed with justification.



### Partitioned survival analysis models

Partitioned survival analysis models are conceptually similar to state transition models in that they are characterised by a series of health states, however, the proportion of patients in each health state is determined by the area under the non-mutually exclusive survival curves (e.g. overall survival and progression-free survival curves), rather than matrices of transition probabilities (as for Markov models). They are commonly used to evaluate cancer drugs but can be used for other conditions. Partitioned survival analysis models should be developed in line with published good practice guidelines.<sup>27</sup>

### Individual-level (or microsimulation) models

Individual-level modelling approaches (such as individual-based state transition models or discrete event simulation models) should only be used when a defined model structure cannot be feasibly implemented as a cohort-based model. Describe the characteristics<sup>xxiii</sup> of the model structure that prevent a cohort-based model from being used and explain how incorporation of these characteristics in an individual-level model are expected to produce a more accurate representation of the condition pathways, costs and patient outcomes. Individual-level models should be developed in line with published good practice guidelines.<sup>26,28</sup>

#### 3A.1.7 Fully executable electronic copy of the economic model

Models should be developed in Microsoft Excel and/or TreeAge Pro. Use of advanced features or plug-ins (e.g. Crystal Ball) in Excel, or alternative software packages should be avoided unless agreed by ACE prior to submission. All models should include clear instructions on their use.

Provide access to the electronic copy of the economic model. It should be fully executable (unlocked and editable) to allow model inputs to be verified and changed independently (e.g. if the ERC or ACE are required to conduct additional sensitivity or scenario analyses).

If an economic evaluation has been previously submitted to an overseas HTA agency (e.g. PBAC (Australia) or NICE (England)) to inform national funding decisions, the model may be adapted (i.e. inputs and structure modified to reflect the Singapore setting) and submitted to ACE.

#### 3A.1.8 Time horizon

Define and justify the time horizon over which the costs and outcomes of the proposed medicine and its main comparator(s) are estimated. Ensure that the time horizon captures all important differences in costs and outcomes between the proposed medicine and the comparator(s), as a result of the choice of treatment.

The time horizon should never be determined by the length of time for which evidence is available. Where data are not available to inform an appropriate time period, projection of costs and outcomes into the future will be required.

Where there is evidence that a treatment affects mortality or long-term outcomes and/or quality of life that persist for the remainder of a person's life, then a time horizon sufficiently long enough to reflect the time span required for nearly all of the cohort in the model to die according to their life expectancy should be used. Life expectancy estimates should be based on recent [Singapore age-specific life tables](https://www.singstat.gov.sg/publications/population/complete-life-table).<sup>xxiv</sup>

The validity of a time horizon should be determined by the population in the model and the inputs. Unrealistic

---

<sup>xxiii</sup> Potential factors include, but are not limited to, baseline heterogeneity, time-varying event rates and the influence of previous events on subsequent event rates.

<sup>xxiv</sup> <https://www.singstat.gov.sg/publications/population/complete-life-table>

inputs will lead to the model predicting an implausible duration of outcomes or survival and therefore, an implausible time horizon. An assessment of the plausibility of the chosen time horizon should be described, including an explanation of how the model extrapolates the clinical data to reach this time horizon.

Economic claims based on a model with a very extended time horizon and predominantly extrapolated benefits are likely to be more uncertain and should be explored through sensitivity analyses.

Where interventions do not affect mortality, and have temporary health or quality-of-life effects (e.g. for treating acute conditions), a shorter time horizon may be appropriate. Adequate justification should be provided if a shorter time horizon is chosen.

### 3A.1.9 Model inputs

Economic evaluations should be informed by results from direct randomised trials, or indirect comparisons where direct comparisons are not available (as described in Section 2), with any adjustments or additions to the trial data to account for differences in the population and setting, timeframe of analysis or outcomes of interest clearly described.

Describe the methods used to identify data to populate the model input parameters. The method of identifying the data should be robust and transparent (e.g. systematic reviews of the literature and well-designed clinician surveys). Where multiple sources of data exist, the choice of the source used in the base case should be justified. The impact on the ICER of using alternative data sources, where relevant, can be tested in sensitivity analyses.

For partitioned survival analysis where survival curves are used, any adjustment made for treatment switching should be justified and conducted in line with Subsection 2.6.4.

If clinical experts have assessed the applicability of model inputs or approximated any of the clinical parameters, provide sufficient detail on the method used to collect their opinions (e.g. self-administered questionnaire, advisory panel etc.), the number of experts who provided input, and their names, specialties and institutions. Include copies of the questions they were asked and their responses as an attachment. If the majority of clinical parameters are approximated by clinical experts, this will potentially reduce the validity of the model and increase the uncertainty surrounding the base-case ICER.

## 3A.2 Population and setting

### KEY INFORMATION REQUIRED

- Describe the demographic and patient characteristics for the modelled population
- Describe any quantitative adjustments to model inputs that are necessary due to differences between the trial and target populations

### 3A.2.1 Patient characteristics and circumstances of use

The modelled population should represent the target Singapore population defined in the evaluation framework (Subsections 1.1.2 and 1.1.3) who are expected to use the proposed medicine in line with the defined clinical treatment algorithm and any proposed clinical criteria (Subsection 1.2.1).

Describe the demographic and clinical characteristics of the modelled population including age, sex, ethnicity, medical condition (and level of severity if applicable), comorbidities and prior treatments (if relevant) using summary statistics (including SD and 95% CI). Indicate which patient characteristics are incorporated into the model. Describe and justify how heterogeneity in patient characteristics (if relevant) is represented in the cost-effectiveness analysis.

Provide details of any additional circumstances relating to the use of the proposed medicine that are relevant to the modelled population, such as restrictions on the position of the proposed medicine in the clinical management algorithm (e.g. first-line or second-line treatment), stopping criteria, continuation rules or specific requirements (facilities, equipment, care setting etc.) for administration of the proposed medicine. Explain how these circumstances have been accounted for in the model.

Determine whether any quantitative adjustments to model inputs are necessary due to differences (applicability concerns) between the trial population(s) and the target population in Singapore, and, if so, describe the method(s) for translation. Common methods for translation include subgroup analyses, regression analyses, meta-regression or use of other published studies (only if it is not possible to inform translation using direct clinical evidence for the proposed medicine). Justify the selected approach.

Take care when converting relative treatment effects across jurisdictions with different baseline risks. Ensure that the baseline risk (i.e. prognostic characteristics) of patients does not differ between the trial evidence and the target population, or that patients are not expected to respond better to the proposed medicine or the main comparator(s) in one setting over another.

Where a regression or meta-regression analysis is used, present and interpret the results in the main body of the submission, and provide a clear description of the regression method, the associated assumptions, and how the assumptions were tested in an attachment and include all statistical commands and output.

### 3A.3 Transition probabilities

#### KEY INFORMATION REQUIRED

- Present the transition probabilities and any modelled variables that are incorporated into the economic model, and identify data sources and any associated translation requirements
- Explain and justify methods used to extrapolate data, where necessary, beyond the trial follow up period(s)

#### 3A.3.1 Transition probabilities and variables

Transition probabilities inform the movement of patients between health states in decision trees or state transition models<sup>xxv</sup>. They may differ by treatment or by how long a patient has been in a particular health state (time-varying probabilities).

Describe and justify the methods used to identify and analyse relevant data to derive transition probabilities and/or variables. Transition probabilities that differ by treatment should be estimated using the clinical evidence described in Section 2. Other transition probabilities may be required that describe the progression of a condition following the experience of an intermediate outcome event, regardless of treatment allocation.

---

<sup>xxv</sup> In discrete event simulations, time-to-event parameters are analogous to transition probabilities.

If there is evidence that transition probabilities may change over time for the treatment effect or the condition, describe how this has been accounted for in the model. Where external sources of data (other than clinical evidence from Section 2) are used to inform transition probabilities, or other variables in the model, assess the applicability of these sources of data with respect to the Singapore setting. Note and justify whether the data are applicable, if they require translation (and describe how this was done) and if they are a source of uncertainty within the model. Describe where the model uses other variables instead of, or in addition to, transition probabilities.

For each transition probability or variable, present the point estimate and interval estimates (e.g. 95% confidence intervals). Ensure that values taken from all sources of evidence are appropriately adjusted to represent the transitions required by the model structure (e.g. translate reported rates or cumulative probabilities to the probabilities for timeframes associated with a model cycle, if necessary).<sup>29,30</sup> Assess any potential correlation between transition probabilities and/or input variables (e.g. parameters describing a survival function used for survival extrapolation). Correlation between parameters is particularly relevant when conducting analyses to address uncertainty (Subsection 3A.9.2).

### 3A.3.2 Extrapolation

Extrapolation may be justified when all important differences in costs and outcomes between the proposed medicine and comparator(s) groups are not represented over the time horizon for which observed data are available in the clinical trial. Many sources of advice on extrapolation techniques for economic evaluations are available in the literature.<sup>31-37</sup> Describe the methodology, limitations and any possible biases associated with extrapolating data required for the base-case economic model.

#### *Extrapolating individual patient time-to-event data*

Where extrapolation is undertaken, use observed time-to-event data in preference to modelled data up to the time point at which the observed data become unreliable as a result of small numbers of patients remaining event-free.

Describe and justify the selected time point beyond which extrapolated transition probabilities are applied. External data may be used to justify the selected time point (e.g. the point at which one or more of the curves fitted to the clinical trial data deviates from a curve fitted to observational data from a similar patient cohort with a larger sample over a longer follow-up period). Test alternative truncation points in a sensitivity analysis.

Present appropriately estimated parametric survival curves based on the observed data (using individual patient data, if available) to extrapolate transition probabilities beyond the data truncation point.

Describe whether an assumption of proportional hazards for the entire time horizon is appropriate. Graphs such as  $\log(-\log(\text{survival}))$  plot or relevant statistical tests may be useful for testing the proportional hazards assumption within the observed data. Fit a range of alternative survival models to the observed data (e.g. exponential, Weibull, log-normal, log-logistic, gamma, Gompertz). Multiple points of inflexion (e.g. piecewise spline models) may be appropriate to better facilitate extrapolation based on the section of the Kaplan–Meier curve that is most representative of long-term survival.<sup>38</sup>

Assess and discuss goodness of fit using visual inspection (e.g., Quantile–Quantile (Q–Q) plot for accelerated failure time models), Akaike’s information criterion and Bayesian information criterion. Present all Kaplan–Meier plots along with the corresponding chosen modelled curves in a graph.

Discuss the plausibility of the predictions in the unobserved period (e.g. the ongoing hazard ratio and/or treatment effect, the point of convergence and/or residual survival in each arm). Justify the most appropriate model for the base case and test a number of the best-fitting models in sensitivity analyses.

The treatment effect resulting from the independent extrapolation of the survival curves should be plotted over the time horizon of the model. If the treatment effect is maintained or increasing beyond a point which is no longer considered clinically plausible, apply a hazard ratio such that the proposed medicine and comparator curves converge at a plausible time point. The assessment of plausibility should be linked to the justification for the chosen time horizon (Subsection 3A.1.8).

### *Extrapolating published time-to-event data*

If individual patient time-to-event data are not available, extrapolate survival probabilities from published Kaplan–Meier curves using graph digitiser software and established statistical methods for recovery of individual patient survival data.<sup>39,40</sup> Fit a range of alternative survival models (e.g. exponential, Weibull, log-normal, log-logistic, gamma, Gompertz) to the extracted survival data beyond the last point of inflexion to the time point at which the observed data become unreliable because of small numbers of patients remaining event-free.

Present tests of the relative and absolute goodness of fit of the alternative curves. Justify the most appropriate model for the base case, taking into consideration goodness of fit as well as clinical plausibility. Test alternative models in sensitivity analyses.

## 3A.4 Measuring and valuing health outcomes

### KEY INFORMATION REQUIRED

- Describe the clinical health outcomes included in the model
- Describe how utility weights were identified and applied, if applicable
- Provide details of the multi-attribute utility instrument, or other patient-reported outcome measures used to inform the model, if applicable
- Describe any other sources of utility data applied in the model

### 3A.4.1 Health outcomes

The measure of health outcome should capture positive and negative effects on length of life and/or quality of life. Nominate and justify the patient-relevant health outcome that will be presented as the denominator in the base-case ICER. Explain whether the outcome was reported directly from identified clinical trials (in Section 2), and, if not, summarise the transformations required to derive the outcome for the economic model.

For cost-utility analyses, **quality adjusted life years (QALYs)** should be calculated. A QALY combines both quality of life and life expectancy into a single index. The valuation methods for health-related quality of life should be equal for the proposed medicine and the comparator(s). In calculating QALYs, each of the health states experienced within the time horizon of the model is given a utility reflecting the health-related quality of life associated with that health state. The duration of time spent in each health state is multiplied by the utility. Deriving the utility for a particular health state usually comprises two elements: measuring health-related quality of life in people who are in the relevant health state and valuing it according to preferences

for that health state relative to other states (usually perfect health [=1] and death [=0]).

If available, use quality-of-life or utility data reported in clinical studies in Section 2 to estimate QALYs in the model, or, justify the use of alternative indirect methods to estimate QALYs when direct data are not available. Data should be presented as the point estimate of the mean elicited utility weight for each health state (including its standard deviation and 95% confidence interval, where available).

If a claim is made for a change in a non-health outcome that is relevant to the patient, or the proposed medicine is expected to have a measurable but indirect impact on the quality of life of caregivers (e.g. family of the patient), do not include these in the base-case evaluation. They can be presented in supplementary analyses and will be considered on a case-by-case basis at the discretion of ACE's committees.

### *Use of quality-of-life data from the clinical trials to estimate QALYs*

Estimates of quality of life or utility from clinical studies (from Section 2) may inform direct estimates of QALY gains in the populations receiving the proposed medicine and the comparator(s), or inform utility values applied to health states in the cost-effectiveness model.

If a MAUI has been used in an included study to estimate utility weights (as described in Subsection 2.4.4), state where and when the scoring algorithm was derived, and consider how applicable it is to the general population in Singapore. Preference weights based on the general population in the UK (which ideally have been previously accepted by NICE) should be used in the scoring algorithm to calculate utility weights, where available. Singapore-based preference weights can be used in sensitivity analyses.

If patient-reported outcome data from a clinical study are incorporated into the economic model, provide a brief description of the following:

- the duration over which the patient-reported outcome measure informing the utilities was administered during the study compared with the duration of the condition under evaluation;
- if the study participants who reported the outcome measure are representative of the target population;
- if the patient-reported outcome measure (or MAUI) captures all important condition-specific factors.

If there is no reliable method of transforming the patient-reported outcome data into utility weights for the model, describe why it is not possible and detail whether the patient-reported outcome data from the clinical study can still be used to inform or validate the economic model.

### *Use of other sources of data to estimate utility weights*

Where utility weights or QALY changes cannot be directly estimated from data collected in the clinical studies (Section 2), or there are concerns about the reliability and relevance of the available study-based utilities, provide sufficient justification, and consider other published studies to estimate utility weights for health states in the economic model.

The validity of the derived utility weights depends on the applied elicitation methods and the relevance of the study populations. If utility weights are sourced from the literature, present the search strategies and any inclusion and exclusion criteria used to identify relevant utility studies. Assess the validity of all identified studies, and describe:

- how the health state was captured (e.g. MAUI, scenario-based);

- how the preference was elicited (e.g. standard gamble, time trade-off);
- whether the health state in each study is representative of the health state in the economic evaluation;
- the sample that was chosen to respond to the MAUI questionnaire or scenario (e.g. the general public, patients, carers, health care professionals etc.); and
- how any potential biases were addressed in the studies.

Depending on the clinical context and available data, there may be more than one acceptable source of utility weights. In this instance, reflect the uncertainty in selecting a specific source by using utility weights from other sources in sensitivity analyses.

### *Mapping of generic and disease-specific scales*

Non-preference-based patient-reported outcome measures will require a mapping algorithm to be transformed into preference-based measures to estimate utilities. Where this occurs, the use of the mapping algorithm should be conducted in line with good practice guidelines.<sup>41</sup> Detail the source of the mapping algorithm and describe the estimation sample (population demographic and clinical characteristics, sample size etc.) including its applicability to the target population evaluated in the submission. Provide details of the source and target measures (e.g. index, dimensional), and the statistical properties of the mapping algorithm. Discuss methods used to measure the algorithm performance and validity. Present the resulting predicted utilities with their associated uncertainty.

### *Scenario-based methods to indirectly elicit utility weights*

Scenario-based methods use vignettes to describe the symptoms of a health state to a sample of the general population, to derive utility weights elicited using an accepted preference-based method. The most common methods to elicit preferences include the standard gamble or time trade-off.

Describe the scenario-based methods used, if applicable, and explain efforts to minimise potential bias.<sup>xxvi</sup>

### *Population matching method to indirectly elicit utility weights*

Utility weights for the health states in the cost-effectiveness model can be elicited through a population matching study whereby a sample of patients with characteristics similar to those enrolled in the clinical studies (reported in Section 2) are recruited and complete a MAUI reflecting their current health state which can then be used to estimate utility weights. Matched patients should complete all patient-reported outcome measures that were completed by the study participants. Describe the population-matching methods used, if applicable, and efforts to minimise potential bias.<sup>xxvii</sup>

### *Presentation of outcomes and health utility value information*

If presenting a CUA, summarise the health outcomes (including adverse events) included in the economic evaluation, and any associated utilities or disutilities in Table 3A.4.1.

---

<sup>xxvi</sup> There are many sources of analyst bias that are intrinsic to the scenario-based utility approach, including the non-blinded nature of the presentation of the scenarios, the design of the methods to elicit values, and the analysis and interpretation of the results.

<sup>xxvii</sup> Potential sources of bias for population matching studies include systematic differences between the clinical study participants and the matched patients, and the inability to blind the sampled patients from the objectives of the study.

**Table 3A.4.1: Identification of health outcomes used in the model**

Health state or event	Mean utility (SD and/or 95% CI) or QALY	Nature of estimate and any translations	Source of estimate	Alternative estimates of utility value (and sources)	Average duration of application in the model: proposed medicine	Average application in the model: comparator
[Health state 1]	[Utility estimates for health state 1]	[e.g. EQ5D data (UK value set)]	[e.g. Study ID (see Section 2)]	[e.g. non-pooled data from study]	[e.g. days/months]	[e.g. days/months]

Note: Adapt table as necessary and present in landscape format if more space is required.  
 CI = confidence interval; QALY = quality-adjusted life year; SD = standard deviation

## 3A.5 Healthcare resource use and costs

### KEY INFORMATION REQUIRED

- Identify and define the direct healthcare resource items and their associated costs used in the economic model
- Non-healthcare costs or indirect healthcare costs **should not** be included
- Cost of proposed medicine used for the base-case analysis should be aligned to the Request for Proposal

All healthcare resources and costs used to inform the model should be clearly presented in a table with details of data sources. For continuous variables, mean values should be presented and used in the analyses. For all variables, measures of precision should be detailed.

### 3A.5.1 Healthcare resource use

For trial-based economic evaluations, identify the healthcare resource items where a change in use is associated with substituting the proposed medicine for the main comparator in the target population.

For model-based evaluations, identify the resources used within a relevant time period (e.g. a model cycle for a state transition model) for every health state.

#### Healthcare resource items

Where appropriate, include the following resource items in the economic model:

- medicines (direct costs of treatment(s), including medicines used to treat adverse reactions and monitoring costs);
- administration of medicines (e.g. materials required to deliver an infusion, preparation of medicine in a laboratory etc.);
- medical services, including procedures;
- hospital services (inpatient and outpatient costs);
- diagnostic and investigational services;
- services in the primary care setting (such as general practitioner consultations, patient co-payments, aged care services);
- palliative care; and
- any other direct medical costs.



Describe and justify all resources included in the model and specify their source(s). Describe how the usage pattern of healthcare resources has been measured (e.g. reviewing relevant hospital records, administering a questionnaire to each public healthcare institution etc.). Expert opinion from local healthcare professionals should be sought to validate applicability of resource use (provide details of experts consulted in an attachment). Avoid double counting if the services provided have already been billed as a single charge item to the patient.<sup>xxviii</sup>

For each resource item, quantify the number of units provided to patients in each treatment group, or to patients remaining in a health state for a relevant time period (e.g. number of packs of medicine dispensed, number of general practitioner consultations, number of episodes of hospital admission).

Use of the proposed medicine and comparator treatments should be based on the approved dosing regimens, and/or consistent with the dosing regimens used in local clinical practice (provided there is sufficient evidence of efficacy to substantiate this dosing regimen if it is different from the approved dose). Any dose adjustments over time should be taken into consideration. The amount of a medicine or other resource that is dispensed is the relevant economic measure rather than the amount of resource consumed. It is important to incorporate wastage in the model (e.g. due to inappropriate vial size, non-compliance or if infusions cannot be stored once prepared), because it is an incurred cost. For the avoidance of doubt, vial sharing should not be considered. Resources to monitor patients for adverse events after administration with the proposed medicine or the comparator(s) should also be defined, if relevant. Any treatments or resources required to manage adverse events should be presented and accounted for in the model.

Exclude types of healthcare resources that are unlikely to have a material influence on the conclusion of the economic evaluation, if appropriate. State and justify the exclusion of any resources and explain how their exclusion is likely to affect the incremental cost of the proposed medicine or the comparator(s).

### 3A.5.2 Allocation of prices (unit costs) to resources

The identification, measurement and valuation of **direct costs** should be consistent with the perspective of the Singapore healthcare system (including all contributions paid for by the government, insurance provider and patient healthcare costs). Non-healthcare costs or indirect healthcare costs **should not** be included.

Present all unit prices and costs in Singapore dollars with a consistent year of analysis (preferably as close as possible to the submission date). International costs should not be used in the economic model due to differences in resource use in Singapore, even after exchange rate adjustments. Obtaining Singapore costs may require approaching a variety of sources including ACE, public healthcare institutions (PHIs), and using commercially available sales data.

Where available, use the costs recommended in the [Singapore Healthcare Resource Sheet](#)<sup>xxix</sup> to ensure that costs associated with medical and other health-related services are measured consistently. If there are valid reasons to use different unit prices, describe their source(s) and present them as a sensitivity analysis, with appropriate justification.

---

<sup>xxviii</sup> For example, if a patient is charged \$50 for drug administration on their bill (and nothing else), then the cost of materials for infusion, or chair time should not be separately included in the model as these services are all covered in the single charge item of \$50.

<sup>xxix</sup> <https://go.gov.sg/sg-resourcesheet>

The selling price to patients (including pharmacy margins, but before subsidy or insurance is applied) should be used for all medicines. Please specify the cost price of the proposed medicine and the margin that has been applied to calculate the selling price. The cost price should include any price reduction offered in the [Request for Proposal](#)<sup>xxx</sup> or other arrangements (contingent on a positive funding decision).

Costs that are the same for the proposed medicine and the comparator(s) can be validly excluded if there are no significant differences in mortality rates or time periods between treatments.

If multiple cost estimates are identified for specific resources, justify the estimate used in the base case and present alternative plausible estimates in sensitivity analyses. Use of historical estimates of costs is discouraged. However, if they are required, detail the information sources and the methods used to estimate them. Justify the use of the historical cost source as the best estimate available. Use the most relevant Singapore price index (e.g. MOH [healthcare consumer price indexes](#)<sup>xxxi</sup>) to adjust for inflation to estimate current prices. Value future costs at current prices (i.e. do not allow for future inflation in the calculations).

Clearly present all steps taken to calculate costs in the economic evaluation so the calculations can be independently replicated and verified (it may be necessary to include an unlocked spreadsheet with detailed calculations as an attachment).

Present all healthcare resource items and their associated unit costs relevant to the economic evaluation in Table 3A.5.2 (adapt as necessary). Costs associated with the entire episode of care (i.e. all costs directly relating to the diagnosis and resulting treatment or follow-up) should be included.

**Table 3A.5.2: Health care resource items, unit costs and usage included in the economic evaluation**

Resource item category	Type of resource item	Unit of measurement	Unit cost (SGD)	Source of unit cost	Usage for proposed medicine	Usage for comparator
Medicines	Proposed medicine	Quantity dispensed	[add]	Proposed selling price	[add usage]	[add usage]
	Comparator	Quantity dispensed	[add]	Average selling price in PHIs	[add usage]	[add usage]
Medical services	Diagnostic service	Service rendered	[add]	Average cost from PHIs	[add usage]	[add usage]
Hospital services	Hospital admission	Episode	[add]	Average cost from PHIs	[add usage]	[add usage]
[add rows as necessary]						

PHI = public healthcare institutions; SGD = Singapore dollar

<sup>xxx</sup> <https://go.gov.sg/company-RFPtemplate>

<sup>xxxi</sup> [www.moh.gov.sg/resources-statistics/singapore-health-facts/consumer-price-indices-\(cpi\)-household-healthcare-expenditure](http://www.moh.gov.sg/resources-statistics/singapore-health-facts/consumer-price-indices-(cpi)-household-healthcare-expenditure)

## 3A.6 Summary of base-case model inputs and assumptions

Tabulate all variables included in the base-case analysis, detailing the values used, range (e.g. confidence interval, standard error or distribution) and sources in Table 3A.6a. Provide a list of all assumptions used in the model in Table 3A.6b.

**Table 3A.6a: Summary of variables applied in the economic model**

Variable	Value	Range	Source
[Age]	[Mean 56 years (SD 6.8)]	[42 to 77 years]	[Patient registry]
[Overall survival]	[Median 4 months]	[95% CI: 0.2 to 21 months]	[Study ID]
[Add more rows as needed]			

Note: inputs are examples only. Adapt the table as required to capture all relevant variables. CI = confidence interval

**Table 3A.6b: List of assumptions used in the economic model**

Area	Assumption	Justification
[Time horizon]	[10 years]	[The average age of patients with metastatic cancer in the model is 65 years. An average of 10 more years of life expectancy has been assumed.]
[HRQoL]	[The quality of life of patients is appropriately captured by considering time to death utilities]	[Clinical opinion suggests there is a decline in HRQoL in the final months of life of patients which supports the use of a disutility associated to the terminal stage. Given the limitations of the progression-based approach to reflect appropriate utilities post-progression, a time to death approach was considered in the base case. The impact of considering an alternative approach (i.e. progression-based only) was considered in sensitivity analyses.]
[Add more rows as needed]		

Note: inputs are examples only. Adapt the table as required to capture all relevant assumptions.

## 3A.7 Model validation

### KEY INFORMATION REQUIRED

- Provide model traces and demonstrate the face validity of the economic model
- Compare modelled outcomes with outcomes from similar published models (if available) and describe any consistencies and differences

Validation of an economic model to confirm that the computed results depict what they are intended to represent will help to reduce some of the uncertainty associated with modelling, and give decision-makers more confidence in the model predictions. The Assessment of the Validation Status of Health-Economic Decision Models (AdViSHE) Study Group describe a range of validation processes which should be considered in the submission.<sup>42</sup>

Compare the base-case outcomes from the model with the corresponding trial outcomes in Table 3A.7 and discuss any differences.

**Table 3A.7: Comparison of model and trial outcomes**

Outcome	Proposed medicine		Comparator	
	Base Case	[Study ID]	Base Case	[Study ID]
[Median PFS (months)]	2.2	2.1	3.4	3.2
[Median OS (months)]	10.3	10.3	7.1	6.9
[1-year OS]	45.1%	43.9%	29.8%	30.4%

[2-year OS]	30.2%	-	16.4%	-
[5-year OS]	16.7%	-	7.8%	-
[Add rows as needed]				

Note: inputs are examples only. Adapt the table as required to capture all relevant outcomes. The outcomes should be consistent with those defined in the evaluation framework in Subsection 1.1.2.

PFS = progression-free survival; OS = overall survival

Model traces for the proposed medicine and its comparator(s) provide a clear depiction of the implications of the model and can inform the face validity of the model logic. Use traces to track patients through the model and demonstrate that the logic of the model is correct. Present traces representing the proportions of the cohorts in each health state over time, and the cumulative sum of the undiscounted costs and outcomes (e.g. QALYs) over time. If applicable, state the number of events over time where patient-relevant events occur within a health state.

Compare model traces with corresponding empirical data (e.g. clinical trials), where possible, to identify whether outcomes are consistent. Explain any differences indicated by these comparisons.

Additional cross-validation of the modelled outcomes should be undertaken, where possible, by comparing results with outcomes from similar economic models to identify consistencies or differences.

## 3A.8 Results of the base-case economic evaluation

### KEY INFORMATION REQUIRED

- Present the base-case estimate of the incremental outcome(s), incremental cost and ICER(s)
- Calculate the cost per patient per course of treatment (for acute conditions) or per year (for chronic conditions) with the proposed medicine and the comparator(s)
- Present disaggregated costs and outcomes for the proposed medicine and the comparator(s)

### 3A.8.1 Base-case results

Present the base-case estimate of the incremental outcome(s), incremental cost and the cost-effectiveness ratio(s) from the economic evaluation in Table 3A.8.1. If a price reduction or PAP, contingent on funding of the proposed medicine, has been included in the Request for Proposal, this should be reflected in the base-case analysis.

**Table 3A.8.1: Base-case results (discounted)**

Medicine	Total Costs (SGD)	Total LYG	Total QALYs	Incremental costs (SGD)	Incremental LYG	Incremental QALYs	ICER (SGD/QALY)
Comparator	20,000	1.62	1.09	-	-	-	
Proposed medicine	60,000	2.81	1.96	40,000	1.19	0.87	45,977

ICER = incremental cost-effectiveness ratio; LYG = life years gained; SGD = Singapore dollar; QALY = quality-adjusted life years

Note: Comparator should reflect standard of care in line with the evaluation framework in Subsection 1.1.2. Inputs are an example only. Present incremental ICERs and indicate “dominated” or “extendedly dominated” where applicable. If more than one comparator is being considered, present ICERs compared with the next cheapest, non-dominated treatment option. Adapt table as necessary.

### *Cost of proposed medicine or comparator treatment per patient*

For acute conditions, present the expected costs of the proposed medicine and comparator(s) separately per patient per course of treatment. For long-term, chronic conditions, present the cost of each treatment per patient per year.

### 3A.8.2 Disaggregated and aggregated base-case results

If a decision-tree model is used, present disaggregated costs incurred at each branch by resource type for the proposed medicine and comparator groups. For state transition models, present disaggregated discounted costs by resource type for each health state for the proposed medicine and comparator groups. In all models, report the proportions of patients predicted to experience alternative target clinical outcomes in the proposed medicine and comparator groups.

Identify which health states and resources contribute the greatest incremental differences between the proposed medicine and the comparator(s). Examples of tables to present disaggregated results are shown below (Tables 3A.8.2a – 3A.8.2c).

**Table 3A.8.2a: Health care resource items - disaggregated summary of cost impacts in the economic evaluation by category of resource item**

Type of resource item	Subtype of resource item	Costs for proposed medicine (SGD)	Costs for comparator (SGD)	Incremental cost (SGD)	% of total incremental cost
<b>Medicines</b>	Treatment cost for proposed medicine				
	Administration				
	Monitoring				
	[add as needed]				
	<b>Total</b>				
	Treatment cost for comparator				
	Administration				
	Monitoring				
<b>Medical services</b>	GP consultation				
	Genetic test				
	[add as needed]				
	<b>Total</b>				
<b>Hospital services</b>	Hospital admission				
	[add as needed]				
	<b>Total</b>				
<b>Palliative care</b>	[add as needed]				
	<b>Total</b>				

SGD = Singapore dollars; Note: Indicate clearly whether cost values are discounted costs (use of discounted costs is appropriate). Inputs in the table are an example only. Adapt the table as required.

**Table 3A.8.2b: List of health states and disaggregated summary of cost impacts included in the model**

Health state in model	Resource use by health state (modelled)	Proposed medicine costs (SGD)	Comparator costs (SGD)	Incremental cost (SGD)	Total incremental cost (%)
[Health state 1]	Resource type 1				
	Resource type 2				
	[etc]				
	<b>Total for health state 1</b>				
[Health state 2]	Resource type 1				
	Resource type 2				
	<b>Total for health state 2</b>				

[add rows as needed]					
<b>Total</b>					<b>100%</b>

SGD = Singapore dollars

**Table 3A.8.2c: List of health states and disaggregated summary of health outcomes included in the economic evaluation**

Health state in model	Outcome for proposed medicine	Outcome for main comparator	Incremental outcome	Total incremental outcome (%)
[Health state 1]				
[Health state 2]				
[add rows as needed]				
<b>Total</b>				<b>100%</b>

Define the outcome in the first row of the table. Adapt the table as required.

## 3A.9 Sensitivity analysis

### KEY INFORMATION REQUIRED

- Explain the methods used to represent the uncertainty around the model's input parameters, translations and structure
- Define the uncertain parameters and variables, and their alternatives, that are tested in sensitivity or scenario analyses
- Present and discuss the one-way sensitivity analysis conducted
- Present and discuss any relevant scenario analyses conducted
- Present and discuss any multivariate analyses and/or probabilistic sensitivity analysis conducted

All economic evaluations involve a degree of uncertainty. It is important that all types of uncertainty are appropriately described, including uncertainty about the source of parameters used in the economic evaluation, the precision of the parameters, and whether the model accurately simulates the cost and effects of the proposed medicine and the comparator(s). Companies are encouraged to refer to the report by *ISPOR-SMDM Modeling Good Research Practices Task Force Working Group 6*<sup>29</sup> which provides comprehensive recommendations on characterising and reporting uncertainty in economic models.

### 3A.9.1 Defining uncertainty in the model

The types of uncertainty which can affect the results from the economic model are typically divided into two broad areas:

- Structural uncertainty – which includes structural and methodological uncertainty relating to the model; and
- Parameter uncertainty – which includes data uncertainty due to variability in data and/or data sources, and the generalisability of the study results to other populations and/or other contexts.

#### *Structural uncertainty*

Models are subject to uncertainty around the structural assumptions used in the evaluation (e.g. how different health states are categorised, or how different treatment pathways are represented). Uncertainty

relating to the structural assumptions used in the economic evaluation should be clearly documented. The impact of the structural uncertainty on the cost-effectiveness estimates should be explored by separate analyses of a representative range of plausible scenarios.

Include an analysis of the impact of variation in the time horizon chosen.

If multiple plausible model structures are defined, assess the potential impact of the alternative structures on the model outputs through scenario analyses. If a substantial impact is predicted, use a formal approach to characterise the structural uncertainty. Report the results of each set of plausible structural assumptions.

Conduct other scenario analyses to assess the effects of substantial use of the proposed medicine beyond the intended population. This wider population is expected to have demographic and patient characteristics and circumstances that differ from the target population which may impact the cost effectiveness of the proposed medicine.

### *Parameter uncertainty*

Uncertainty can arise from the choice of data sources to provide values for key parameters in the model, such as different costs and utilities, estimates of relative effectiveness, and the duration of treatment effects. Use commonly adopted statistical standards to represent the uncertainty around the true value of each uncertain input parameter (e.g. beta distributions for transition probabilities; log-normal for relative risks or hazard ratios; logistic distributions to calculate odds ratios; and gamma or log-normal for costs and utility parameters). Justify using alternative distributions.

Use interval estimates (e.g. 95% CIs) derived from fitted probability distributions to define the ranges of the parameter values tested in the deterministic sensitivity analyses. Where there is very little information on a parameter, adopt a conservative approach by defining a broad range of possible parameter values.

Consider correlations between input parameters. If applicable, represent the joint uncertainty of two or more input parameters in sensitivity analyses. It is preferable to characterise the joint uncertainty around transition probabilities in the proposed medicine and comparator groups through the application of a relative treatment effect parameter.

The estimation of multiple input parameters when using regression analysis produces relevant correlation parameters. For example, regression involving time to event data, correlation between the parameters describing a particular survival function is captured in the Cholesky matrix, which is used in probabilistic sensitivity analysis.

### **3A.9.2 Handling uncertainty - one-way sensitivity analyses and scenario analyses**

Univariate deterministic sensitivity analysis (also known as one-way sensitivity analysis [OWSA]) and/or scenario analyses should be conducted for all economic evaluations, to help determine the importance of the different assumptions and modelling parameters on the results in line with good practice guidelines.<sup>29</sup> Tabulate all parameter values and assumptions tested in OWSA or scenario analyses in Table 3A.9.2 and 3A.9.3 respectively. Ensure that the values tested are clinically plausible and not extreme (e.g. do not present analyses assuming no treatment effect for the comparator(s)).

Create a tornado diagram to provide a visual interpretation of the relative effect of the variability of each

parameter on the incremental cost-effectiveness result. Identify the input parameters and model assumptions which are key drivers of the economic model.

At a minimum, OWSA should be presented for each uncertain parameter in the economic evaluation. Multivariate and probabilistic sensitivity analysis may also be performed to address simultaneous impact of all uncertain parameters (Subsection 3A.9.3).

Discuss the implications of the OWSA (and scenario analyses if applicable) with respect to the certainty of the base-case ICER estimate. Discuss the likely overall effect of deficiencies in the evidence base on the reported cost-effectiveness of the proposed medicine.

**Table 3A.9.2: Results of OWSA characterising the uncertainty around the ICER**

Variable or assumption	Base-case value (LL, UL)	Incremental outcomes		Incremental costs		ICER		Description of impact on ICER
		LL	UL	LL	UL	LL	UL	
Base case								
Discounting rate (outcomes and cost)	3% (0%, 5%)	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Plausible range of treatment effect, if modelled as a variable (e.g. hazard ratio or relative risk)	[add] [e.g. upper and lower 95% confidence intervals around estimate]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Altered patient characteristics, if relevant	[add] [e.g. upper and lower age range]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Transition or event probabilities	[add] [e.g. upper and lower 95% confidence intervals around estimate]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Cost-related assumptions or variables	[add] [e.g. upper and lower 95% confidence intervals around estimate]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Time horizon	[add] [e.g. trial based; 5, 10, 20 years]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
[add rows as necessary]								

ICER = incremental cost-effectiveness ratio; LL = lower limit; UL = upper limit



**Table 3A.9.3: Results of scenario analyses characterising the uncertainty around the ICER**

Variable or assumption	Base-case value	Plausible alternative	Incremental outcomes	Incremental costs	ICER	Description of impact on ICER
Base case						
Altered patient characteristics, if relevant	[add]	[e.g. different condition severity]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Outcome-related assumptions or variables (e.g. alternative methods or sources of utility weights)	[add]	[add]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Alternative extrapolation variables or assumptions (e.g. assumption regarding ongoing treatment effect)	[e.g. maximum follow-up]	[e.g. median follow-up]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Any other translation assumptions	[add]	[add]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
Alternative assumptions regarding model structure	[add]	[add]	[alternative estimates]	[alternative estimates]	[alternative estimates]	[describe as required]
[add rows as necessary]						

ICER = incremental cost-effectiveness ratio

### 3A.9.3 Multivariate and probabilistic sensitivity analyses

Where applicable, describe any multivariate sensitivity analyses undertaken to test the combined effects of the uncertainty around the true values of input parameters to which the base-case incremental cost-effectiveness result was shown to be sensitive in the OWSA. Clearly present all results and justify the inclusion and exclusion of parameters in these analyses.

A probabilistic sensitivity analysis (PSA) may be presented in addition to deterministic sensitivity analyses to characterise parameter uncertainty.<sup>xxxii</sup>

The distributions used in the PSA should be justified and should reflect the available evidence on the parameter of interest.

If undertaking a PSA on a cohort-based state transition model, the number of iterations (sets of randomly sampled input parameter values included in the analysis) should provide stability in the model outputs across multiple analyses using alternative random number seeds. Provide the random seed associated with the presented results to enable replication, and also ensure that the model permits alternative seeds.

If undertaking a PSA on an individual-level model (e.g. a discrete event simulation), the number of iterations may be selected to balance stability of model outputs and a reasonable time required to undertake a PSA.

<sup>xxxii</sup> PSA cannot address translational or structural uncertainty. It can only address uncertainty surrounding the parameters.

Present the results of the PSA using cost-effectiveness planes and acceptability curves, and tabulate the interval estimates for the ICER or the incremental net benefits of the proposed medicine. Describe and explain any variation between the incremental cost-effectiveness analysis results estimated in the base-case analysis and the PSA, if applicable.

### 3A.10 Summary of economic evaluation

Provide a brief summary of the results and conclusion of the economic evaluation.

## Section 3B Cost minimisation

### 3B.1 Overview and rationale for the cost-minimisation approach

Complete Table 3B.1 to summarise the key assumptions and components of the cost-minimisation approach presented in the submission.

**Table 3B.1: Key assumptions and components of the cost-minimisation approach**

Component	Claim or assumption
Therapeutic claim: effectiveness	Based on evidence presented in Section 2, effectiveness is assumed to be [non-inferior/superior]
Therapeutic claim: safety	Based on evidence presented in Section 2, safety is assumed to be [non-inferior/superior]
Evidence base	[direct randomised trials/indirect comparison of randomised trials]
Equi-effective doses	Proposed medicine [describe dose/day/course] and comparator [describe dose/day/course]
Direct medicine costs	[Cost of proposed medicine] vs [cost of comparator] (costs are per patient per course for an acute or self-limited therapy, or per patient per year for a chronic or continuing therapy)
Other costs or cost offsets	[Yes/No] [if yes; brief description – e.g. adverse effect–related costs, monitoring costs, administration costs]

### 3B.2 Estimation of equi-effective doses

#### KEY INFORMATION REQUIRED

- Calculate equi-effective doses for the proposed medicine and the comparator(s)

When estimating equi-effective doses, the following sources of evidence should be considered (presented in order of preference):

- direct randomised trials where doses of the proposed medicine and the comparator(s) are titrated against a response, or where doses of both medicines are fixed if the medicines are administered in routine local clinical practice according to the fixed protocol used in the trials; or
- direct randomised trials where doses of either or both the proposed medicine and comparator(s) are fixed in a way that does not reflect routine local clinical practice. In this instance, present dose-response data for the two medicines to indicate whether the fixed doses are derived from a similar point on the respective dose-response curves, and to confirm that the selected doses do not represent suboptimal doses or doses on the plateau of the dose-response curve. Fixing the dose of just one medicine introduces an unbalanced approach; or
- indirect comparisons of two or more sets of randomised trials involving one or more common references; or
- non-randomised studies.

Indicate whether the doses and methods of titration are consistent with those approved by HSA for the proposed medicine and comparator(s). For medicines administered in line with fixed protocols, compare the total doses required over the entire duration of therapy.

For medicines that require dose titration calculate equi-effective doses at steady state (i.e. the average dose after dose titrations are complete and after excluding participants who discontinue the medicine). Assess the impact of extrapolating dose titration if there is evidence that the trial was of inadequate duration for the doses to have reached steady state.

If there is more than one trial or study, calculate the weighted average dose using the number of participants still on the medicine at steady state as the weighting factor. If the study's primary data is unavailable, the average doses might have to be weighted by the number of participants enrolled (as per published report) rather than the number of participants at steady state. Justify the exclusion of any studies not incorporated into the equi-effective dosing calculations.

If overseas HTA agencies (e.g. PBAC or NICE) have previously agreed on equi-effective doses for the proposed medicine and comparator, provide details in the submission.

### 3B.3 Additional costs and cost offsets

#### KEY INFORMATION REQUIRED

- Identify any additional costs or cost offsets that are accounted for in the analysis. This could include cost offsets due to differences in the administration profiles and safety management profiles of the proposed medicine and comparator(s)

The nature of additional costs and cost offsets will differ across submissions. The most common additional costs are those associated with treatment administration and managing adverse events; however, this does not preclude other possible cost offsets. Justify any other additional costs and cost offsets in terms of how they are realisable and patient relevant, and show how they differ between the proposed medicine and the comparator(s) in the cost-minimisation analysis.

#### 3B.3.1 Comparison of administration profiles

Identify differences in the costs of prescribing or administering the proposed medicine and the comparator(s).

If the proposed medicine and its main comparator are available in different dosage forms (e.g. tablets, injections, infusions), the different modes of administration might have cost consequences. In this case, identify the types of other health care resources affected, estimate the extent to which the quantity of each type of resource provided would change (in its natural units of measurement) if the proposed medicine is funded, and multiply by the appropriate unit costs.

#### 3B.3.2 Comparison of safety and toxicity management profiles

Only use the cost-minimisation approach where the proposed medicine has a safety profile that is superior or non-inferior to the main comparator. Identify any differences in the costs of monitoring or managing adverse events associated with the medicines.

If the proposed medicine is demonstrated to be no worse in terms of effectiveness, but has a superior safety profile to the main comparator, a price advantage for the proposed medicine over its main comparator could be proposed on the basis of cost offsets because of reduced costs of monitoring and managing adverse

reactions. Provide supporting evidence (e.g. from clinical trials or the HSA product insert) to substantiate a claim that monitoring costs are reduced.

Where safety profiles are similar, but the proposed medicine has a lower magnitude of adverse effects (either in terms of severity or incidence), quantify the safety profile differences between the medicines, and estimate any corresponding resource-use implications.

Where the adverse effect profiles of a proposed medicine and its main comparator are different in nature, a cost-effectiveness or cost-utility analysis is preferred (Section 3A).

## 3B.4 Results

List all identified costs associated with both the proposed medicine and the comparator, then aggregate these with the selling price of each medicine (based on the equi-effective doses) to estimate the net cost difference.

The economic claim should be that, at the price requested, the overall cost of therapy with the proposed medicine is the same as, or less than, the overall cost of therapy with the main comparator.

Provide copies of the original sources of all data (beyond those already presented in Section 2), and expert opinion used to inform the cost-minimisation approach. To enable independent verification of each analysis, provide an electronic copy (e.g. in Excel) of any computer-based calculations of the analysis.

# Section 4 Utilisation and financial impact

## Introduction

In Section 4, present the expected utilisation of the proposed medicine in local clinical practice if it is recommended for funding, and the associated financial impact, in line with the parameters described in Table 4.

**Table 4: Parameters considered when estimating utilisation and financial impact of proposed medicine**

Parameter	Base-case analysis
<b>Target population</b>	<ul style="list-style-type: none"> <li>▪ Consistent with the patient population (and any relevant subgroups) defined in the evaluation framework</li> <li>▪ Potential population size should be specified, and the estimation method described and justified. Attention should be paid to the evolution of the size of the target population over time with and without funding of the medicine.</li> <li>▪ Singapore resident population (citizens + permanent residents) should be used in the calculations</li> <li>▪ Diagnosis rates in line with local clinical practice should also be taken into account when calculating the proportion of patients who are likely to receive treatment</li> </ul>
<b>Comparator(s)</b>	<ul style="list-style-type: none"> <li>▪ Consistent with the comparator(s) defined in the evaluation framework</li> </ul>
<b>Health outcomes</b>	<ul style="list-style-type: none"> <li>▪ No health outcomes are presented in the analysis</li> </ul>
<b>Costs</b>	<ul style="list-style-type: none"> <li>▪ Only the cost of the proposed medicine should be included (i.e. excluding margins)</li> <li>▪ If a price reduction, PAP or risk-sharing arrangement has been included in the pricing proposal for the proposed medicine (contingent on a positive funding recommendation), the net cost price after the price reduction, PAP or other arrangements are applied should be used in the base case</li> <li>▪ Constant costs, that are not subject to inflation, should be used</li> </ul>
<b>Time horizon</b>	<ul style="list-style-type: none"> <li>▪ Analyses should be conducted over a six-year period (to represent year of DAC meeting, then five years post-funding decision)</li> </ul>
<b>Discount rate</b>	<ul style="list-style-type: none"> <li>▪ No discount rate should be applied</li> </ul>

Epidemiological and market-share analyses are the two broad approaches for estimating utilisation, although their use is not mutually exclusive. An epidemiological approach is typically preferred for generating estimates if the submission indicates a superior therapeutic conclusion. However, a market-share approach might be preferred if the submission indicates a non-inferior therapeutic conclusion.

### *Epidemiological approach*

An epidemiological approach estimates the number of people with the medical condition in Singapore, and then estimates the use of the proposed medicine and the comparator(s) by the eligible resident patient population (and subgroups where relevant) defined in the evaluation framework.

### *Market-share approach*

The market-share approach estimates the extent of the current market represented by the proposed target population (or subgroup) and, consequently, the share likely to be taken by the proposed medicine if it is recommended for funding.

### Chosen analysis

Justify the approach taken. Demonstrate consistency in results across both approaches where data inputs from one approach (epidemiological or market share) are uncertain.

Ensure that any estimates of the extent of use of the proposed medicine and the comparator(s) are consistent with evidence presented in the submission. Ensure that uptake of the proposed medicine and any change in the use of the comparator(s) are consistent with their expected use in local clinical practice (defined in Subsection 1.2.1) and the circumstances presented in the economic evaluation (Section 3). Explain and justify any discrepancies.

Provide sufficient information in Section 4 of the submission so the analyses can be clearly interpreted and replicated if necessary. Describe the approach, methods, and potential biases. All calculations, assumptions and data sources should be clearly described within the submission and/or the costing template. Where multiple sources of data are available for an individual variable, present sensitivity analyses for the different estimates across the sources.

Describe how the data are relevant to the present Singapore context. Where data from overseas are used in the absence of local estimates, discuss the applicability of these data to the Singapore setting.

A commissioned study may be required to fill a gap in the data (e.g. conducting a medicine utilisation survey or extracting registry data). When reporting the results of a commissioned study, provide sufficient background and methodological information to facilitate interpretation of the results. Where a survey of healthcare professionals is conducted, provide their details and public healthcare institution for verification, and indicate the number of patients they treat annually with the condition under evaluation.

When analysing administrative data and registries, provide sufficient information about the method used to sample the dataset, the proportion of the target population included in the dataset, and any assumptions made during the analysis.

### Costing template

A standardised Excel template ([Costing template for company submissions to ACE<sup>xxxiii</sup>](#)) which should be completed with each submission (using the epidemiological and/or market share approach) is available from the [ACE website<sup>xxxiv</sup>](#). Additional spreadsheets can be created to present sensitivity or scenario analyses or provide additional data to support assumptions, where required.<sup>xxxv</sup>

Ensure that the calculations flow through the spreadsheets, so that changes to any variable in the base case flow on to the results. Apply clear labels to spreadsheet values (where required), and provide the data sources. To facilitate independent assessment of the data, attach copies of the data used.

---

<sup>xxxiii</sup> <https://go.gov.sg/company-costingtemplate>

<sup>xxxiv</sup> [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg)

<sup>xxxv</sup> Additional spreadsheets should be stand-alone worksheets and should not be linked backed to any existing worksheets that inform the base-case calculations. Results for sensitivity or scenario analyses should be manually computed and all calculations should be reproducible (unlocked).

## 4.1 Utilisation and financial impact of the proposed medicine

### KEY INFORMATION REQUIRED

- For an **epidemiological approach**, complete the relevant spreadsheets of the [Costing template for company submissions to ACE](#) to estimate the number of:
  - patients with the condition under evaluation in Singapore;
  - patients who are likely to be eligible for the proposed medicine; and
  - units of the proposed medicine that would be required for the target population
- For a **market share** approach, complete the relevant spreadsheets of the [Costing template for company submissions to ACE](#) to estimate:
  - the number of units of the comparator(s) currently dispensed for the condition under evaluation, and the number of patients this represents;
  - the proportion of patients who are likely to switch from the comparator(s) to the proposed medicine if it is recommended for funding (where applicable); and
  - the market growth rate if the proposed medicine is recommended for funding
- Estimate the cost of each form and strength of the proposed medicine over a 6-year period (to represent year of DAC meeting, then five years post-funding decision)
- Discuss any uncertainties surrounding the utilisation and cost estimates
- Describe any proposed risk-sharing arrangements (RSA) contingent on a positive funding recommendation for the proposed medicine

### 4.1.1 Epidemiological approach

#### *Incidence or prevalence data*

For an epidemiological approach, describe the methods and assumptions for converting incidence or prevalence data to the number of patients likely to be receiving the proposed medicine each year in Singapore.

The choice to use incidence or prevalence data depends on several factors, including the nature of the medical condition, its treatment and the available data. Usually, incidence estimates are most suitable for treatments of short duration while prevalence estimates may be more appropriate for long-term treatments (e.g. for chronic conditions). A combination of prevalence and incidence estimates (denoted as “Mixed” in the costing template) may be required (e.g. to capture intermittent treatments for a chronic condition).

Consider the current prevalent patient population in addition to the incident population – for example, if patients are receiving best supportive care before the proposed medicine becomes available (as there are no alternate treatments available), only calculating the incident population would underestimate the likely number of patients treated in the early years once funding is available.

#### *Estimate the total number of patients with the condition in Singapore*

Estimate the likely number of patients over a 6-year period, using the incidence or prevalence approach. If using an incidence approach, also estimate the prevalent population (from years before DAC meeting) that may add to the patient pool treated with the proposed medicine in Year 1. Justify when the addition of a prevalent population is not required.



### *Estimate the number of patients eligible for the proposed medicine*

Estimate the proportions of patients with the condition under evaluation each year who are expected to be eligible for the proposed medicine. Treatment eligibility should be considered in line with the local clinical treatment algorithm and any proposed clinical criteria to determine appropriate use, described in Subsection 1.2.1.

### *Estimate the number of patients in the target population likely to receive the proposed medicine*

Using the annual numbers of eligible patients, estimate the proportions likely to receive the proposed medicine each year. Ensure that the estimates reflect the predicted rate of diagnosis of the condition, the predicted uptake of the proposed medicine, and include the impact of the use of other medicines (comparators most likely to be replaced by the proposed medicine). Justify the diagnosis and uptake rates assumed, and assess variations to these estimates, if necessary, in a sensitivity analysis.

The total number of eligible patients should reflect all patients in the target population, irrespective of whether they are treated in the public or private sector. Indicate in the costing template (under “Reference/Sources/Assumptions” column, but do not adjust the calculations) and in the submission the estimated market share split between the public and private sector in Singapore and justify the estimate assumed.<sup>xxxvi</sup>

Present a table(s) in the submission which summarises the assumptions and patients estimated in the costing template using the epidemiological approach.

#### **4.1.2 Market-share approach**

To generate estimates of expected utilisation and patient numbers using the market-share approach, use utilisation data or studies for currently available alternate treatments (comparators) that are most likely to be replaced by the proposed medicine (or that are currently used for the target population if the proposed medicine is an add-on therapy to existing standard of care). This is the basis for predicting whether the market will change when the proposed medicine is funded.

#### *Units dispensed for comparator(s)*

Estimate the units of the comparator(s) dispensed during the most recent 12 months. Ensure that the estimates reflect the quantities of the medicine **dispensed**, rather than the quantities of medicine **consumed**, which may be affected by compliance, dose reductions, discontinuations and wastage.

Estimate the proportion of total units that would have been used by the target population in the public sector with the condition under evaluation. Vial sharing should not be included.

Estimate the market growth (for the current market) over six years in the absence of funding for the proposed medicine based on historical trends or other influences.

If patients are expected to switch from more than one comparator to the proposed medicine, present the market share and rate of growth for each comparator. Disaggregating the estimated growth according to each comparator is important if they are likely to have different rates of growth, or are likely to be replaced by the

---

<sup>xxxvi</sup> This estimate will be verified by ACE and used to inform internal calculations to estimate the financial impact of funding on the Government budget, if applicable.

proposed medicine at different rates. Where all comparators are from the same drug class and the proposed medicine is being considered on a cost-minimisation basis, disaggregation of the estimated growth for each comparator is less important.

#### *Estimate the market share for the proposed medicine*

Estimate the rate of switching from the comparator(s) to the proposed medicine where applicable. If the proposed medicine is used as an add-on therapy to standard of care, switching rates do not need to be calculated. Justify the rate assumed (e.g. provide market uptake rates from other countries where the proposed medicine is already used and discuss the applicability of these rates to the Singapore setting).

Present a table in the submission which summarises the assumptions and uptake/switching rates used to estimate market share in the costing template.

#### *Estimate the growth of the market if the proposed medicine is funded*

Report the expected increase in patient numbers anticipated once the proposed medicine is funded. Multiple factors may influence growth, and it may not be appropriate to assume linear growth in the estimates, particularly if the proposed medicine is not the first entrant to the market for the target population. Justify when no additional growth in the market is predicted. When the proposed medicine may be used in clinical practice to treat people who are intolerant to an existing (comparator) medicine, or following failure with that medicine, it is likely that availability of the proposed medicine will increase the overall number of people treated.

Provide references to justify all assumptions relating to the data inputs, and discuss any risks associated with market growth in the submission, to increase the certainty of the financial implications of funding the proposed medicine.

### **4.1.3 Cost impact**

Only the cost of the proposed medicine (excluding margins) should be included in the costing template. If a price reduction has been proposed in the Request for Proposal for the proposed medicine (contingent on a positive funding recommendation), the net cost price (after the price reduction is applied) should be used. The cost consequences of comparator(s), treatment effect, adverse events and any other short-term or long-term consequences do not need to be included. If warranted, either time-on-treatment, time-to-discontinuation or time-to-progression curves from relevant pivotal RCTs may be used to account for treatment discontinuations to provide a robust estimation of mean treatment duration.

### **4.1.4 Uncertainty surrounding utilisation and cost estimates**

There are a number of factors that may influence the predicted utilisation patterns and financial implications associated with funding the proposed medicine for the target population. These include, but are not limited to:

- The duration of therapy might be longer than expected from the randomised trials, particularly if trials are truncated;
- Patients could be treated more or less often than expected, particularly in the case of medical conditions with episodic manifestations;
- Epidemiological or market-share trends may have been inaccurately forecast;
- Outcomes of ongoing or related research might have a positive or negative effect on uptake of the proposed medicine over the forecasted period;

- More prescribers and patients might seek treatment if the proposed medicine treats a medical condition for which the alternatives are considered to be substantially inferior to the proposed medicine (e.g. in terms of effectiveness, tolerability, patient acceptability, convenience); and
- Prescribers could find it difficult to determine whether patients are eligible for the proposed medicine (e.g. a difficult differential diagnosis, or poor precision or accuracy in a diagnostic test etc.) leading to lower or higher rates of use.

Describe any of these factors that are expected to have an impact on the patient numbers and costs estimated in the costing template. It might not be necessary to address any or all of these factors if their impact is expected to be small. For any factors described, discuss and quantify (if possible) the direction (underestimate or overestimate) and magnitude of the impact on the estimate(s). Indicate any instances where the effects of some uncertainties are difficult to quantify.

Uncertainty can be reduced by using data from multiple sources, if available, or by using epidemiological and market-share approaches to derive estimates.<sup>xxxvii</sup> Where estimates derived from different sources or by using different methodological approaches are concordant, this may give decision-makers more confidence in the resulting estimates. Sensitivity analyses using multiple sources or methods to explore any uncertainties should be described in the submission.

Current or future activities to reduce existing uncertainties should also be described including:

- proposed educational activities for healthcare professionals that are expected to help identify patients eligible for treatment and ensure that the proposed medicine is used appropriately (e.g. to avoid leakage outside target population); or
- any monitoring efforts or patient/treatment registries that are being set up to ensure that the proposed medicine is being used appropriately.

The role of any proposed risk-sharing arrangement (RSA) in managing these existing uncertainties should also be discussed. When discussing the proposed activities, state when they will be implemented, and whether such activities will be available to all prescribers (or other healthcare professionals, where applicable), public healthcare institutions and patients. If restrictions are proposed (e.g. limited to specific patients or public healthcare institutions), please provide sufficient details.

#### 4.1.5 Risk-Sharing Arrangements

Risk-sharing arrangements (RSAs) are instruments used to address substantial uncertainties surrounding proposed medicines that are likely to affect the DAC's decision. Financial-based RSAs such as price-volume agreements (PVAs) in particular, are specifically designed to address the following types of uncertainties commonly associated with cancer medicines:

- number of patients that are expected to be eligible for funding;
- potential use of the medicine in non-cost effective, off-label, or non-subsidised populations;
- potential for dose escalation beyond what is expected or presented in the submission;
- potential for use beyond disease progression, for a longer duration than is cost-effective or in non-responding patients; and
- risk of use in combination with, or in addition to, current therapy rather than replacing existing therapies.

---

<sup>xxxvii</sup> This is sometimes referred to as 'triangulation' (the use of multiple sources of data or multiple approaches to determine the consistency or otherwise of the conclusions from those sources or approaches).

### Proposing risk-sharing arrangements

PVAs are the main type of RSAs considered by the DAC. They enable companies to propose defined annual expenditure caps that manage the risk of inappropriate usage and/or usage not defined by the clinical criteria for funding of the medicine. In general, companies are required to include PVA proposals for **all new cancer medicines** and provide sufficient justification for the expenditure caps proposed. Any expenditure caps exceeding S\$2M in any year within the first 5 years of listing will require additional financing approval from MOH which may lengthen the time to funding implementation.

The company should prepare any RSA proposals in consultation with ACE to ensure that they are feasible to implement and in line with the criteria described in Table 4.1.5 below. Companies should describe the proposed RSA(s) in their Request for Proposal and explain which uncertainties will be addressed through the proposed arrangement(s). The expected financial impact of the proposed RSA should also be captured in relevant scenario analyses in the economic evaluation and/or budget impact analyses.

**Table 4.1.5: Criteria for RSAs in Singapore**

General criteria for medicines subject to a risk-sharing arrangement
<ol style="list-style-type: none"><li>1. The medicine treats a significant medical condition and the MOH Drug Advisory Committee (DAC) considers that it will generate substantial incremental benefit for the intended patient population</li><li>2. The DAC advises that the medicine is recommended for funding for a specific clinical indication(s) or that it has unique characteristics compared to any available alternative therapies and addresses a therapeutic gap</li><li>3. The DAC considers that the RSA will accrue significant financial benefits to the Singapore healthcare system</li><li>4. The company has advised MOH that the effective price and/or any proposed arrangements are consistent with or more advantageous than those in other countries</li><li>5. The RSA is operationally feasible within the context in which it is intended to be implemented</li><li>6. Data gathering requirements for the arrangement can be performed to a high degree of fidelity with existing IT infrastructure or the company is able to provide the required infrastructure otherwise</li><li>7. The company advises or is advised that not entering into a risk-sharing arrangement would prevent a positive funding recommendation, and provides:<ol style="list-style-type: none"><li>i. the reason(s), including financial implications, why this arrangement is required</li><li>ii. acknowledgement that acceptance of an agreement to any arrangement, is at the discretion of the Singapore Government</li><li>iii. acceptance that the list of medicines eligible for government subsidies and/or MediShield Life coverage may allude to the “existence of a Deed of Agreement which contains a ‘Risk-Sharing Arrangement’” for the submitted medicine in the event of a positive recommendation by the DAC; details of the Deed of Agreement however, will be kept confidential, and</li><li>iv. acceptance that to give effect to any risk-sharing arrangement, a Deed of Agreement is required between the company and the Singapore Government.</li></ol></li></ol>

### *Deed of Agreement for risk-sharing arrangements*

An RSA is established through a Deed of Agreement between the Government (as represented by MOH Singapore) and the company. A standard [Deed of Agreement template](#) is available on ACE's website. Amendments to the standard clauses in the Deed of Agreement are not accepted unless the attributes of a particular arrangement proposed for a medicine are identified by the DAC as requiring different considerations. All Deeds will need to be executed before a medicine is listed on SDL/MAF and/or on the CDL.

Deeds are required to generally cover a period of five years. MOH will review all Deeds towards the end of their term. Deeds can either lapse or be renewed following review. If an agreement cannot be reached between MOH and the company prior to the expiry of a Deed, the terms of the existing Deed will remain in force until such time an agreement can be reached. This is necessary to ensure the risks associated with the listing can continue to be managed.

The DAC may also periodically review and recommend changes to the list of clinical indications eligible for government subsidies and/or claims or benefits under the MediShield Life scheme for cancer medicines with existing PVAs. When this occurs, the DAC will advise ACE whether any increases to the existing caps are warranted from a clinical and/or cost-effectiveness perspective. Companies will be notified of any updates to affected Deeds following DAC's review.

All Deeds agreed between MOH and any company are strictly confidential and will not be made publicly available. The confidentiality of all Deeds (and the information contained within) will be preserved through the mandatory Confidentiality Agreement signed between MOH and companies. All documents will also be handled in accordance with MOH's standards for confidentiality and transparency (Section 2.1).

#### **4.1.6 Patient assistance programmes**

Describe any proposed patient assistance programmes (PAP) included in the Request for Proposal for the proposed medicine. Justify why the proposed PAP is required and confirm that the administrative requirements to implement the PAP are acceptable to all public healthcare institutions that will be prescribing the proposed medicine.

#### **4.1.7 Summary of costing template calculations**

Briefly summarise the results of any calculations (including sensitivity analyses) from the costing template in the submission. Supporting calculations do not need to be replicated in the submission but should be provided in the costing template in sufficient detail to allow independent verification. Discuss any differences between the results in the base case and the sensitivity analyses, if applicable.

# References

---

1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.4 (updated August 2023). Cochrane, 2023. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
2. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009; 62(10):1006–1012.
3. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009; 151(4):W65-W94
4. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. *Value in Health* 2011; 14(4):417-428.
5. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R et al. Conducting indirect-treatment-comparison and network meta-analysis studies: Report of the ISPOR taskforce on indirect treatment comparisons good research practices: Part 2. *Value in Health* 2011; 14(4):429-437
6. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.4 (updated August 2023). Cochrane, 2023. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
7. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* 2007;7:10.
8. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J, Schünemann HJ. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol*. 2011; 64: 407-415.
9. Sterne J, Higgins J, Reeves B, on behalf of the development group for ROBINS-I. ROBINS-I: a tool for assessing Risk Of Bias In Non-randomized Studies of Interventions, version 7, March 2016.
10. Kim SY, Park JE, Lee YJ, Seo H-J, Sheen S-S, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *J Clin Epidemiol* 2013;66(4):408-414
11. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Ann Intern Med* 2010;152. Epub 24 March
12. Fleming TR and De Mets DL. Surrogate End Points in Clinical Trials: Are We Being Misled? *Ann Intern Med*. 1996;125:605-613.
13. International Conference Harmonization (ICH) E9 guideline ‘statistical principles for clinical trials’, 1998. Available at: [https://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E9/Step4/E9\\_Guideline.pdf](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf)
14. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. *Control Clin Trials* 1989;10(4):407–415.
15. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. *J Clin Epidemiol* 1994;47(1):81–7.
16. Cochrane Collaboration. Review manager (RevMan)[computer program]: Version, 2011.
17. Sterne JA, Bradburn MJ, Egger M. Meta-analysis in Stata™. In: Egger M, Smith G, Altman D, eds. *Systematic reviews in health care: meta-analysis in context*. 2nd edn. London: BMJ Publishing Group, 2008;347–369.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-188
19. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment

- comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol* 1997;50(6):683–91.
20. Signorovitch JE, Wu EQ, Andrew PY, Gerrits CM, Kantor E, Bao Y et al. Comparative effectiveness without head-to-head trials. *Pharmacoeconomics* 2010;28(10):935–945.
  21. Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. *Pharmacoeconomics* 2010;28(10):957–967.
  22. Wells GA, Sultan Sa, Chen L, Khan M, Coyle D. Indirect evidence: indirect comparisons in meta-analysis, March 2009. Available from [www.cadth.ca/indirect-evidence-indirect-treatment-comparisons-meta-analysis](http://www.cadth.ca/indirect-evidence-indirect-treatment-comparisons-meta-analysis).
  23. Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP et al. Adjusting survival time estimates to account for treatment switching in randomized controlled trials – an economic evaluation context: methods, limitations, and recommendations. *Med Decis Making* 2014;34(3):387–402.
  24. Atkins D, Chang SM, Gartlehner G, Buckley D, Whitlock EP, Berliner E, & Matchar, D. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. *J Clin Epidemiol* 2011;64(11), 1198-1207.
  25. Detsky AS, Naglie G, Krhn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2 – Building a tree. *Med Decis Making* 1997;17(2):126-135.
  26. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. *Med Decis Making* 2012;32(5):690-700.
  27. Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19. Partitioned survival analysis for decision modelling in health care: A critical review. 2017. Available from <http://www.nicedsu.org.uk>
  28. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. *Med Decis Making* 2012;32(5):701-711.
  29. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practice Task Force Working Group-6. *Med Decis Making* 2012;32(5):722-732.
  30. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. *Pharmacoeconomics* 2007;25(1):3-6.
  31. Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. Available from <http://www.nicedsu.org.uk>
  32. Latimer NR. Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data: inconsistencies, limitations and a practical guide. *Med Decis Making* 2013;33(6):743-754.
  33. Bagust A, Beale S. Survival analysis and extrapolation modelling of time-to-event clinical trial data for economic evaluation: an alternative approach. *Med Decis Making* 2014;34(3):343-351.
  34. Grieve R, Hawkins N, Pennington M. Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play. *Med Decis making* 2013;33(6):740-742.
  35. Karnon J, Vanni T. Calibrating models in economic evaluation. *Pharmacoeconomics* 2011;29(1):51-62.
  36. Royston P. Flexible parametric alternatives to the Cox model, and more. *Stata J* 2001;1(1):1-28
  37. Whyte S, Walsh C, Chilcott J. Bayesian calibration of a natural history model with application to a population model for colorectal cancer. *Med Decis Making* 2011;31(4):626-641.
  38. Royston P, Lambert PC. Flexible parametric survival analysis using Stat: beyond the Cox model. College Station, TX: Stata Press, 2011.

39. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res Methodol* 2012;12(1):9.
40. Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. *BMC Med Res Methodol* 2011;11(1):139.
41. Longworth L, Rowen D. NICE DSU Technical Support Document 10: The use of mapping methods to estimate health state utility values. 2011. Available from <http://www.nicedsu.org.uk>
42. Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: A validation-assessment tool of health-economic models for decision makers and model users. *Pharmacoeconomics* 2016;34(4):349-361



# Appendix 1 Submission Checklist

The documents that should be sent to ACE as part of a company submission are shown in the table below. Companies should complete this table and include it as part of their submission. ACE will use it as a checklist to ensure that all relevant documents have been received.

Category	Document required	Included? Y/N
General information	Signed cover letter	
	Executive summary	
	Completed <a href="#">Request for Proposal</a> including PVA proposal	
Regulatory information – If HSA-approved	Most recent version of the HSA product information and HSA summary report of benefit-risk assessment (if available)	
Regulatory information – If not yet HSA-approved	US FDA and/or EMA assessment report	
	HSA approvable letter	[If not available at time of submission, indicate when it will be provided]
Evidence submission	Completed evidence submission that addresses Sections 1-4 in the guidelines (not exceeding 150 pages, excluding appendices)  Include name(s) of third-party consultant(s) appointed to prepare the evidence submission in the cover page (if relevant)	
Documents to support evidence submission	Full clinical study report(s) of key evidence, including trial protocols and amendments. The list of appendices for the clinical study report should be provided, but the appendices are not required in the submission.	
	Publications of all references with filenames in the format <i>reference number_ author_ year_</i> .	
	Statistical appendix for analyses used in the submission, including any relevant code for statistical software used	
	Search strategy and literature yield from Pubmed (MEDLINE). Literature searches should be updated within four months of the date of evidence submission.	
	Full reports of patient or clinician surveys that were used to inform the submission	
	Minutes from Advisory Board meetings or workshops with clinical experts or patients/carers who informed the submission	
	Unlocked and fully executable economic model or cost-minimisation spreadsheet	
	Completed <a href="#">Costing template for company submissions to ACE</a>	
	Reference list of all publications that informed the submission	
	Other <sup>a</sup>	[complete if relevant]

<sup>a</sup> Documents cannot be removed from this list. If a document is not available or not relevant, please explain why. Additional relevant documents can be included in the list under the “other” category.

The Agency for Care Effectiveness was established by the Ministry of Health Singapore to drive better decision-making in healthcare through health technology assessment, clinical guidance, and education.

© **Agency for Care Effectiveness, Ministry of Health, Republic of Singapore**

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Drug and Vaccine Evaluation Team  
Agency for Care Effectiveness  
Email: ACE\_HTA@moh.gov.sg

In citation, please credit the “Ministry of Health, Singapore” when you extract and use the information or data from the publication.